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ABSTRACT 
Milk and egg allergy is increasing in Europe and the United States, showing a 
very high incidence, especially in children. Major allergens of these products are 
glycoproteins, and to induce an allergic response, they should be able to cross the 
intestinal barrier maintaining sufficient structural integrity to interact with the immune 
system. Therefore, one of the main characteristics of food allergens is their resistance to 
gastrointestinal digestion and it is important to assess whether the fragments generated 
during this process retain IgE binding epitopes. Given the multiple factors involved in 
physiological digestion, the validity of the stability to the in vitro digestion as a criterion 
to assess the potential allergenicity of proteins is still controversial. 
In this thesis, digestions with oral, gastric and duodenal human and simulated 
fluids of three commercial allergenic food proteins, β-lactoglobulin (β-LG), β-casein (β-
CN), and ovalbumin (OVA) have been performed. The results showed that beside the 
degradation profiles of the two models were different, the residual immunoreactivity, 
cleavage site of enzymes and the resultant peptides were very similar. The results of 
microarray and dot blot analysis showed that some of the peptides resulting from 
digestion maintain their allergenicity being the most immunoreactive areas β-LG (43-65), 
β-LG (86-99) and β-LG (124-140) in the case of β-LG, β-CN (57-68) and β-CN (82-93) 
for β-CN and OVA (370-385) for OVA. 
Furthermore we also studied the effect of carbohydrate residues attached to the 
ovomucoid (OM), immunodominant egg allergen, on its allergenicity and digestibility. 
Results indicated that after enzymatic deglycosylation, the structure of OM was 
unmodified and 80% of the patients used in the study showed reduced IgE binding 
capacity compared with OM glycosylated. The presence of IgE-reactive epitopes specific 
for glycosylated protein was also demonstrated. Deglycosylated OM was more 
susceptible to proteolysis during digestion but the resultant peptide pattern was very 
similar. Immunoreactivity of the digests measured by inhibition ELISA decreased to 
values between 1 and 4% at the end of digestion, but some of the identified peptides such 
as OM (80-89) and the regions OM (36-61), OM (100-122) and OM (133-180) showed 
maintain their IgE binding capacity reacting in 40-100% of patients tested. 
The last part of this thesis describes the identification of peptides generated during 
the in vitro gastrointestinal digestion of a major egg allergen, lysozyme (LYS). The 
results indicated that the gastric and duodenal digests retained their IgE binding and 
basophils activation capacities. This biological activity may be attributed to the presence 
of intact LYS, to the fragment LYS (24-129) produced by the action of chymotrypsin or 
to the immunoreactive peptides released during digestion and linked by disulphide 
bridges, containing the epitopes LYS (57-83) and LYS (108-122). 
The fact that major linear epitopes can be released during digestion of LYS led to 
study the case of an egg allergic child, which tolerate egg after a immunotherapy 
treatment, suffered a severe allergic reaction to a medication containing LYS and papain 
The hypothesis that the presence of papain, could increase the allergenic potential of the 
LYS was raised. The results indicated that LYS treated with papain produced fragments 
with a high IgE-binding capacity and they were identified as LYS (22-129), LYS (34-96) 
and LYS (62-128). Furthermore, these fragments could be linked by disulphide bridges 
forming large structures that could have an IgE-binding capacity increased. 
 
  
RESUMEN 
La alergia a leche y huevo presenta una alta incidencia y va en aumento en Europa 
y Estados Unidos, sobre todo en la población infantil. Los principales alérgenos de estos 
productos son glicoproteínas, y para inducir una respuesta alérgica, deben ser capaces de 
atravesar la barrera intestinal manteniendo la suficiente integridad estructural como para 
interactuar con el sistema inmune. Por ello, una de las características principales de los 
alérgenos alimentarios es su resistencia a la digestión gastrointestinal y es importante 
evaluar si los fragmentos generados durante este proceso retienen epítopos de unión a 
IgE. Dados los múltiples factores que intervienen en la digestión fisiológica, la validez de 
la estabilidad frente a la digestión in vitro como criterio para estimar el potencial 
alergénico de las proteínas está siendo muy discutida.  
Durante la realización de la tesis doctoral, se han llevado a cabo digestiones con 
fluidos orales, gástricos y duodenales humanos y simulados con enzimas comerciales de 
tres proteínas alimentarias alergénicas, β-Lactoglobulina (β-LG), β-caseína β-CN, y 
Ovoalbumina (OVA). Los resultados mostraron que aunque los perfiles de degradación 
de los dos modelos fueron diferentes, la inmunoreactividad residual de los digeridos, los 
puntos de corte de las enzimas y los péptidos resultantes fueron muy similares. Los 
resultados de los análisis por microarray y dot blot mostraron que aLGunos de los 
péptidos resultantes de la digestión mantienen su capacidad alergénica. Siendo las áreas 
inmunorreactivas más destacadas, β-LG (43-65), β-LG (86-99) y β-LG (124-140) en el 
caso de la β-LG, β-CN (57-68) y β-CN (82-93) para β-CN y OVA (370-385) para OVA. 
Por otro lado también se estudió el efecto de los residuos de carbohidratos unidos 
al ovomucoide (OM), alérgeno inmunodominante del huevo, en su alergenicidad y 
digestibilidad. Se comprobó que tras la desglicosilación enzimática del OM, la proteína 
mantenía su estructura inalterada y 80% de los pacientes estudiados mostraron una menor 
capacidad de unión a IgE comparado con el OM glicosilado. Además, se demostró  la 
presencia de epítopos reactivos frente a IgE específicos para la proteína glicosilada. El 
OM desglicosilado fue más susceptible a la proteólisis durante la digestión pero el patrón 
peptídico resultante fue  muy parecido. La inmunorreactividad de los digeridos medida 
por ELISA de inhibición disminuyó hasta valores de entre el 1 y el 4% al final de la 
digestión pero algunos de los péptidos identificados demostraron mantener su capacidad 
de unión a IgE entre los que destacan el péptido OM (80-89) y las regiones OM (36-61), 
OM (100-122) y OM (133-180) que reaccionaron en el 40-100% de los pacientes 
ensayados. 
La última parte de  la tesis doctoral ha consistido en la identificación de los 
péptidos generados durante la digestión gastrointestinal in vitro de uno de los mayores 
alérgenos del huevo, la lisozima (LYS). Los resultados indicaron que los digeridos 
gástrico y duodenal mantenían su capacidad de unión a IgE y de activar basófilos. Esta 
actividad biológica podría ser atribuida a la presencia de LYS  intacta, al fragmento (24-
129) producido por la acción de la quimiotripsina o a la liberación durante la digestión de 
péptidos inmunorreactivos unidos por puentes disulfuro que contenían los epítopos LYS 
(57-83) y LYS (108-122).  
El hecho de que importantes epítopos lineales puedan ser liberados durante la 
digestión de la LYS llevó a estudiar el caso de un niño alérgico al huevo, que tolerando 
huevo después de un tratamiento de inmunoterapia, sufrió una fuerte reacción alérgica a 
un medicamento que contenía LYS  y papaína por lo que se planteó la hipótesis de que la 
presencia de papaína, podría incrementar el potencial alergénico de la LYS. Los 
resultados indicaron que la LYS tratada con papaína dio lugar a fragmentos con una alta 
capacidad de unión a IgE que fueron identificados como LYS (22-129), LYS (34-96) y 
LYS (62-128). Además estos fragmentos podrían permanecer unidos por puentes 
 disulfuro formando grandes estructuras que podrían tener una capacidad de unión a IgE 
aumentada. 
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11 Introduction 
1.1. FOOD ALLERGY OVERVIEW 
The newly created International collaboration in Asthma, Allergy and 
Immunology (iCAALL) defines food allergy as an "adverse health effect arising from a 
specific immune response that occurs reproducibly on exposure to a given food" (Boyce 
et al., 2010). This definition agrees with other international guidelines and encompasses 
immune responses that are IgE-mediated, non-IgE-mediated, or a combination of both 
(Sackeyfio et al., 2011; Urisu et al., 2011). IgE-mediated food allergy is believed to be 
responsible for most of the food induced hypersensitivity reactions and it is characterized 
by an acute onset of symptoms usually within 2 hours after ingestion or exposure to a 
food product. Those symptoms typically involve the skin (urticaria and angioedema), 
gastrointestinal tract (vomiting, diarrhea, abdominal pain), respiratory tract (asthma and 
rhinitis) and, in the most severe cases, they may result in a rapid and progressive systemic 
reaction involving multiple systems that might end up in a cardiovascular collapse 
(anaphylaxis) (Burks et al., 2012). Unfortunately, the current management of food allergy 
is limited to strict dietary avoidance, nutritional counselling and emergency treatment of 
adverse reactions. There have been attempts to desensitize patients with food allergy for 
more than 100 years (Schofield, 1908), however there are still no accepted therapies to 
accelerate the development of oral tolerance or to provide effective protection from 
unintentional exposures (Nowak-Wegzryn & Sampson, 2011). 
Briefly, allergic sensitization occurs when the allergen enters the body, typically 
through the mucous membranes, and it is taken by antigen presenting cells, which 
eventually trigger the differentiation of naïve allergen-specific T cells into Th2 cells. This 
is followed by the activation of B lymphocytes into IgE antibody-producing plasma cells. 
The specific-IgE antibodies bind to the surface of tissue mast cells and blood basophils so 
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that, on re-exposure to the food, antigenic proteins bind to and cross-link these cell 
surface-bound specific IgE antibodies, triggering the release of symptom-causing 
mediators, such as histamine and leukotrienes (Figure 1) (López-Expósito et al., 2013). 
Subjects can be allergically sensitized and produce specific-IgE to food allergens without 
having clinical symptoms of an allergic reaction on exposure. Thus, sensitization alone is 
not sufficient to define food allergy. There have to be specific signs and symptoms on 
exposure to the offending food together with a measurable food-specific IgE (Boyce et 
al., 2010). 
 
Figure 1. Schematic representation of the events leading to sensitization and allergic 
response. (López-Expósito et al., 2013). 
 
 
 
 
13 Introduction 
Nowadays the causes responsible for food allergies remain unknown, although it 
has been recognized that several environmental and mainly genetic factors might 
influence susceptibility to food allergy. The true prevalence of food allergy is difficult to 
establish because most prevalence studies differ in their design and in the definition of 
food allergy, or focus only on the most common foods (Boyce et al., 2010). The World 
Allergy Organization estimated the frequency of food allergy in 8% of children and 2% of 
adults (Sicherer et al., 2004; Pereira et al., 2005; Venter et al., 2008). However, there are 
wide variations in each country with respect to the most common food allergies, which 
suggests that, in addition to a significant genetic component to food allergy, there is also a 
significant contribution of local diet (Branum and Lukacs, 2009; Sicherer, 2011) as well 
as of other factors, such as the timing of first exposure, the performance of the digestive 
processes or the diversity of gut microbiota, many of which have not yet been identified 
(Berin, 2013).  
More than 170 foods are reported to cause food allergies, but only eight “the big 
8” (peanut, tree nuts, milk, egg, wheat, soy, fish and shellfish) account for 90% of all 
food-allergic reactions (Boyce et al., 2010), being egg and milk the most common 
offending foods in children from continental Europe (Rona et al., 2007). A meta-analysis 
involving double-blind placebo-controlled food challenges confirmed a varied prevalence 
from 0.2% to 7% of egg allergy and from 1.2% to 17% of milk allergy (Rona et al., 
2007). Egg and milk allergy mainly affect children below the age of three, and although 
most of them outgrow their allergy by the age of 16 years, a significant proportion of the 
population retains the allergy throughout life (Savage et al., 2007; Skaripak et al., 2007).  
Allergic reactions to egg and milk occur, sometimes, after the first known 
exposure to the food, therefore it has been speculated that they could be attributed to 
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uterine sensitization (Vance et al., 2005) or contact through breast milk (Denis et al., 
2012) but this theory is controversial. Other possible routes of sensitization are 
respiratory, due to inhalation of egg and milk particles in dust (Roberts and Lack, 2003), 
and cutaneous, described as bird-egg syndrome in some patients sensitized to egg through 
avian proteins, as alpha-livetin (Gal d 5), by contact with feathers or bird droppings 
(Nowak-Wegrzyn and Sampson, 2006). There are also cross-reactions between egg and 
chicken meat, among the proteins from egg white and yolk (Besler et al., 2001) and 
between eggs from different birds (Fox and Lack, 2003), as well as between milk from 
different species (Restani et al., 1999). However, the most common route of sensitization 
is through the gastrointestinal tract (Lehrer et al., 1996; Mills et al., 2003; Bannon, 2004). 
 
1.2. DIGESTION AND FOOD ALLERGY 
 1.2.1. Digestibility of food allergens 
Most relevant allergens are glycoproteins, soluble in water, with a molecular mass 
between 10 and 70 kDa, and stable to heat, acid and proteases. Only some regions of the 
proteins are recognized by the immune system. Such regions are called epitopes and can 
be linear (uninterrupted sequences of amino acids) or conformational (maintained due to 
the tertiary structure). Because of their stability against acids and proteases, digestive 
functionality and gut permeability are considerer key factors that may affect the allergenic 
potential (Lehrer et al., 1996) (Moreno, 2007). Moreover, although there are no molecular 
properties common to food allergens, stability to digestion is a shared feature among the 
allergenic food proteins (Metcalfe et al., 1996) (Taylor and Leher, 1996). The abundance 
in the food and the ability to develop a biological function and to maintain a stable 
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structure influence digestibility, bioavailability and the subsequent allergenicity of a 
protein.  
Most allergens such as casein (CN) from milk or ovalbumin from egg, represent 
between 20 to 80% of the total protein content of the food. Therefore it appears that 
allergenicity is related to the degree of exposure throught the gastrointestinal tract to a 
particular protein. However, it is remarkable that there are abundant proteins that are not 
allergens, indicating that the intrinsic immunogenicity of a protein is more important than 
the exposure dose (Taylor and Lehrer, 1996).  
It is difficult to establish a relationship between biological function and 
allergenicity but many allergenic proteins have a particular biological activity. Enzymes 
such as papain, with cysteine protease activity (Baur et al., 1982), or lysozyme with 
muramidase activity (Holen and Elsayed, 1996), are good examples, because they are 
relatively stable in hostile environments in order to carry out their duties efficiently. Other 
allergenic proteins exert transport, storage and ligand-binding functions. This is the case 
of β-LG, whose primary function appears to be the transport of retinol (Ball et al. 1994), 
which reduces the mobility of the protein peptide chain and gives rise to an increased 
resistance to heat treatment and digestion (Douliez et al., 2001).  
The mechanisms which confer a high integrity to protein structure may be 
important in the stability during digestion. Ovotransferrin and ovomucoid with fifteen and 
nine disulphide bridges respectively, or β-LG with a great tendency to adopt beta 
structures (Thompson and Eisenberg, 1999) are good examples of this. Other allergens 
such as CNs, unlike globular proteins which possess well-defined three-dimensional 
structures, contain large regions of disordered structure (Dunker et al., 2001). These 
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proteins, called reomorphic, not undergo an abrupt transition from one conformational 
state to another, but they adopt a dynamic set of secondary structures which are in 
equilibrium with each other and preserve stable potential epitopes (Holt and Sawyer, 
1993). Glycosylation can have a significant stabilizing effect on protein structure 
modifying the physical properties of the protein, altering its solubility, hydrophobicity 
and electric charge, among others, affecting their stability (Wormald, 1991) and exerting 
a protective effect against gastroduodenal digestion. It has been shown that N-
glycosylation can have a significant stabilizing effect on protein structure (wormald and 
Dwek, 1999) and there is evidence that it increases the stability of, for example, the 7S 
globulin of pea and its resistance to chemical denaturation (Pedrosa et al., 2000). 
Moreover, covalent modification of the proteins through Maillard reactions resulting in 
products that have been shown to destabilize the quaternary structure of proteins, such as 
reducing the stability at low pH of the triple helix of collagen (Breiteneder and Mills, 
2005). 
Other physicochemical features of the proteins could also influence their 
stability during digestion. The trend of some proteins to aggregate under physiological 
conditions, or as result of food processing, may increase their allergenicity (Chirino et al., 
2004), probably due to the presentation of multiple IgE epitopes, which may lead to 
histamine release with greater efficiency than soluble monomeric forms. In fact, it has 
been indicated that the aggregates with a molecular weight greater than 100 kDa are 
efficient inductors of the immune response (Rosenberg, 2006). Jiménez-Saiz et al. 
(2011b) found that lysozyme could aggregate and precipitate at pH values and surfactant 
concentrations typical of the duodenal medium helping it to resist digestion by pancreatic 
enzymes.  
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 1.2.2. Food processing 
Food processing can induce physical and chemical modifications to the proteins, 
such as aggregation or denaturation among others, affecting their structure and their 
resistance to digestive enzymes. For instance, it has been shown that β-LG resistance to 
digestive enzymes is reduced under heat treatment in a temperature-dependent manner 
(Ehn et al., 2004; Taheri-Kafrani et al., 2009; Morisawa et al., 2009). During processing, 
proteins can also interact with other components of the food matrix and consequently 
their allergenic properties, their digestibility or both can be modified (Teuber, 2002). 
Examples include protein- sugar interactions that occur during heating such as Maillard 
reaction (Gruber et al., 2004), or interactions with food lipids forming emulsions 
(Breiteneder and Mills, 2005). Corzo-Martínez et al. (2010) demonstrated that interaction 
with sugars induced by Maillard reaction protect β-LG during in vitro gastrointestinal 
digestion. On the other hand, Jiménez-Saiz et al. (2012) showed that the presence of egg 
proteins as part of an emulsion do not change their IgE binding, but it slightly increase the 
digestibility of the main allergens present in the egg-white. It has also been reported that 
the polymerization of chemically denatured β-LG facilitate the action of the 
gastrointestinal enzymes, and their digestion products present low antigenic properties 
(Villas-Boas et al., 2012). 
 
 1.2.3. Digestion parameters 
Proteins with the capacity to induce sensitization and elicitation of an allergic 
response must retain, after digestion, sufficient structural integrity to induce T-cell 
differentiation and IgE-mediated activation of effector cells (Polovic et al., 2007; Ruiter 
and Shreffler, 2012). In this regard, the degree of hydrolysis achieved during digestion, 
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determined to a great extent by the conditions of the digestive tract, defines the peptide 
fragments that interact with the intestinal mucosa where absorption occurs and their IgE 
binding and T-cell stimulating capacities. In this respect, when using in vitro models to 
simulate digestion, the choice of proteolytic enzymes, digestion conditions, and methods 
for the analysis of protein hydrolysates have a considerable impact on protein digestibility 
assessment.  
1.2.3.1. Enzymes 
Different enzymes with different functions are produced along the digestive tract 
but the most relevant to protein digestion studies are, without any doubt, proteinases and 
peptidases such us pepsin, trypsin, chymotrypsin and carboxypeptidases. It is difficult to 
know the amount of enzymes secreted under physiological conditions because there is a 
wide individual variation, and therefore it is not easy to choose an optimal enzyme to 
substrate ratio. It has been estimated that pepsin secretion in adults is between 20 and 30 
kUnits of enzyme activity/24 h at 37 °C whereas a typical adult dietary intake of protein 
could be estimated around 75 g/24 h (Moreno et al., 2005). These estimations clearly 
indicate that protein would normally exceed pepsin but it has been stated that pepsin in 
human gastric samples can vary over 10,000 fold (Moreno et al., 2007) and depending on 
the amounts used, the degradation of the protein will occur with to various extents (Fu et 
al., 2002). Due to the difficulty in obtaining human enzymes, bovine and porcine 
enzymes are mainly used. Thus, it is important to considerer differences in the specificity 
of the enzymes to be used in experimental models (Guillou et al., 1991). 
1.2.3.2. pH 
The pH is critical in gastrointestinal hydrolysis of proteins because it directly 
affects the degree of activity of the digestive enzymes. Pepsin activity is optimal at pHs 
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between 1.8 and 3.2 (Jensen-Jarolim, 2006) with any elevation in the pH having a 
negative effect on peptic degradation (Untersmayr and Jensen-Jarolim, 2006). The gastric 
pH can oscillate substantially depending on the age, (Koldovski, 1984) pre- or 
postprandial conditions or ingested food (Tyssandier et al., 2003). Adult stomach under 
fasting conditions presents a pH of about 2, but this value may increase to more than 4 
after the food intake (Tyssandier et al., 2003). In addition, the acidity of the stomach in 
children is much lower, with a pH value of about 4 (Schmidt et al., 1995). Extrinsic 
factors such as the consumption of antacids in patients in which the digestive process is 
compromised can enhance the pH found in the stomach increasing risk of sensitization to 
certain food allergen (Untersmayr et al., 2008). The pH of the intestine is also important 
because, it can also influence the activity of some enzymes (Hamosh et al., 1981), and 
although it has been described that may vary within the range 5-7 (Friend, 1991). The pH 
also modified protein structure and flexibility (Horng et al., 2003) and therefore, the 
digestibility pattern of the allergens (Moreno et al., 2005).  
1.2.3.3. Bile salts 
Bile is an alkaline solution consisting of water, hormones, pigments, electrolytes 
(Na
+
, K
+
, Ca
+
, Cl
-
, HCO3
-
) and lipids. Among lipids, the most important according to 
their abundance are bile salts (6-10%), phospholipids (95% phosphatidylcholine, PC) and 
cholesterol (0.5-5%). In the duodenal environment, these three lipids interact 
hydrophobically to form mixed micelles and liposomes, but phospholipids such as PC, is 
also secreted by the gastric mucosa, so are present in the stomach at an early stage of the 
digestion process. It has been shown that interactions between PC and proteins can impact 
on rates of digestion protecting or making the protein more susceptible against digestion. 
In this regard, it was shown that the low pH found in the stomach (pH 2.5) induced a 
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structural change in the α-LA to the molten globule state enabling it to penetrate the PC 
vesicles and this was thought to be the mechanism responsible for decreasing the rate of 
simulated gastric pepsinolysis (Moreno et al., 2005). In contrast, bile salts could bind into 
the hydrophobic pockets of the β-LG, which might destabilise the protein structure and 
made additional interior domains of the protein available for the protease action (Gass et 
al., 2007). 
1.2.3.4. Other factors 
Others factors, such as, gastric emptying time (McClements et al., 2009), ionic 
strength of the digestive fluids (Boisen and Eggum, 1991), mechanical stresses (Minekus 
et al., 1995) or substrate concentration (Boisen and Eggum, 1991) could also play an 
important role in the digestibility of proteins as well as the maturity of the gut and its 
healthy functioning. In this regard, it is important to take into account the conditions 
found in the immature gastrointestinal tract of infants. A model of infant gastrointestinal 
digestion, with pH between 3 and 4, an enzymes to substrates ratios lower than in the 
adult model and with reduced concentrations of PC and bile salts, should be used when 
the objective of the study is focus on infant digestion instead of using general conditions 
of digestion which reflect the mature adult digestive system. 
 
 1.2.4. Food digestion models 
In vivo research on food digestion is ethically and technically difficult and also 
expensive to perform. Therefore, in vitro digestion models have been developed over the 
years. Some models focus on one particular region of the gastrointestinal tract (Fu et al., 
2002; Jakobsson et al., 1982; Chatterton et al., 2004), whereas other models are 
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developed following a number of sequential steps (Moreno et al., 2005), usually gastric 
and duodenal. Moreover there are discrepancies between models in the kind and amount 
of enzymes used. One of the most broadly accepted models was described by Moreno et 
al. (2005) who used physiologically relevant conditions of digestion based on in vivo data 
obtained from gastric and duodenal aspirations. In this line there is an action granted by 
the European Cooperation in Science and Technology (COST) within the domain of food 
and agriculture, “Infogest”, which is trying to harmonise in vitro digestion methods in a 
unique static in vitro digestion model validated with available in vivo data.  
If the samples are solid the mechanical effect of the mouth could be crucial. 
Similarly, engineered in vitro dynamic models have been developed to mimic stomach 
contractions (Kong and Singh, 2010), peristaltic movements and intestinal flow (Spratt et 
al., 2005). In this regard, a complete artificial digestive system of the human upper 
gastrointestinal, including a food matrix as part of the design, has been patented by 
Mainville et al. (2005). In any case, and in order to mimic the physiological conditions of 
digestion, the characterization of human gastroduodenal juices (Ulleberg et al., 2011) is 
essential to develop an in vitro digestion model as close as possible to the in vivo 
conditions. In fact, results so far have demonstrated that proteins digested by human 
gastroduodenal juices produced different peptides as compared to those digesed with 
porcine digestive enzymes (Eriksen et al., 2010) highlighting the importance of a 
comparison between studies. 
The logical step after performing in vitro digestion models is to validate them 
against data collected in vivo. There are some digestion studies in humans collecting the 
gastric and duodenal effluents after ingestion of food (Mahé et al., 1991; Mahé et al., 
1996; Kuwata et al., 1998; Furlund et al., 2012), but the results so far are controversial. 
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Because of the difficulty and expense associated with human fluids, several animal 
models such as piglets (Bouzerzour et al., 2012), calves (Scanff et al., 1992), mice (Joo 
and Kato, 2006) or rats (Kitabatake and Kinekawa, 1998) are an alternative to human 
digestibility studies. 
Another approach to the study of digestibility is based on in silico methods (Pal et 
al 2004; Ferrua and Singh, 2010). Jiang et al. (2007) performed a computational analysis 
of the relationship between allergenicity and digestibility. Food allergen data were 
obtained from a structural database of allergenic proteins and were subjected to a virtual 
digestion using two proteolytic enzymes present in human stomach during the digestion. 
They concluded that according to their in silico resistance to digestion, the allergens could 
be classified into two groups according their pathway for sensitization, gastrointestinal 
tract sensitizing and non-gastrointestinal tract sensitizing allergens, being the former 
relatively resistant to gastric fluid digestion while the later are relatively labile. A recent 
study, tried to found descriptors of intestinal stability. For that, 228 dipeptides were 
synthesized and their intestinal stability was obtained by in vitro digestion. Database were 
constructed to study the relationship between structure and stability showing the N-
terminal residues Asp, Gly, and Pro as well as the C-terminal Pro, Ser, Thr, and Asp as 
peptide stabilizing factors (Foltz et al., 2009). Computational simulation has the potential 
to substitute manual experiments but despite the advances made to date, more research 
and validation with real data are needed to develop an accurate in silico digestion model. 
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1.3. EFFECT OF GASTROINTESTINAL DIGESTION ON THE 
ALLERGENICITY OF MILK AND EGG PROTEINS  
To date, there are several studies about digestibility of allergenic proteins, but 
establishing a comparison of the results is difficult because most of them employ different 
models of digestion with different enzymes, conditions and enzyme to substrate 
relationships. In addition, only a few of the published studies try to find a correlation 
between the hydrolysis products and the allergic response. This section of the 
introduction will review the main research carried out regarding the digestibility of milk 
and egg allergens. Results regarding protein degradation, models employed and 
immunoreactivity of the resultant products will be discussed. 
 
 1.3.1. Milk proteins 
Cow's milk contains between 3-3.5% proteins and includes approximately 20 
different proteins that may be involved in allergic sensitization (Herz, 2008). Milk 
proteins are classified as caseins (CNs, Bos d8), which constitute 80% of the total milk 
proteins and they are described as the most allergenic ones, and whey proteins (Monaci et 
al., 2006), being β-lactoglobulin (Bos d 5) and α-lactalbumin (Bos d 4) the major 
allergens from this fraction (Table 1). 
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Table 1. Main proteins in bovine milk. 
Milk Proteins 
% of total 
protein content 
Concentration 
in milk (g/L) 
Whey proteins 20  
    β-lactoglobulin 10 3-4 
    α-lactalbumin 5 1-1.5 
    Immunoglobulin 3 0.6-1 
    Bovine serum albumin 1 0.1-0.4 
    Lactoferrin Traces 0.09 
Whole Casein 80  
    αS1-Casein 32 12-15 
    αS2-Casein 10 3-4 
    β-Casein 28 9-11 
    κ-Casein 10 3-4 
 
 
1.3.1.1. Caseins 
CNs are considered the most allergenic proteins in milk, as it was demonstrated by 
Shek et al. (2005) who reported that patients with IgE-mediated cow´s milk allergy had 
higher specific IgE concentrations to casein compared with whey proteins. Because of 
that, a number of studies regarding the digestibility and allergenicity of the different 
casein types (β-, κ- and αs-CN) have been carried out. Resistance to pepsinolysis of β-CN, 
one of the most immunoreactive fractions, was tested using different enzymatic sources 
and different pHs, such as porcine pepsin at pHs ranging from 1.2 to 3.0 (Mandalari et al., 
2009a; Dupont et al., 2010a), and human gastric fluid at pHs from 2 to 6.5 (Jakobsson et 
al., 1982; Chatterton et al., 2004). All those experiments agreed to conclude that β-CN 
was easily degraded by pepsin. Some differences were detected by Dupont et al. (2010a) 
when they compared an infant gastric digestion model at pH 3, with an adult model at pH 
2.5. They observed that bovine β-CN was digested more slowly in the infant model, not 
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only due to the higher pH but also to a 8-fold reduction in pepsin concentration. 
Furthermore, changes in the hydrophobicity of β-CN at pH 3.0 might contribute to its 
resistance to pepsinolysis. Using human gastric fluid, Chatterton et al. (2004) observed 
that bovine β-CN, as part of a whey protein concentrate, and human β-CN were 
completely degraded by human gastric juice at pH levels lower than 4. This fact is 
remarkable because gastric pH is not expected to fall below 4.0 in healthy term infants 
(Mason, 1962). However, αs1-CN was particularly resistant to the effects of gastric 
proteases even at pH 2.0. On the contrary, Fu et al. (2002) reported that αs-CN was 
completely degraded after 1 min of porcine pepsin digestion, but probably because of a 
higher ratio of pepsin to protein was used, which was about 13:1 (w:w), and to the pH 
1.2. In vivo studies have been reported by Mahé et al. (1991) showing the presence of 
intact CN in gastric aspirates collected 1 hour after drinking skim milk, probably because 
of the high pH measured of the effluents, with values between 4 and 6 during the 
digestion process. 
A crucial information to take into account when evaluating the digestibility and 
allergenicity of food proteins is the matrix effect. Macierzanka et al. (2009) compared β-
CN gastric digestion when the protein was presented in solution or as part of an emulsion. 
The authors found that digestion of β-CN was faster when presented as an emulsion, 
suggesting that there were changes in the adsorved β-CN conformation that allowed 
pepsin to cleave the protein more effectively than in solution. Moreover, when they 
studied the effect of the inclusion of PC in the digestion model, they observed that when 
the protein was in solution, the kinetics of pepsinolysis was not affected, but when β-CN 
was in an olive oil-in-water emulsion the digestion rate was reduced because PC 
displaced the protein from the oil droplet surface so that gastric digestion mainly take 
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place in solution. Similarly, Dupont et al. (2010a) did not report a significant effect of PC 
on gastric hydrolysis of β-CN in solution. 
CNs are also susceptible to hydrolysis by duodenal enzymes as it was 
demonstrated by Mandalari et al. (2009a) and Jakobson et al. (1982) when β-CN was 
directly digested with pancreatin and human duodenal fluid respectively, without a 
previous gastric stage. αs-CN was also easily digested by duodenal enzymes (Fu et al., 
2002). There are a few studies dealing with gastric digestion of β-CN followed by a 
duodenal stage (Macierzanka et al., 2009; Mandalari et al., 2009a; Dupont et al., 2010a; 
Dupont et al., 2010b; Alessandri et al., 2012). As expected, intact β-CN was not found at 
the end of the complete gastrointestinal digestion despite the use of different matrixes, 
pHs and enzyme concentrations in the different studies. Similar results were reported for 
κ-CN (Dupont  et al., 2010b), αs-CN (Morisawa et al., 2009) and β-CN with the use of 
human gastric and duodenal fluids (Jakobsson et al., 1982). Although the previously 
described studies have investigated different aspects of β-CN digestion, the residual IgE-
binding or the presence of IgE epitopes in the digestion products has not been evaluated. 
 
1.3.1.2. β-lactoglobulin 
Most of the available in vitro studies on digestibility of bovine β-LG use porcine 
pepsin in the simulated gastric phase, but they differ in the pepsin:β-LG ratio used. 
However, results agree that native bovine β-LG is highly resistant to peptidic digestion, 
although they differ on the percentage of intact protein remaining after pepsinolysis with 
values from 68% (Bossios et al., 2011) to 100% (Mandalari et al., 2009a), possibly 
because between both studies there is a difference in the concentration of pepsin of 19-
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fold. This resistance is probably due to its special folding forming a β-barrel core 
structure where the cleavage sites of pepsin could be located (Dalgalarrondo et al., 1995). 
In addition, variant B has been shown to be more resistant than A against pepsinolysis (Fu 
et al., 2002). Pepsinolysis resistance is also dependent of the β-LG species as it has been 
demonstrated that caprine β-LG is easily digested than bovine B-LG (Almaas et al., 
2006a). 
It has also been demonstrated that bovine β-LG could not be hydrolysed by human 
pepsin when human gastric fluid was used (Chatterton et al., 2004; Jakobsson et al. 1982; 
Almaas et al., 2006b) but this fact was problably because they used a low amount of fluid 
to performed the digestion of a high concentration of protein and therefore the enzyme to 
substrate ratio employed was very low. 
β-LG has also shown to be resistant to human pepsin when it is involved in skim 
cow milk (Almaas et al., 2006a), whey protein concentrate (Chatterton et al. 2004) or 
phosphate buffer (Jakobsson et al. 1982) and to porcine pepsin in whey protein isolated 
(Kitabatake and Kinekawa, 1998), simulated gastric fluid (Herman et al. 2007), water-
soluble cheese extracts (Alessandri et al., 2012), olive oil-in-water emulsion 
(Macierzanka et al., 2009) or water (Morisawa et al., 2009). Jakobsson et al. (1982) 
showed that the hydrolysis of β-LG occurred at a slower rate when it was in bovine milk 
or in infant formula than when it was in a purified form, althogh this effect was probably 
due to the buffer capacity of milk which have an impact on the enzymatic activity, 
alkalinizing the medium and leaving the pepsin away from its optimum pH.  
Mandalari et al. (2009b) reported that the addition of PC did not affect the 
resistance of β-LG to gastric pepsinolysis and Macierzanka et al. (2009) studied the 
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combined effect of matrix and PC in digestion of β-LG showing that when the protein 
was in an olive oil-in-water emulsion, the presence of PC retarded hydrolysis compared 
with digestion without PC. It has been suggested that a lipid-induced β to α transition in 
the secondary structure of β-LG is accompanied by substantial disruption in tertiary 
structure, which is mainly driven by strong electrostatic interactions (Zhang et al., 2007). 
Once the tightly packed β-Lg is disrupted, hydrophobic residues could become exposed 
and available for insertion into a lipid bilayer, where hydrophobic interaction with the 
lipids may play a role in stabilizing the helical components. This could be the mechanism 
that provides protection against digestion in solution through the simulated duodenal 
digestion (Macierzanka et al., 2009). 
Several studies have shown that β-LG is more sensitive to duodenal enzymes than 
gastric enzymes. β-LG has been directly hydrolysed with duodenal enzymes resulting in 
no detection of intact protein after 60 min of digestion with enzymes from human 
(Jakobsson et al., 1982), pig (Kitabatake and Kinekawa, 1998, Fu et al., 2002) or rat 
(Kitabatake and Kinekawa, 1998) origin. Other studies, although differing in the digestion 
model applied, used a combination of both phases (gastric followed by duodenal stage) 
and coincided on the fact that β-LG is degraded in the duodenal stage although they 
differed in the degree of hydrolysis achieved, with values ranging from complete 
hydrolysis (Macierzanka et al., 2009) to 3% (Bossios et al., 2011) or 72% intact protein 
(Dupont et al., 2010a). 
It has been shown that other components present in the digestion media as bile 
salts may also have an influence in the results. In this sense, Gass et al. (2007) 
demonstrated that the addition of a bile acid mixture significantly enhance the digestion 
of β-LG by trypsin and chymotrypsin. In contrast, β-LG was significantly protected from 
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simulated duodenal digestion as a result of complex formed with the PC (Macierzanka et 
al., 2009). This is the reason why β-LG is most extensively degraded in infant models as 
compare with adult models which contains a ten-fold concentration of PC (Dupont et al., 
2010a). 
To date, there are only a few studies assessing the immunological potential of β-
LG digestion products (Table 2). In addition, and although it can be assumed that there is 
a relationship between resistance to digestive enzymes and allergenicity of β-LG, in most 
of these studies there is a lack of correlation between digestibility and allergenicity. 
There are also some in vivo studies about β-LG digestion showing very similar 
results. Scanff et al. (1990) used preruminant calves to observe the gastric digestion of 
raw milk, pasteurized milk and yogurt and in the three matrices studied, β-LG was 
resistant to proteolysis. The same results were obtained by Mahé et al. (1991) in the 
stomach of human adults with jejunostomy after 30 min of skimmed milk ingestion and 
by Kitabatake and Kinekawa (1998) using rats as a model. Bouzerzour et al. (2012) used 
piglet as a model of the newborn child where piglets were fed infant formula by an 
automatic delivery system during 28 d, and slaughtered 30, 90 and 210 min after the last 
meal. Contents of stomach, proximal and median jejunum and ileum were collected and 
characterised and the results indicated that β-LG partially resisted gastric digestion but 
completely disappeared in the stomach after 210 min, probably because the pH of 
stomach contents did not drop below 4 until 210 min after meal ingestion. Moreover, they 
observed that β-LG exhibited about 45% of residual IgE binding in the samples collected 
after 30 min in the stomach, values close to zero after 120 min and completely 
disappeared in the samples from jejunum and ileum.  
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Alessandri et al. (2012) observed no effect on the reactivity against IgE of both 
bovine β-LG variants, A and B, after gastric digestion of water-soluble extracts of 
Parmigiano-Regiano of three different maturation stages with porcine pepsin, and a little 
reduction of the IgE inhibition capacity after a complete simulated gastroduodenal 
digestion. In addition to IgE binding assays, basophil activation and in vitro proliferation 
test of sensitized PBMCs were used by Bossios et al. (2011) to quantify the residual 
immunoreactivity of β-LG after digestion. Their results indicated that IgE binding 
capacity of β-LG was not modified after gastroduodenal digestion in the presence of PC 
but it was reduced when digestion performed in the absence of PC, in agreement with the 
higher quantity of intact β-LG remaining in the digests. Overall both gastric and 
gastroduodenal digestion enhanced activation of sensitized basophils and proliferation of 
sensitized lymphocytes by β-LG. 
 
.
  
 
Table 2. Digestibility and immunogenicity of native β-LG after an in vitro digestion model using porcine and bovine enzymes.  
 
NQ: unquantified. SGF: Simulated gastric fluid. G: Gastric phase. D: Duodenal phase. PBMCs: Peripheral blood mononuclear cells. 
 
enzymes Ratio E:S Surfactant pH
time 
(min)
Intact 
protein 
enzymes Ratio E:S Bile salts pH time (min)
Intact 
protein 
Alessandri et al. 
(2012)
β-LG A
Cheese water soluble 
extracts
pepsin 1:100 (v:v) - 2.2 180 - trypsin and chymotrypsin   1:100 (v:v) - 7.5 240 - IgE binding 100%
Alessandri et al. 
(2012)
β-LG B
Cheese water soluble 
extracts
pepsin 1:100 (v:v) - 2.2 180 - trypsin and chymotrypsin   1:100 (v:v) - 7.5 240 - IgE binding 100%
Morisawa et al. 
(2009)
β-LG           
(A and B)
water pepsin 1% (v:v) - 3 90 YES (NQ) trypsin                                1% (v:v) - - 60 YES (NQ) Histamine release assay 11-85%
porcine pancreatic lipase 0.1% (w:v)   IgE binding    G: = /  D ↓       
porcine colipase 0.055% (w:v) Basophil Activation  ↑
β-lg;trypsin:chymotrypsin 400:4:1 (w:w:w) PBMC proliferation  ↑
porcine pancreatic lipase 0.1% (w:v)   IgE binding    G =, D =       
porcine colipase 0.055% (w:v) Basophil Activation  ↑
β-lg;trypsin:chymotrypsin 400:4:1 (w:w:w) PBMC proliferation  ↑
Results 
Immunologic 
assays 
Gastric Duodenal
Reference Protein Presentation
Digestion phase
Immunologic 
assays
60 3%Bossios et al. (2011)
β-LG           
(A and B)
SGF pepsin 3500 U / mg - 2.5
PC
60 70% 7.4 mM Bile salts 6.5
Bossios et al. (2011)
β-LG           
(A and B)
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1.3.1.3. α-lactalbumin 
Regarding α-LA, the second most prevalent protein in bovine whey, Fu et al. 
(2002) showed it was rapidly degraded by pepsin to protein ratio of 13:1 (w:w) in SGF at 
pH 1.2 and no intact protein was detected after one min of digestion. Contrary to β-LG, α-
LA seems to be more resistant to duodenal rather than to gastric enzymes as it was 
demonstrated by Fu et al. (2002). They submitted the protein to digestion with corolase 
PP
®
, a mixture of enzymes from porcine pancreas containing the pancreatic 
endopeptidases trypsin and chymotrypsin and various exopeptidases, and found that it 
was able to resist digestion for 15 min. 
There are very few reports on the complete digestion of α-LA by both gastric and 
duodenal enzymes and there are even less studies showing the immunoreactivity and 
characterization of the resultant peptides. Moreno et al. (2005) carried out the digestion of 
α-LA using a physiologically relevant model that took into account the presence of 
physiological surfactants found in both milk and in the environment of the gastrointestinal 
tract. They showed that the interaction between PC and α-LA at gastric pH was strong 
enough to retard the breakdown of the α-LA during the digestion, with traces of the 
protein partially trimmed still evident after 1 h of digestion, while it was completely 
degraded in a similar model without PC. They also indicated that PC altered the 
fragmentation pattern of α-LA, probably because the partially unfolded state of the 
protein adopted at the acid pH of the stomach promotes the interaction between the 
hydrophobic residues of the protein and the alkyl chains of PC (Hanssens et al.,1985), 
hindering the access of pepsin to the cleavage sites. At the end of the duodenal stage no 
intact protein was detected either, with or without PC (Moreno et al., 2005). A high 
sensitivity to pepsinolysis has also been described by Jakobsson et al. (1982) when α-LA 
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was treated with human gastric fluid. In contrast, Chatterton et al. (2004) found intact 
protein after 1 hour of digestion of whey protein concentrate with human gastric fluid, 
probably due to the use of a low enzyme/substrate ratio. In vivo studies performed by 
Mahé et al. (1991) found 44% of intact α-LA in the stomach of human adults with 
jejunostomy 60 min after drinking skimmed milk, probably due to a higher pH in the 
stomach induced by the buffering capacity of milk.  
In terms of immunoreactivity of the resultant products of digestion of α-LA, there 
are hardly any studies on the subject. Alessandri et al. (2012) observed that after gastric 
and duodenal simulated digestion, the IgE binding capacity of α-LA from ripened cheese 
water soluble extracts remained almost intact.  
 
1.3.1.4. Minor whey proteins 
Lactoferrin (LF) is a minor component of milk, and allergic reactions caused by 
LF are infrequent. Therefore, although it has been shown that possesses allergenic sites 
that may qualify it to be an allergen (Sharma et al., 2001) few studies have evaluated its 
allergenicity. However, and due to the high antibacterial activity of LF (López-Exposito 
and Recio 2006), several studies have evaluated its digestibility. Reports are contradictory 
with regard to the resistance of LF to hydrolysis by various commercial enzymes 
(Gonzalez-Chavez et al., 2009). Furlund et al. (2013) demonstrated that the in vitro 
hydrolysis of LF with pepsin, as it is the case of other milk proteins, is strongly pH 
dependent. They adjusted the pH of human gastric fluid either slowly or rapidly to 2.5 or 
4.0 at the end of digestion and observed that a fast pH reduction to 2.5 resulted in a 
complete degradation in the gastric step, but a slow reduction to 2.5 or 4.0 resulted in an 
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incomplete degradation in the gastric step, and as a result in a delayed duodenal digestion. 
This pH dependence could be attributable to the different conformation of the protein at 
pH 4 or to the fact that pepsin is not fully active (Sreedhara et al., 2010). The results were 
compared with in vivo digestion of LF performed in 2 volunteers showing a complete 
hydrolysis of the protein but the authors attribute this difference to a low concentration of 
enzyme in the in vitro system used compared with that in vivo. In contrast, the in vivo 
gastric resistance of LF was reported previously by Troost et al. (2001). They tested the 
digestion of a drink containing LF in 12 healthy volunteers and the gastric survival ranged 
between 62% and 79%.  
There are few studies about digestibility of other minor milk proteins such as 
BSA. Some authors demonstrated that BSA was very susceptible to pepsinolysis when 
porcine pepsin at pH 1.2 was used to carry the digestion (Fu et al., 2002; Herman et al. 
2007). However, when human gastric fluids were used, pepsinolysis reported to be pH 
dependent. Chatterton et al. (2004) found intact amount of these protein when gastric 
digestion was performed at pH higher than 4 and complete degradation was observed 
only at lower pHs. IgE binding of products of digestion of BSA have been reported to 
decrease compare with native protein (Alessandri et al., 2012) but there are very few 
reports in the literature about the digestibility and allergenicity of these minor proteins 
making it difficult to draw any conclusions. 
 
 1.3.2 Egg proteins 
Egg white is the main source of allergens in egg. Four proteins, ovalbumin (55%), 
ovomucoid (11%), ovotransferrin (12%) and lysozyme (3%), named from Gal d 1 to Gal 
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d 4, have been identified as the major ones. Besides, other minor proteins such as 
ovomucin, ovoflavoprotein, avidin and ovoinhibitor have also been identified. The yolk 
has various proteins such as apovitelines, phosvitins and livetins which may also be 
allergenic, although to a lesser extent (Mine and Yang, 2008). 
 
1.3.2.1. Ovalbumin 
Several studies have evaluated OVA resistance against pepsinolysis, and even 
when very different enzyme to protein ratios were used, the results coincide that OVA is a 
protein very stable to pepsin action (Fuchs and Astwood, 1996; Dearman et al., 2002; Fu 
et al., 2002; Takagi et al., 2003; Thomas et al., 2004). Using a ratio that would resemble a 
physiological situation, 182 U/mg, the main degradation products were two hydrolysis 
fragments of 40.1, corresponding to Ala23-Pro385, and 4.1 kDa (López-Expósito et al., 
2008; Martos et al., 2010), in agreement with digestion patterns previously described 
using different enzyme to protein ratios (Dearman et al., 2002; Thomas et al., 2004; 
Quirós et al., 2007; Takagi et al., 2003). Martos et al. (2010) went a step further and 
studied the effect of different gastric pHs (1.2, 2 and 3.2) on the hydrolysis of OVA with 
pepsin showing that the hydrolysis was much faster at the lowest pH. Moreover, they 
showed that the susceptibility to pepsinolysis of OVA was unmodified when PC was 
included in in vitro digestion because OVA has not enough flexibility to penetrate into PC 
vesicles as it has been demonstrated that OVA assumes a highly ordered molten-globule 
conformation at pH 2.2 which confer it a high degree of conformational stability (Tatsumi 
et al., 1999).  
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Under duodenal conditions, OVA was prone to digestion with pancreatin (Takagi 
et al., 2003), but in contrast, when physiological conditions were used, OVA and the 
previously described hydrolysis product of 40.1 kDa were very resistant to pancreatic 
enzymes, persisting for 120 min (Takagi et al., 2003; Martos et al., 2010). In presence of 
PC and bile salts, OVA and the large fragment of 40.1 kDa generated after pepsin 
digestion were more sensitive to proteolytic degradation, probably due to the association 
of the protein with the surfactants, increasing the exposure of the protein to pancreatic 
proteinases (Martos et al., 2010). A similar enhancement of hydrolysis in presence of bile 
salts was previously described by Gass et al. (2007) when β-LG digestion was performed 
probably through the destabilization of its tertiary structure. Bile salts could bind into the 
hydrophobic pockets of the protein molecule, which might destabilise the protein 
structure and made additional interior domains of the protein available for the protease 
action. 
Martos et al. (2010) reported a correlation between digestibility and allergenicity 
of OVA, showing that the immunoreactivity against IgE was retained after in vitro gastric 
digestion, especially due to the 40.1 kDa fragment, decreasing considerably after in vitro 
duodenal digestion. Nevertheless, the residual IgE binding response after the duodenal 
stage suggested the presence of peptides containing intact binding sites recognizable by 
serum IgE. 
During the storage of eggs, OVA is converted into a more heat stable form called 
S-OVA with a lower reactivity against IgE than native OVA (Jiménez-Saiz et al., 2012). 
S-OVA was more resistant to in vitro digestion under physiological conditions, possibly 
as a result of the structural changes associated to the transition of OVA into S-OVA that 
provide S-OVA with greater stability (Huntington and Stein, 2001). Despite the lower 
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IgE-binding of S-OVA, this difference was minimized after simulated gastrointestinal 
digestion, so that the duodenal digests of OVA and S-OVA formed in vitro showed a 
reduced but comparable reactivity towards IgE due to the similarity in their duodenal 
digestion patterns (Jiménez-Saiz et al., 2012).  
Similarly, Maillard reaction of OVA with glucose reduced its IgE-binding but this 
effect was counteracted by a reduction of digestibility of the protein induced by glycation, 
therefore the gastroduodenal digests of glycated ovalbumin showed a similar reactivity to 
the digests of the native protein (Jiménez-Saiz et al., 2011a). In contrast, when OVA was 
mixed with pectin, gum arabic and xylan, functional biopolymers commonly used in the 
food industry, the reactivity towards human IgE was considerably increased as well as the 
resistance to digestion (Jiménez-Saiz et al., 2013). Polovic et al. (2009) reported the 
existence of a protective matrix effect on the digestion as polysaccharides. Gels can 
provide a physical obstacle to the mobility of enzymes and substrates. Similarly, OVA 
attached to palmitoyl residues has also been reported to remain longer in the stomach 
when compared with native OVA (Oliveira et al., 2007). These results underline the 
importance of the food matrix in both the digestibility and the potential ability to trigger 
an immune response of OVA. In this regard, Martos et al. (2013) investigated the 
existence of matrix effects on the proteolytic stability and resultant IgE-binding of egg 
allergenic proteins. The presence of egg yolk slightly increased the susceptibility to 
digestion of OVA, but the gastric and duodenal digests had comparable IgE-binding 
capacities. On the other hand, Jiménez-Saiz et al. (2012) showed that the presence of 
OVA as part of an emulsion, increased its digestibility resulting in a slightly lower IgE-
binding capacity of the in vitro gastric and duodenal digests compared to those obtained 
from the protein in solution. 
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1.3.2.2. Ovomucoid 
Ovomucoid (OM) is a protein highly sensitive to proteolytic degradation. Kovacs-
Nolan et al. (2000) reported a rapid degradation of OM during in vitro gastric digestion 
with the formation of large fragments exhibiting reduced IgE-binding activity as 
compared with the native protein. Little changes in the digestion pattern were observed 
during the duodenal phase, probably because the peptides released by pepsin action retain 
trypsin inhibitory activity that helps to maintain OM peptide fragment integrity. A later 
study demonstrated that after in vitro gastric and duodenal digestions, the 
immunoreactivity of OM towards IgE from egg-allergic patients was reduced to a great 
extent (Jiménez-Saiz et al., 2011a) although it still maintained residual IgE binding in 
accordance with previous findings (Matsuda et al., 1985; Takagi et al., 2005). Moreover it 
has been showed that in vitro digested OM has a diminished basophil activation capacity 
when compared with the intact protein (Martos et al., 2011). 
Chemical modifications could affect the structure of OM modifying its 
susceptibility to gastrointestinal digestion. Kovacs-Nolan et al. (2000) showed that 
reducing the disulphide bonds in OM enhanced its digestibility and decreased its 
allergenicity in vitro (Kovacs-Nolan et al., 2000). On the contrary, it has been shown that 
Maillard reaction with glucose did not affect the digestibility of OM, although it increased 
the immunoreactivity with respect to the intact protein (Jiménez-Saiz et al., 2011a). 
 
1.3.2.3. Lysozyme 
The information available related to the behaviour of lysozyme (LYS) towards 
gastrointestinal digestion is limited and sometimes contradictory due to the employment 
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of different digestion models. Mine et al. (2004) reported the complete hydrolysis of LYS 
after 60 min of treatment with pepsin at pH 1.0, while other authors reported that LYS is 
resistant to pepsin action (Fu et al., 2002; Polverino de Laureto et al., 2002). Ibrahim et 
al., (2005) found up to 60% of intact protein after 120 min of digestion with pepsin at pH 
4. Later experiments carried out by Jiménez-Saiz et al. (2011b) using physiological 
conditions showed that in vitro gastric digestion of LYS was extremely pH dependent and 
at values equal to or higher than 3.2, there was no hydrolysis of the protein, even at pH 2 
intact protein was still found at the end of the gastric phase. LYS was only completely 
degraded at pH 1.2. The presence of 4 disulphide bonds in the structure of LYS provided 
a great stability to the protein and the presence of PC, slightly increased LYS resistance to 
digestion (Jiménez-Saiz et al., 2011b), likely due to the association between LYS and PC 
films (Mudgil et al., 2006).  
LYS may also be resistant to trypsin and chymotrypsin hydrolysis or just slightly 
hydrolysed, as it has been reported by During et al., (1999) and Mine et al., (2004) 
respectively. This resistance could be enhance due to the precipitation of LYS in the 
presence of bile salts impairing its hydrolysis by duodenal enzymes (Jiménez-Saiz et al., 
2011b). Probably, precipitation of LYS is caused due to an electrostatic interaction with 
negatively charged bile salts at pH 6.5 (Jiménez-Saiz et al., 2011b). Therefore, in a 
duodenal environment, intact LYS could be absorbed, as it has been demonstrated by 
Takano et al. (2004), with the possibility of eliciting and allergic reaction. On the other 
hand, the presence of PC partially avoided LYS precipitation (Jiménez-Saiz et al., 2011b), 
suggesting a positive effect on solubilisation of the mixed bile salt-PC micelles present in 
the duodenal medium (Mandalari et al., 2009). 
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A matrix effect has also observed by Jiménez-Saiz et al. (2012), who described a 
high resistance of LYS to hydrolysis by pepsin when it was included in egg solution 
rather than in egg emulsion, probably because of a higher exposure of the protein to the 
enzyme. 
Regarding to immunoreactivity of the products generated during digestion, 
Jiménez-Saiz et al. (2011b) reported that gastric digests of LYS showed high IgE-binding 
capacity using sera from egg-allergic patients but there is no more available information 
in the literature related to this issue. 
 
1.4. FUTURE PROSPECTS 
Significant progress has been made in the study of digestibility and allergenicity 
of food proteins. A multitude of methods of different complexity, biological significance 
and requirements now exist to increase knowledge in this topic. However, some questions 
such as if in vitro digestibility is a good predictive tool for the evaluation of protein 
allergenicity, or which digestion model should be used, remain unresolved. Any factor 
that potentially affects protein digestibility could modify the proteolysis pattern of a 
protein during the digestion process and therefore change its capacity to induce or trigger 
an allergic reaction. This fact highlights the need to establish standardized assay 
conditions, so that digestibility results can be compared between different studies. Also, 
criteria need to be established to relate in vitro digestibility to allergenic potential. Ideally, 
the combination of immunological assays, such as IgE binding capacity, with in vitro 
gastrointestinal digestion models simulating physiological conditions must be required to 
study the potential allergenicity of food proteins. More research is needed to understand 
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the underlying mechanism of food allergy and to understand the relationship between 
protein digestibility and allergenicity. 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
2. OBJECTIVES 
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Cow’s milk allergy is defined as an immunologically mediated adverse reaction to 
cow’s milk protein and it is usually the first food allergy identified in childhood. With an 
incidence that ranges from 1.2 to 17% in population-based studies in different countries, 
allergy to cow’s milk often precedes the development of other IgE-mediated allergies. 
Although most children outgrow cow’s milk allergy by the age of 4 years, a significant 
proportion of the population retains the allergy throughout life. Similarly, egg allergy is 
one of the most frequent food allergies in children below the age of three, with common 
symptoms frequently involving the skin as well as the gut and, in more severe cases, 
anaphylaxis. A meta-analysis of double-blind placebo-controlled food challenges 
confirmed a prevalence between 0.2 and 7%, with most children not outgrowing their egg 
allergy by school age but, instead, showing a long progression to egg allergy resolution. 
 One of the main aspects to consider when evaluating the allergenic potential of 
food proteins is the effect of gastrointestinal digestion. It is known that allergens are 
usually able to survive the harsh acidic environment of the stomach, tolerate the presence 
of surfactants and resist digestion by gastrointestinal enzymes, in order to reach the gut 
associated lymphoid tissue. They might also be digested into high molecular weight 
peptide fragments, which retain the same, or sometimes increased, IgE binding and T-cell 
stimulating capacities. So far, the studies investigating the gastrointestinal stability of the 
main food allergens have been performed in vitro by the use of enzymes of bovine or 
porcine origin as part of different digestion models, ranging from simple one-step 
hydrolyses, to advanced physiologically relevant systems where subsequent gastric and 
duodenal digestions are conducted under conditions that mimic the in vivo processes in 
infants and adults. These latter studies have highlighted the effect that the enzyme to 
substrate ratio, pH and concentration of physiological surfactants, such as 
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phospatidylcholine and bile salts, exert on the gastrointestinal stability of OVA and their 
influence in the resulting immunoreactivity of the digests. However, these relevant 
parameters regarding digestion, such as enzyme activity, volume of digestive juices 
secreted, pH or surfactants level, vary widely among individuals and also with the type 
and amount of food ingested and the time of the day, making in vivo conditions very 
difficult to simulate. In addition, human gastrointestinal juices contain complex mixtures 
of enzymes which could present either broader or different specificities or vary in their 
functional parameters with respect to purified commercial enzymes from animal sources. 
Given the importance of the resistance of food proteins to gastrointestinal 
digestion in their capacity to modulate the immune response, the aim of this work was to 
compare the digestibility of β-CN, β-LG and OVA, considered relevant cow’s milk and 
egg allergens, in two different in vitro systems using simulated and human fluids, and to 
assess the immunochemical properties of the resulting digests. To this aim, the products 
of protein digestion in both systems were identified by RP-HPLC-MS/MS and the IgE 
binding epitopes were characterized. In addition, the influence of gastrointestinal 
digestion on the immunological properties was further assessed in two major allergens of 
egg white: OM and LYS. In the first case, particular attention was paid to elucidate the 
role of the carbohydrate moieties of OM in its allergenic properties. In the second case, 
and since no relevant LYS IgE-binding epitopes had been previously reported, it was 
attempted to identify the main LYS IgE-binding areas following proteolysis, either 
mimicking gastrointestinal digestion or with papain, which is used together with LYS in 
LYS-containing drugs.  
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3.1. MATERIALS 
 3.1.1. Proteins 
β-CN (EC 232-555-1) and β-LG (EC 232.928.9) from bovine milk and OVA (EC 
232-692-7), OM (EC 232-906-9) and LYS chloride (Grade VI, ~60000 units/mg protein, 
EC 3.2.1.17) from chicken egg white were purchased from Sigma-Aldrich (St. Louise, 
MO, USA). 
 
 3.1.2. Human digestive fluids 
 
Saliva was collected from 3 healthy donors after 2 h fasting. Human gastric and 
duodenal fluids were collected by gastroscopy from 4 different patients without any 
gastrointestinal pathology at the Hospital Universitario La Paz (Madrid, Spain) after 8 
hours of fasting. Aspirates were collected on ice and gastric and duodenal fluids were 
separately pooled and frozen to stop any enzymatic reaction. Pepsin activity was assayed 
spectrophotometrically as recommended by Sigma with haemoglobin as a substrate 
(Anson, 1938). The activities of trypsin and chymotrypsin were also measured 
spectrophotometrically following a continuous rate determination recommended by 
Sigma, using N-benzoyl-L-arginine-ethylester (BAEE) and N-benzoyl-L-tyrosine-
ethylester (BTEE) as substrates respectively (Bergmeyer et al., 1974; Wirnt, 1974). The 
determinations showed a pepsin activity of 728.9 U/mL in the pooled gastric fluid (pH 
2.13) and trypsin and chymotrypsin activities of 167.2 and 2.8 U/mL, respectively, in the 
duodenal fluid (pH 7.8). The bile salt concentration in the duodenal fluid was 0.7 mM, as 
estimated by a commercial bile acids determination kit from Trinity Biotech (Bray, 
Wicklow, Ireland). 
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 3.1.3. Human sera 
Individual serum samples from children with proven allergy to bovine milk and 
egg proteins were collected from the Hospital Infanta Sofia (San Sebastián de los Reyes, 
Madrid, Spain), the Hospital Infantil Universitario Niño Jesús (Madrid, Madrid, Spain) 
and the Mount Sinai Medical Center (New York, NY, USA). The diagnosis of IgE-
mediated milk and egg allergy was made by an allergist on the basis of objective 
symptoms of an acute reaction after milk or egg ingestion, together with evidence of 
specific IgE antibodies against milk or egg. The specific IgE levels of the sera used are 
shown in Annexes 1-5. Serum samples from non-allergic donors were also used.  
 
Ethics statement: All human samples were obtained with written consent of the patients. 
All experiments were approved by the Bioethics Committee from the Consejo Superior de 
Investigaciones Científicas (CSIC), Spain.  
 
3.2. METHODS 
 3.2.1. Sample preparation  
 
3.2.1.1. Ovomucoid enzymatic deglycosylation 
OM was dissolved in 5 mM potassium phosphate, 4 mM CaCl2, 0.04 % NaCl, pH 
7.5, at a concentration of 20.7 mg/mL and deglycosylated with PNGase F (500 U/mL, 
Sigma-Aldrich, 1 U/0.8 mg of OM) at 37 °C, with constant stirring for 24h. PNGase F 
was added again to the solution at the same ratio and incubated for a further 4 days at 37 
°C. A control without PNGase F was also included. Free sugars were removed from 
deglycosylated OM (dOM) by centrifugation at 4000g for 5 min at 4 °C in ultrafiltration 
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devices of 10.000 Da cut off from Millipore (Billerica, MA, USA), until no sugars were 
detected in the permeates according to the phenol-sulfuric acid method (Masuko et al., 
2005). Briefly, 50 μL of permeate were added to a 96-well microplate and 150 μL of 
concentrated sulphuric acid was added rapidly to cause maximum mixing, followed by 30 
μL of 5% phenol (Sigma-Aldrich) in water. After incubating for 5 min at 90ºC in a static 
water bath, the plate was cooled to room temperature and the absorbance at 490 nm 
recorded with a Multiskan FC microplate reader  from Thermo Scientific (Waltham, MA, 
USA). The concentration of deglycosylated ovomucoid was measured 
spectrophotometrically (490 nm) by the Pierce
®
 BCA Protein Assay Kit from Pierce 
Scientific (Rockford, IL, USA) following the manufacturer´s instructions. 
 
3.2.1.2. Reduction and alkylation of lysozyme 
LYS was reduced and alkylated as previously described (Mine and Zhang, 2002a). 
A solution of 1 mg/mL of LYS in denaturation buffer (6 M guanidinium hydrochloride in 
0.6 M Tris-HCl, pH 8.6) was prepared. Then, an equal volume of 4 mM 1,4-dithiothreitol 
(Sigma-Aldrich) was added to give a final concentration of 2 mM and 400 μL of 
iodoacetic acid (Sigma-Aldrich) were added dropwise with stirring in the dark. The 
sample was incubated in the dark for 1 h at 37 °C followed by dialysis against 50 mM 
ammonium bicarbonate, pH 7.8, for 24 h. The protein content was determined with the 
BCA Protein Assay Kit from Pierce Scientific. 
 
3.2.1.3. Hydrolysis of lysozyme with papain 
LYS was hydrolysed with papain (76218, Papain from Carica papaya, 12 U/mg, 
EC 232.627.2, Sigma-Aldrich) for 3 h at 54ºC at an enzyme to substrate ratio of 2:5 
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(w:w), similar to that found in Lizipaina
®
, a drug employed for the symptomatic relief of 
mild conditions of the throat and mouth. The reaction was stopped by heating at 100ºC 
for 10 min. 
 
 3.2.2. Digestion models 
 
3.2.2.1. In vitro digestion with simulated fluids 
Preparation of phospholipid vesicles 
Phospholipid vesicles were prepared by dissolving egg L-alpha-
phosphatidylcholine from Larodan (Limhamn, Malmo, Sweden) in simulated gastric fluid 
(35 mM NaCl pH 2.0) at a concentration of 9.58 mg/mL. Then, the solution was 
sonicated in ice (raising the power from 10% to 50% in 5 min, and keeping it 5 min at 
60% power), not exceeding a sample temperature of 40ºC, following Martos et al. (2010). 
Phospholipid vesicles were filtered through Filtropur 0.45 µm polyethersulfone from 
Sarstedt (Nümbrecht, North Rhine-Westphalia, Germany) to remove any possible 
titanium particles. 
Oral digestion 
Proteins were dissolved in simulated saliva fluid (potassium phosphate 0.005 M, 
CaCl2 0.004 M, NaCl 0.04 %, pH 6.5) at a concentration of 46 mg/mL. After incubation 
at 37 °C for 15 min, a solution of α-amylase (EC 3.2.1.1, 210 U/mg solid, Sigma-Aldrich) 
was added at the physiological ratio of 150 U/mL (Bernard, 1953) of simulated saliva 
fluid. In vitro oral digestions were performed at 37 °C in an incubator with moderate 
shaking and aliquots were taken after 2 min. The digestions were stopped by decreasing 
the pH to 3.5 with 1N HCl. 
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Gastric digestion 
In vitro gastric digestions were performed either using the 2 min-oral digests as 
the starting material, previously adjusted to pH 2.0 with 1N HCl, or using the proteins 
dissolved in simulated gastric fluid. Samples were mixed with the phosphatidylcholine 
vesicle solution (1:1.2, v:v), and after incubation at 37 °C for 15 min, pepsin (EC 
3.4.23.1, 3640 U/mg protein, Sigma-Aldrich) dissolved in simulated gastric fluid pH 2.0 
was added at a physiological enzyme to substrate ratio (1:20, w:w) (182 U/mg of protein) 
(Moreno et al., 2005). The gastric digestions were performed at 37 °C in an incubator 
with moderate shaking and aliquots were taken at different time-points from 0 to 60 min. 
The digestions were stopped by increasing the pH to 7.5 with 1M NaHCO3 to irreversibly 
inactivate pepsin, giving a final concentration of 5.3 mg/mL of protein and 4.8 mg/mL of 
phosphatidylcholine. 
Duodenal digestion 
Duodenal digestions were performed on the 60 min gastric digests, re-adjusted to 
pH 6.5, with the addition of 0.25 M Bis-tris, pH 6.5 (Sigma-Aldrich), 1 M CaCl2 (7.6 mM 
final concentration) and a 0.25 M bile salt mixture containing equimolar quantities of 
sodium glycodeoxycholate and sodium taurocholate (Sigma-Aldrich) (7.4 mM final 
concentration of bile salt). After preheating at 37 °C for 15 min, pancreatic porcine lipase 
(EC 232-619-9; type VI-S, 47900 U/mg protein, Sigma- Aldrich), pancreatic porcine 
colipase (EC 259-490-1; Sigma-Aldrich), pancreatic bovine trypsin (EC 232-650-8, type I 
10100 BAEE U/mg protein, Sigma-Aldrich), and pancreatic bovine a-chymotrypsin (EC 
232-671-2; type I-S; 55 U/mg protein, Sigma-Aldrich), were added to the duodenal mix at 
enzyme to substrate ratios of 24.7 U/mg protein, 1:895 (w:w), 34.5 U/mg protein and 0.44 
U/mg protein respectively (Moreno et al. 2005). The reactions were carried out at 37 °C 
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for different periods from 0 to 60 min and stopped by adding a solution of Bowman–Birk 
trypsin-chymotrypsin inhibitor from soybean (T9777; Sigma-Aldrich), at a concentration 
calculated to inhibit twice the amount of trypsin and chymotrypsin present in the 
digestion mix. The final composition of the mixture was 3.3 mg/mL phosphatidylcholine, 
3.9 mg/mL protein, 7.4 mM bile salt mixture, 7.6 mM CaCl2 and 20.3 mM Bis-tris.  
 
3.2.2.2. In vitro digestions with human fluids 
In vitro protein digestion with human fluids was performed in 3 steps, simulating 
the oral, gastric and duodenal phases. First, protein was dissolved in saliva (20 mg/mL, 
pH 6.5) and incubated at 37°C for 2 min, followed by a pH decrease to 3.5 with 1N HCl. 
For gastric digestions, 112 μL of the protein solution (20 mg/mL) were mixed with 560 
L of the pool of human gastric fluids at pH 2.1, so that the pepsin to protein ratio was 
the same as that employed in the digestion with commercial pepsin (182 U/mg). After 1 
hour of gently shaking at 37°C, the pH was adjusted to pH 6.5 with 1 M NaHCO3 and 
300 L of the gastric digest were mixed with 198 L of the pool of human duodenal 
fluids at pH 6.7, so that the enzyme to substrate ratios were 34.5 U/mg of trypsin and 0.49 
U/mg of chymotrypsin. Aliquots were taken at different time-points during the 
incubation. The reaction was stopped with a solution of Bowman–Birk trypsin-
chymotrypsin inhibitor from soybean as described above. 
 
 
 
 
 
  
 
 
55 Materials and Methods 
 3.2.3. Sample characterization 
 
3.2.3.1. Circular Dichroism 
Circular dichroism spectra were obtained in a Jasco J-810 spectropolarimeter from 
Jasco Corporation (Tokyo, Japan). Far (195-260 nm) and near (250-350 nm) ultraviolet 
circular dichroism spectra of samples, in phosphate buffer 50 mM pH 7.0, were recorded 
at 20 °C using cells with respective path lengths of 0.1 and 0.2 cm. Spectra represent the 
average of three accumulations collected at 20 nm/min, with a 2 s time constant, a 0.2 nm 
resolution, and a sensitivity of 100 mdeg. The samples were dissolved at 0.2 mg/mL for 
the analysis in the far ultraviolet region and at 0.5 mg/mL for the near ultraviolet region. 
The buffer blanks were subtracted from each circular dichroism spectrum. Empirical 
determinations of protein secondary structure were obtained employing the CDNN 
secondary structure analysis software from Applied Photophysics Ltd (Leatherhead, 
Surrey, UK).  
 
3.2.3.2. Electrophoresis SDS–PAGE 
SDS–PAGE analyses were performed using Bis-Tris or Tris-Tricine acrylamide 
gels from Bio-Rad Laboratories (Richmond, CA, USA). Samples were diluted 1:4 (v:v) in 
0.5 M Tris-HCl buffer, pH 6.8, containing 1.6% SDS, 8% glycerol, 4% 2-β-
mercaptoethanol and 0.002 % bromophenol blue or in Tricine sample buffer (Bio-Rad), 
respectively, and heated at 95 °C for 4 min.  Electrophoresis were carried out at 150V in 
XT running buffer MES, when Bis-Tris gels were used, and at 100V in Tris-Tricine 
running buffer, when Tris-Tricine gels were used. A molecular mass marker ranging in 
molecular mass from 10 to 250 kDa was used, when the electrophoresis was carried out 
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using the Bis-Tris gels (Precision Plus Protein standards, Bio-Rad), and ranging from 
1.42 to 26.62 kDa, when the Tris-Tricine gels were employed (Precision Plus Protein 
Kaleidoscope standards, Bio-Rad). Gels were stained with Coomassie Blue G-250 (Bio-
Rad) or Periodic Acid Schiff. For the Coomassie blue staining, proteins were fixed with a 
solution of 40% methanol (v/v) and 10% acetic acid (v/v) for 30 min. Afterwards, the gels 
were incubated with Bio-SafeTM Coomasie G-250 (Bio-Rad) overnight and rinsed with 
water until the background was clear. Periodic Acid Schiff staining was performed by 
fixing the protein bands with 12.5% trichloroacetic acid (w/v) for 30 min. After removing 
the excess of acid by washing with water, a solution of 1% (w/v) periodic acid in 3% 
(v/v) acetic acid was added. Excess periodate ions were removed by washing with water 
and the color was developed by dipping the gel in Schiff's reagent for 1 h in the dark. 
Finally, the gel was washed with a solution of 0.5% (w/v) Na2S2O5 and rinsed with water. 
 
3.2.3.3. Reversed Phase-High Performance Liquid Chromatography (RP-HPLC) 
Native proteins and their hydrolysates, at a concentration of 3.9 mg/mL, were 
analysed in a Waters 600 HPLC system using a RP318 C18 column (250x4.6 mm, 5 µm 
of particle size, 300 A pore size, Bio-Rad). The injection volume was 50 µL and the 
digests were eluted by using 0.37% (v/v) trifluoroacetic acid from Scharlau Chemie 
(Barcelona, Spain) in double-distilled water as solvent A, and 0.27% (v/v) trifluoroacetic 
acid in HPLC-grade acetonitrile from Lab-Scan (Gliwice, Poland) as solvent B. A linear 
gradient of solvent B in A ranging from 0% to 60% in 60 min was used to fractionate the 
peptides contained in the samples at 1 mL/min followed by washing 35 min with 60% of 
solvent B and 10 min with 100% of solvent B. Detection was carried out at 220 nm and 
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data were processed by using Empower 2 Software from Waters Corporation (Milford, 
Massachusetts, USA).  
 
3.2.3.4. Peptide sequencing by RP-HPLC-MS/MS 
RP-HPLC-MS/MS analyses of the digested samples were performed on an 
Agilent 1100 HPLC System (Agilent Technologies, Waldbronn, Baden-Württemberg, 
Germany) with a HiPore column from Bio-Rad (RP318 C18 column 250x4.6 mm, 5 mm 
of particle size). The HPLC system was connected on-line to an Esquire 3000 quadrupole 
ion trap equipped with an electrospray ionisation source from Bruker Daltonik (Bremen, 
Bremen, Germany). The mobile phases used were 0.37% (v/v) trifluoroacetic acid in 
double-distilled water as solvent A, and 0.27% (v/v) trifluoroacetic acid in HPLC-grade 
acetonitrile as solvent B. A linear gradient of solvent B in A ranging from 0% to 60% in 
60 min was used to fractionate the peptides contained in samples. The injection volume 
was 50 µL and the flow rate 0.8 mL/min. Mass spectra were acquired over the range 100-
3000 m/z. Using Data Analysis
TM 
version 4.0 from Bruker Daltonik, the m/z spectral data 
were processed and transformed to spectra representing mass values. BioTools version 
3.1 (Bruker Daltonik) was used to process the MS(n) spectra and to perform peptide 
sequencing. To aid the identification of disulphide linked fragments, the samples were 
also analysed after a reducing step using 70 mM dithiothreitol (DTT), at pH 7.0, for 1 h at 
37ºC.  
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3.2.3.5. MALDI-TOF/TOF MS 
Size distribution 
 The range of peptide masses in the protein digests was analysed by MALDI-
TOF/TOF MS using a Bruker Autoflex Speed spectrometer (Bruker Daltonik). The 
sample (0.5 L) was loaded on a dry DHB matrix spot (0.5 µL of 20 mg/mL 2,5-
dihydroxybenzoic acid in acetonitrile/H2O/ trifluoroacetic acid (66/33/0.1) (v/v/v) onto a 
Bruker Anchorchip target and allowed to dry. All mass spectra were initially calibrated 
with Peptide Calibration Standard and Protein Calibration Standard I (Bruker Daltonik). 
Analyses of the peptide electrophoretic bands 
The identification of the exact sequence of the IgE reactive peptides detected by 
Western blotting was done by mass fingerprinting and MALDI TOF/TOF analysis of 
tryptic digests, in combination with intact molecular weight determination. Analyses were 
performed on an Autoflex SpeedTM (Bruker Daltonik). Bands were manually excised 
from gels and in-gel digested with trypsin from Promega corporation (Fitchburg, MA, 
USA), at 20 ng/mL in NH4HCO3 25 mM, with or without previous reducing and 
alkylation steps using dithiothreitol and iodoacetamide (Shevchenko et al., 2006). After 
digestion, the supernatants were collected, cleaned with a C18 Zip Tip pipette tips 
(Millipore, Billerica, MA, USA) and spotted onto a MALDI target plate with a DHB 
matrix. For peptide identification, Biotools version 2.1 (Bruker Daltonik) was used. 
Search parameters were carbamidomethyl cystein and oxidized methionine as variable 
modifications, peptide mass tolerance 500 ppm, and MS/MS fragments tolerance 0.5 Da. 
For intact molecular weight determination, proteins were electroblotted and 
directly analysed after dissolving the nitrocellulose membrane in MALDI matrix solution, 
prepared as a saturated solution of -CHCA (alpha-cyano-4-hydroxy-cinnamic acid) in 
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acetonitrile/methanol 70/30%, containing 1% trifluoroacetic acid (Martos et al., 2012). 
Samples were spotted on a Bruker Anchorchip target and spectra were acquired on linear 
mode. 
 
 3.2.4 Sample immunoreactivity 
 
3.2.4.1. Western Blotting 
After SDS-PAGE separations on Precast Criterion gels, the gels were soaked in 
transfer buffer (48 mM Tris, 39 mM glycine, 20% methanol, pH 9.2) for 20 min and 
subjected to semidry transfer in a Trans-Blot SD (Bio-Rad) for 30 min at 18 V. Transfer 
effectiveness was assessed by staining the membrane with Ponceau reagent. Then, the 
nitrocellulose membranes were blocked with Tris Buffer Saline (50 mM Tris, 150 mM 
NaCl, pH 7.6) with Tween 20 (0.05% v/v) (TBST), containing 1% (w/v) bovine serum 
albumin (BSA) for 60 min. The membranes were washed with TBST and incubated 
overnight at 4ºC with human sera diluted in TBST containing BSA 0.1% (w/v). After a 
new washing-step, the membranes were incubated overnight at room temperature with 
biotin conjugated antihuman IgE antibody clone HP6029, from Southern Biotech 
(Birmingham, AL, USA) diluted 1:500 in TBST containing 0.1% (w/v) BSA. After a new 
washing-step, they were incubated with HRP conjugated streptavidin for 1 h at room 
temperature. Finally, the membranes were rinsed and detection with chemiluminescence 
was developed with Amersham TM ECL TM Prime from GE Healthcare (Pittsburgh, PA, 
USA). Image acquisition was performed using the VersaDoc Imaging System (Bio-Rad). 
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3.2.4.2. Human IgE Binding by Inhibition ELISA 
Human IgE binding to LYS and its digests was assessed by inhibition ELISA as 
previously reported Jiménez-Saiz et al. (2013). Single wells of polystyrene Corning 
Costar microtiter plates (Lowell, MA, USA) were coated with 10 μg/mL of protein 
solution in 0.01M phosphate-buffered saline (PBS), pH 7.4, and incubated overnight at 
4ºC. The plates were washed three times with PBS containing 0.05% Tween 20 (PBST). 
Residual free binding sites were blocked by incubation with PBS containing 2.5% Tween 
20 for 4 h at room temperature.  Then, serial dilutions of each sample (not less than 10) 
were incubated during 120 min with sera previously diluted in PBST (1:1 v/v) and, after 
washing the plate, 50 μL was added to each well. Each sample was added in duplicate and 
a negative control without serum (native protein in PBST) and positive controls (sera 
diluted in PBS) were included in each plate. After 120 min of incubation, 50 μL of 
polyclonal rabbit anti-human IgE from Dako (Glostrup, Hovedstaden, Denmark) diluted 
1:1,000 in PBST, were added per well and incubated for 60 min. Then, 50 μL of 
polyclonal swine anti-rabbit immunoglobulin conjugated with horseradish peroxidase 
(HRP) (Dako), diluted 1:2,000 in PBST, were added per well and incubated for 60 min. 
Before the addition of the enzyme substrate, a signal amplification system based on the 
subsequent addition of tyramide-biotin and streptavidin-HRP, was used following the 
instructions of the manufacturer (PerkinElmer, Walthman, MA, USA). Finally, 50 μL of 
3,3’-5,5’-tetramethylbenzidine (TMB) substrate (Sigma-Aldrich) were added to each well 
and after 30 min of incubation, the reaction was stopped with 0.5 M sulphuric acid. 
Absorbance was measured at 450 nm on an automated Multiskan FC microplate reader 
(Thermo Scientific). A nonlinear adjustment of the data obtained for each dilution was 
applied for each serum and sample. The adjustment model was a sigmoidal dose-response 
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curve with variable slope, from which the EC50 (the concentration that binds 50% of 
seric IgE) was obtained with the program GraphPad Prism version 5 (La Jolla, CA, USA). 
The IgE binding capacity was expressed as the percentage of the EC50 of the intact 
protein. 
 
3.2.4.3. Microarray 
Peptides, slides, printing  
The peptide microarray immunoassay was carried out at the Mount Sinai School 
of Medicine in New York as previously described Shreffler et al. (2005) and Lin et al. 
(2009) with minor modifications. Among the peptides identified from the gastric and 
gastroduodenal phases of digestion, the peptides shorter than 8 amino acids, that which 
were part of longer sequences and the peptides that overlapped with well-established 
epitopes for β-CN and β-LG by microarray and SPOT membrane in previous studies were 
discarded. Peptides with 8 and 9 amino acids were extended to 10 amino acids with the 
preceding or following amino acids of the protein chain and the peptides over 20 amino 
acids were replaced by 2 shorter overlapping peptides. Peptides selected from in vitro 
digestions, together with a library of peptides consisting of 20 amino acids overlapping by 
17 (3-offset) corresponding to the primary sequence of β-CN and β-LG, were 
commercially synthesized by JPT peptide Technologies (Berlin, German). Peptides were 
diluted 1:2 in protein printing buffer from Arrayit (Sunnyvale, CA, USA) and printed in 2 
sets of triplicates on epoxy-derivatized glass slides (Arrayit) by using the NanoPrint 
Microarrayer 60 (Arrayit). Protein printing buffer alone, used as a negative control and 
for background normalization, and fluorochrome-labeled BSA, used for the purpose of 
grid alignment during analysis, were included on each slide. 
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Immunoassay 
The printed slides were blocked with 400 mL of 1% human serum albumin (HAS) 
in PBST for 60 min at 31°C, followed by incubation with 250 µL of each patient’s serum 
diluted 1:5 in PBST-HSA overnight at 4°C. For IgE detection the slides were incubated 
overnight at 4°C with 250 µL of a cocktail of 3 biotinylated monoclonal anti-human IgE 
antibodies, one from Invitrogen (Carlsbad, California, USA) diluted 1:250, one from BD 
Biosciences (San Jose, California, USA) diluted 1:250 and one from Phadia (Upsala, 
Upsala, Sweden) diluted 1:1000. Slides were then incubated for 3 hours at 31°C with 200 
µL of a cocktail of anti-biotin dendrimer Oyster 550 (Genisphere, Philadelphia, PA, 
USA) in dendrimer buffer (Genisphere) at 0.6 mg/mL with the addition of 0.02 mg/mL 
salmon sperm DNA (Invitrogen). All incubations were performed in the dark in a 
humidity chamber, followed by washing with PBS, PBST and 15mM Tris buffer pH 8.0 
for different times. Following the last washing, the slides were centrifuge dried and 
scanned with a ScanArrayGx (PerkinElmer). 
Data analysis 
The fluorescence signal of each spot was digitalized with the program ScanArray 
Express (PerkinElmer) and transformed to a z score, as previously described (Lin et al. 
2009). An index z value of each peptide element was generated from the median of z 
scores of the 6 replicate spots. An individual peptide sample was considered positive if its 
z score exceeded 3, meaning that the signal was significantly above the background (P < 
0.003). 
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3.2.4.4. Dot-Blot 
Peptides 
Peptides selected from in vitro digestions, following the same criteria as described 
above, were commercially synthesized (JPT peptide Technologies).  
Immunoassay 
The nitrocellulose membranes were conditioned in Tris buffer (48 mM Tris, 39 
mM glycine, 20% methanol, pH 9.2) for 20 min, and 1µl of each peptide was spotted onto 
the membrane and allowed to dry. Then, the nitrocellulose membranes were blocked with 
TBST with 1% w/v BSA, for 60 min and washed with TBST. Immunolabelling with ten 
individual serum samples was conducted as described for the Western Blotting 
experiments. 
 
3.2.4.5. Basophil activation test 
Basophil activation assays were performed as described by Martos et al. (2011), 
with some modifications. Peripheral blood mononuclear cells (PBMCs) from egg-tolerant 
adult donors were isolated according to standard procedures (Movérare et al., 2000). 
Briefly, blood was diluted 1:1 in PBS and gently layered onto a conical tube with Ficoll. 
After centrifugation at 300g for 30 min using slow acceleration and without deceleration 
to prevent mixing of the liquids, the buffy coat, containing the PBMCs, was aspirated and 
washed with PBS. PBMCs were stripped from bound IgE by treatment with lactic acid 
(13.4 mmol/L lactate, 140 mmol/L NaCl, 5 mmol/L KCl, pH 3.9) for 5 min on ice and re-
sensitized with a 1:1.5 dilution of a pool of sera from children with egg allergy. 
Subsequently, cells were incubated with the samples at a range of concentrations from 
0.01 to 10 g/mL. Cells were stained for CD63, CD123 (BD Biosciences), HLA-DR, and 
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CD203c from Beckman Coulter (Indianapolis, IN, USA), fixed with BD FACS
TM
 Lysing 
Solution (BD Biosciences), and acquired in a Gallios Flow Cytometer (Beckman 
Coulter). Dissociation of IgE with lactic acid and successful re-sensitization, as assessed 
by detection of cell surface IgE using monoclonal anti-human IgE, showed an almost 
complete loss and recovery of bound IgE (94.3, 0.72, and 95.8% of IgE-coated basophils 
in nonstripped, stripped, and re-sensitized cells, respectively). Anti IgE antibody (Dako) 
and fMLP (Sigma-Aldrich) were used as positive controls. Percentage of activation upon 
stimulation with the samples was calculated and normalized according to the value 
obtained for RPMI-IL3 (negative control).   
 
3.2.4.6. Proliferation of PBMCs  
PBMCs from egg-allergic patients were cultured at a concentration of 2x10
6
 
viable cells/mL in a 96-well microplate and stimulated with the samples at 20 and 5 
μg/mL for 5 days at 37ºC. PBMCs proliferation was determined using the MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay following Keller et al. 
(2006). Briefly, 100 μL of MTT (0.5 mg/mL) in PBS was added to the microplate and 
incubated 3 hours at 37ºC. Afterwards, the plate was centrifuged at 600g for 10 min and 
the pellet was dissolved in 1:1 of dimethylsulfoxide:methanol (v:v). Absorbance was 
measured at 570 and 650 nm on an automated Multiskan FC microplate reader (Thermo 
Scientific). PBMCs from egg-tolerant donors were also employed. The results were 
considered positive when the stimulation index (SI) was higher than 1.5. SI on MTT 
assay was calculated according to the formula:  
            OD (570-650 nm) of stimulated cells 
SI=  
        OD (570-650 nm) of non-stimulated cells  
  
 
 
65 Materials and Methods 
3.2.4.7. Skin tests and measurement of IgE and IgG4 
The skin prick test, serum total and specific IgE, and serum specific IgG4 to 
different egg protein fractions, shown in section 4.5.2., were assessed before and after 15, 
30 and 90 days of oral immunotherapy of a 15-year-old boy at the Hospital Infantil 
Universitario Niño Jesús (Madrid). 
 
 3.2.5. Statistical analysis 
All data was analyzed with GraphPad Prism version 5. Student t-test was used for 
comparison between groups. Data were considered statistically significant if P<0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
4. RESULTS AND DISCUSSION 
 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
4.1. In vitro digestibility of bovine β-Casein with simulated and human 
oral and gastrointestinal fluids. Identification and IgE-reactivity of the 
resultant peptides 
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Caseins (up to 80% of the total milk protein content) are one of the most critical 
milk allergens accounting for the highest circulating IgE levels (Restani et al., 2009). 
Among them, β-casein (β-CN, Bos d 8) (approximately 27% of the total milk proteins) 
represents a serious health risk to patients with cow’s milk allergy, since 75% of the sera 
from patients with IgE-mediated allergy to cow´s milk have IgE directed against β-CN 
(Shek et al., 2005).  
β-CN is a protein with a molecular weight of 24,000 Daltons and 209 amino acids, 
including 35 proline residues uniformly distributed in the molecule. This large amount of 
proline prevents the formation of α-helix, β-sheet and β-turns and gives it a very flexible 
three-dimensional structure with large disordered areas (Dunker et al., 2001). It also 
contains 5 phosphoserine residues in the N-terminal end (being phosphorylation highly 
variable depending on the variant gene) and no cysteine residues. These structural 
characteristics prevent β-CN from undergoing an abrupt transition from one type of 
conformational state to another, and its polypeptide chain adopts a set of secondary 
structures which are in equilibrium with each other. Therefore β-CN has a very stable 
structure which could protect many potential epitopes when it is subjected to heating 
(Holt and Sawyer, 1993) or even to hydrolysis with proteases during the digestion 
process. 
There are few published studies describing β-CN digestion with physiologically 
relevant models using commercial enzymes (Dupont et al., 2010a, 2010b). Alternatively, 
other authors have used human gastric and duodenal juices in order to evaluate the 
degradation of milk proteins during digestion (Almaas et al., 2011; Furlund et al., 2013). 
Although those studies have investigated different aspects of β-CN digestion, the 
presence of potential IgE epitopes in the digestion products has not been addressed. In 
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this regard, peptide microarray, a technique based on a similar principle than an ELISA 
protocol, which allows the detection of binding events at an epitope level, could be 
useful. This technique uses a collection of peptides displayed on a solid surface, usually a 
glass chip. After being incubated with a variety of serum samples and several washing 
steps, a fluorescence laballed secondary antibody with the needed specificity is applied. 
Previous studies have demonstrated that peptide microarray immunoassays constitute a 
promising technology for epitope determination (Lin et al., 2009). 
The main aim of this research was to immunologically characterize the digestion 
products of β-CN. For this purpose, in vitro hydrolysis of β-CN was compared using 
simulated and human digestive fluids, mimicking three areas of the gastrointestinal tract: 
the mouth, stomach and small intestine. The reactivity of IgE antibodies towards the 
digests was assessed, the peptide products obtained were identified by RP-HPLC-MS/MS 
and the IgE-binding properties of the most relevant peptides resulting in potential 
epitopes were evaluated by a microarray-based immunoassay. Part of this work was 
carried out during a 4-month stay at the Mount Sinai School of Medicine in New York. 
 
4.1.1. RESULTS 
 4.1.1.1. Digestibility and IgE binding of β-CN 
 
As shown in Figure 2a, 2-min in vitro oral digestion period of β-CN, either with 
simulated oral fluid or human saliva, did not show any effect on the β-CN pattern as 
estimated by SDS-PAGE performed using bis-tris 12% acrylamide gels with reducing 
agents (Figures 2a and 2b, lane 3). Regarding the in vitro gastric phase, digestion with 
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human and simulated fluids also showed similar trends. β-CN was quickly degraded in 
the early stages of digestion and no residual β-CN was observed by the end of the gastric 
phase (Figures 2a and 2b). With porcine pepsin, β-CN was broken down into three 
fragments with molecular masses of, approximately, 23, 18 and 14 kDa, together with 
fragments of 10 kDa and less. The intact protein and the fragment of 23 kDa disappeared 
after about 2 and 4 min of digestion, respectively, while the band of 14 kDa resisted for 
10 min (Figure 2a, lanes 5, 6 and 9). The concomitant appearance of an additional band of 
around 12 kDa, together with lower molecular mass peptides was also observed (Figure 
2a, lanes 9-12).  
 
 
Figure 2. SDS-PAGE patterns, using Bis-Tris 12% acrilamide gels, of β-CN after in vitro oral 
and gastric digestions with simulated (a) and human (b) gastric fluids. Lane 1: molecular mass 
marker; lane 2: β-CN, lane 3: 2-min oral digests (O2); lanes 4-12: 1 (G1), 2 (G2), 4 (G4), 6 (G6), 
8 (G8), 10 (G10), 15 (G15), 20 (G20) and 60-min (G60) gastric digests. 
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Human fluids yielded basically the same profile, but digestion progressed more 
rapidly: β-CN was degraded in only two min and the band of 18 kDa, the product most 
resistant to hydrolysis, was no longer present after 60 min of digestion (Figure 2b, lanes 5 
and 12). No bands were detected by SDS-PAGE in the gastroduodenal digests but, as 
estimated by the number and intensity of the small or hydrophilic peptides with low 
retention time in the RP-HPLC analyses, hydrolysis with pancreatic enzymes was also 
more rapid when human fluids were used (not shown).  
As shown in Figure 3, reactivity against IgE was evaluated by inhibition ELISA 
using the sera from 6 milk allergic patients (nos. 1-6, Annex 1). Immunoreactivity of β-
CN at the end of gastric digestion increased, as detected by 4 out of the 6 sera, to values 
reaching 200% of the initial IgE binding of the undigested protein. Despite individual 
variations, and in agreement with the lowest protein degradation, the highest IgE binding 
corresponded to the digests produced with commercial porcine pepsin. IgE binding fell 
drastically at the end of the duodenal phase of the in vitro digestion either with 
commercial or human enzymes (Figure 3). 
 
 
Figure 3. IgE binding of β-CN, 
expressed as percentage of the EC50 
of the intact protein as estimated by 
inhibition ELISA with sera from six 
allergic patients (nos. 1-6, Annex 1), 
after in vitro gastric digestion with 
simulated (     ) and human (     ) fluids 
and gastroduodenal digestion with 
simulated (     ) and human (     ) 
fluids. 
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Western blotting was used to assess the immunoreactivity against IgE of the 
degradation products (Figure 4). The different individual sera showed different 
specificities, but in general terms, the IgE binding of the proteolysis fragments released 
by pepsin during the first stages of in vitro gastric hydrolyses was progressively reduced 
as the digestions proceeded. However, in the gastric digests with both simulated and 
human fluids, a band of around 6.5 kDa was recognized, even after 60 min of hydrolysis, 
by sera from patients 1 and 4, which gave a high response by inhibition ELISA (Figures 
3, 4b and 4c), but not by serum from patients 2 (Figure 3 and 4d) and 3 (not shown) 
which gave a low response. It is, therefore, likely that this degradation product 
contributed to the residual IgE binding of the in vitro gastric digests, although its actual 
relevance is probably hampered by an inefficient transfer yield in the electroblotting, as 
revealed by Ponceau staining of the nitrocellulose membrane (results not shown). 
 
Figure 4. SDS-PAGE patterns (a), using Tris-Tricine 16.5% acrylamide gels, and Western 
blotting (b, c and d) of β-CN after in vitro gastric and gastroduodenal digestions with simulated 
(lanes 3-6) and human (lanes 7-10) fluids. Lane 2: β-CN; lanes 3-5 and 7-9: 1 (G1), 6 (G6), and 
60-min (G60) gastric digests; lane 6 and 10: gastroduodenal digests (60 min of gastric followed 
by 30 min of duodenal digestion, D30). Sera from patients 1 (b), 4 (c) and 2 (d), described in 
Annex 1. 
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 4.1.1.2. Peptide identification after in vitro digestions and epitope recognition 
 
RP-HPLC-MS/MS was used for the analysis of the gastric (60 min) and 
gastroduodenal (with a further 30 min of duodenal hydrolysis) digests of β-CN. The 
sequences of the 152 peptides identified ranged between 3 and 21 amino acids (Figure 5 
and Annex 6). The sequence coverage was high: 67.0 and 80.4 % after gastric digestion 
and 82.8 and 70.3 after subsequent duodenal digestion with simulated and human fluids, 
respectively. The peptide patterns of the hydrolysates produced in both models were 
fairly similar following gastric digestion, showing 20 peptides in common, although the 
human fluids gave rise to a higher proportion of peptides of less than 1,500 Da. Because 
the range of m/z scanned in RP-HPLC-MS/MS was between 100-3,000 m/z, the peptide 
mass distribution of the gastric digests was analysed by MALDI-TOF MS, that showed 
that 17% of the peptides produced after 60 min of gastric digestion were between 3,000 to 
10,000 Da (Figure 6). Gastroduodenal digestion with human fluids gave less numerous 
peptides, all shorter than 1,500 Da (Annex 6). 
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Figure 6. Peptide mass frequency distribution of the gastric digests with simulated fluids shown 
in a histogram, where each bar corresponds to a peptide size interval of 0.5 kDa. 
 
Among the identified peptides from the duodenal phases in both models of 
digestion, 12 peptides were selected as is described in materials and methods section. 
These selected peptides, together with a library of peptides consisting of 20 amino acids 
overlapping by 17 (3-offset) corresponding to the primary sequence of β-CN, were 
commercially synthesized to performed peptide microarray. Taking together the 20-amino 
acid synthetic peptides, the IgE binding areas identified covered almost the whole β-CN 
sequence, although the area of the protein that was recognized by most sera corresponded 
to that between residues 31-101 and 124-209 (Figure 5). The IgE-binding patterns of the 
12 printed peptides selected from the gastroduodenal digests with simulated and human 
fluids are also shown in Figure 5, and Table 3 compares their binding frequency to the 
individual sera with that of matching sequences from the 20- amino acid peptide library. 
The highest IgE binding (58% of patients) corresponded to the β-CN region comprised 
between positions 57-93 [β-CN (57-68), β-CN (69-80), β-CN (73-84) and β-CN (82-93)]. 
Peptides belonging to the region β-CN (144-163) and to the C-terminus [β-CN (191-209)] 
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showed a moderate IgE binding, being in both cases recognized by approximately 16% of 
the patients included in the study, while peptides corresponding to the regions between 
positions 96-126 [β-CN (96-105), β-CN (106-119), β-CN (108-125) and β-CN(114-126)], 
β-CN (143-156) and β-CN (171-180) did not react with any of the patient’s sera 
employed in the study.  
 
 
 
  
 
 
Figure 5. Peptide sequences, identified by RP-HPLC-MS/MS, in the gastric (60 min) and gastroduodenal digests of β-CN (60 min of gastric followed by 30 min of duodenal digestion), with simulated and human fluids, and IgE binding, 
estimated by peptide microarray with 12 sera of milk allergic patients (patients 7-18, Annex 1), of 12 peptides selected from the simulated digestions and 58 20-amino acids peptides from a peptide library that spans the whole β-CN 
sequence. The intensity of the IgE binding, low (      ), medium (      ) and high (      ) is shown for each individual serum. 
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Table 3. IgE-binding (expressed as the number of allergic patients with a positive response towards each peptide) to synthetic peptides derived from in 
vitro digestions of β-CN and related 20-mer peptides from a peptide library that spans the whole β-CN sequence. The matching β-CN fragments 
identified in the in vitro gastric (60 min, G60) and gastroduodenal digests (60 min of gastric followed by 30 min of duodenal digestion, D30) with 
simulated and human digestive fluids by RP-HPLC-MS/MS are also shown, highlighting in blue the part of the sequence that coincides with the 
synthetic peptide. 
 
Synthetic peptides derived 
from digestions 
β-CN 20-amino acids 
peptides 
β-CN 
fragments 
Reactive 
patients 
RP-HPLC-MS/MS identified peptides 
Simulated fluids Human fluids 
G60 D30 G60 D30 
SLVYPFPGPIPN  57-68 33.3     
 IHPFAQTQSLVYPFPGPIPN 49-68 33.3 LVYPFPGPIPNSLPQNIPPLTQT LVYPFPGPIPN SLVYPFPGPIPNSL SLVYPFPGPI 
 FAQTQSLVYPFPGPIPNSLP 52-71 33.3 VYPFPGPIPNSLPQNIPPLTQT LVYPFPGPIPNSLPQ LVYPFPGPIPNSL SLVYPFPGPIPN 
 TQSLVYPFPGPIPNSLPQNI 55-74 33.3  VYPFPGPIPN LVYPFPGPIPNSLPQNIPPLTQT LVYPFPGPI 
     VYPFPGPIPNSLPQ VYPFPGPIPNSL LVYPFPGPIPN 
      VYPFPGPIPNSLPQNIPPLTQT VYPFPGPI 
       VYPFPGPIPN 
SLPQNIPPLTQT  69-80 8.3     
 PFPGPIPNSLPQNIPPLTQT 61-80 33.3 LVYPFPGPIPNSLPQNIPPLTQT SLPQNIPPLTQT LVYPFPGPIPNSLPQNIPPLTQT NIPPLTQT 
 GPIPNSLPQNIPPLTQTPVV 64-83 8.3 VYPFPGPIPNSLPQNIPPLTQT  VYPFPGPIPNSLPQNIPPLTQT  
 PNSLPQNIPPLTQTPVVVPP 67-86 0 PPLTQT  IPNSLPQNIPPL  
      PQNIPPLTQT  
NIPPLTQTPVVV  73-84 16.7     
 PNSLPQNIPPLTQTPVVVPP 67-86 0 LVYPFPGPIPNSLPQNIPPLTQT SLPQNIPPLTQT LVYPFPGPIPNSLPQNIPPLTQT NIPPLTQT 
 LPQNIPPLTQTPVVVPPFLQ 70-89 16.7 VYPFPGPIPNSLPQNIPPLTQT NIPPLTQTPVVVPPFLQPEVM VYPFPGPIPNSLPQNIPPLTQT PVVVPPFLQPE 
 NIPPLTQTPVVVPPFLQPEV 73-92 83.3 PPLTQT PVVVPPFLQPEV IPNSLPQNIPPL PVVVPPFLQPEV 
    PVVVPPFLQPEV PVVVPPFLQPEVM PQNIPPLTQT  
    PVVVPPFLQPEVM  PVVVPPFLQ  
    PVVVPPFLQPEVMG  PVVVPPFLQPEVM  
      PVVVPPFLQPEVMG  
VVVPPFLQPEVM  82-93 41.7     
 PLTQTPVVVPPFLQPEVMGV 76-95 83.3 PVVVPPFLQPEV NIPPLTQTPVVVPPFLQPEVM PVVVPPFLQ PVVVPPFLQPE 
 QTPVVVPPFLQPEVMGVSKV 79-98 25 PVVVPPFLQPEVM PVVVPPFLQPEV PVVVPPFLQPEVM PVVVPPFLQPEV 
 VVVPPFLQPEVMGVSKVKEA 82-101 25 PVVVPPFLQPEVMG PVVVPPFLQPEVM PVVVPPFLQPEVMG  
    PPFLQPEVM PPFLQPEVM PEVM  
SKVKEAMAPK  96-105 0     
 EVMGVSKVKEAMAPKHKEMP 91-110 0 GVSKVKE VKEAMAPK GVSKVKE EAMAPK 
    SKVKEAMAPKHKEMP EAMAPK GVSKVKEAMAPKHKEMPFPKY  
      AMAPKHKEMPFPKY  
HKEMPFPKYPVEPF  106-119 0     
 EAMAPKHKEMPFPKYPVEPF 100-119 0 SKVKEAMAPKHKEMP HKEMPFPK GVSKVKEAMAPKHKEMPFPKY HKEMPFPK 
 APKHKEMPFPKYPVEPFTES 103-122 0  HKEMPFPKYPVEPF AMAPKHKEMPFPKY EMPFPK 
 HKEMPFPKYPVEPFTESQSL 106-125 0  EMPFPK PVEPFTE YPVEP 
     EMPFPKYPVEPF PVEPFTESQS PVEP 
     EMPFPKYPVEPFTESQSL   
     YPVEPF   
     YPVEPFTESQSLT   
EMPFPKYPVEPFTESQSL  108-125       8.3     
 HKEMPFPKYPVEPFTESQSL 106-125 0 SKVKEAMAPKHKEMP HKEMPFPK GVSKVKEAMAPKHKEMPFPKY HKEMPFPK 
     HKEMPFPKYPVEPF AMAPKHKEMPFPKY EMPFPK 
     EMPFPK PVEPFTE YPVEP 
     EMPFPKYPVEPF PVEPFTESQS PVEP 
     EMPFPKYPVEPFTESQSL PFTESQS  
     YPVEPF   
     YPVEPFTESQSLT   
     TESQSLTL   
YPVEPFTESQSLT  114-126 0     
 MPFPKYPVEPFTESQSLTLT 109-128 8.3  HKEMPFPKYPVEPF PVEPFTE YPVEP 
     EMPFPKYPVEPF PVEPFTESQS PVEP 
     EMPFPKYPVEPFTESQSL PFTESQS  
     YPVEPF   
     YPVEPFTESQSLT   
     TESQSLTL   
WMHQPHQPLPPTVM  143-156 0     
 LLQSWMHQPHQPLPPTVMFP 139-158 8.3 WMHQPHQPLPPTVM WMHQPHQPLPPTVM QSWMHQPHQPLPPTVM MHQPH 
 SWMHQPHQPLPPTVMFPPQS 142-161 8.3  MHQPHQPLPPTVM SWMHQPHQPLPPTVM QPHQPLPPT 
     MHQPHQPLPPTVMFPPQSVL WMHQPHQPLPPTVM PHQPLPPT 
     PPTVMFPPQ  QPLPPT 
       QPLPPTVMFPPQ 
       QPLPPTVMFPPQS 
       LPPT 
MHQPHQPLPPTVMFPPQSVL  144-163 16.7     
 HQPHQPLPPTVMFPPQSVLS 145-164 8.3 WMHQPHQPLPPTVM WMHQPHQPLPPTVM QSWMHQPHQPLPPTVM MHQPH 
    FPPQSVL MHQPHQPLPPTVM SWMHQPHQPLPPTVM QPHQPLPPT 
    PPQSVL MHQPHQPLPPTVMFPPQSVL WMHQPHQPLPPTVM PHQPLPPT 
     PPTVMFPPQ FPPQSVL QPLPPT 
     FPPQSVL  QPLPPTVMFPPQ 
     PPQSVL  QPLPPTVMFPPQS 
       LPPT 
LPVPQKAVPY  171-180 0     
 LSLSQSKVLPVPQKAVPYPQ 163-182 8.3  VLPVPQK AVPYPQRDMPIQA VLPVPQ 
 SQSKVLPVPQKAVPYPQRDM 166-185 8.3  PQK PYPQRDMPIQA LPVPQKAVPY 
 KVLPVPQKAVPYPQRDMPIQ 169-188 16.7  KAVPYPQR  KAVPYPQ 
     AVPYPQR  AVPYPQ 
LLYQEPVLGPVRGPFPIIV  191-209 16.7     
 FLLYQEPVLGPVRGPFPIIV 190-209 16.7 AFLL LLYQEPVLGPVR FLL LLYQEPVLGPV 
    FLL LLYQEPVLGPVRGPFPIIV YQEPVLG YQEPV 
    LLYQEPVLGPVRGPFPIIV LYQEPVLGPVR YQEPVLGPVRGPF PVLGPV 
    LYQEPVLGPVRGPFPIIV LYQEPVLGPVRGPFPIIV YQEPVLGPVRGPFPIIV RGPFPI 
    YQEPVLGPVRGPFPII YQEPVLGPVR PVLGPVRGPF  
    YQEPVLGPVRGPFPIIV YQEPVLGPVRGPF GPVRGPFPIIV  
    PVLGPVRGPFPIIV YQEPVLGPVRGPFPII PVRGPFPIIV  
    GPVRGPFPIIV YQEPVLGPVRGPFPIIV   
    PVRGPFPIIV PVLGPVR   
     PVLGPVRGPFPIIV   
     GPFPIIV   
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4.1.2. DISCUSSION  
The results showed that β-CN was unaffected by oral digestion either with 
simulated oral fluid or human saliva, but quickly degraded afterwards in simulated and 
human stomach fluids, leaving no intact protein at the end of the gastric phase. This is in 
accordance with previous in vitro studies performed with commercial porcine pepsin in 
simulated gastric fluid (Dupont et al., 2010a, 2010b). SDS-PAGE analyses revealed a 
faster degradation of β-CN when digested with human fluids (Figure 2). Even if there is 
not a consensus on the physiologically representative enzyme to protein ratios that should 
be used in a digestibility study, both digestion systems were standardized in terms of their 
proteinase activity on the basis of previously proposed physiologically relevant model 
(Moreno et al., 2005). Therefore, the variations encountered could be attributed to 
differences in the specificity and efficiency between the commercial digestive enzymes of 
porcine (pepsin) and bovine origin (trypsin and -chymotrypsin) and the human digestive 
enzymes, as well as to the presence of peptidases, mainly carboxypeptidases (Lyons and 
Fricker, 2011), in the human pancreatic extracts, which could account for the most 
extensive in vitro duodenal liberation of free amino acids from the peptides previously 
formed during the gastric phase (Figure 4a and Annex 6). On the other hand, it is known 
that interaction with physiological surfactants, such as phospholipids and bile salts, plays 
a key role in protein digestion (Mackie and Macierzanka, 2010). Phosphatidylcholine, a 
phospholipid secreted by the gastric mucosa, was included in our simulated gastric 
system, although it has been reported that it does not affect the kinetics of pepsinolysis of 
β-CN in solution (Macierzanka et al., 2009). Bile acids, that solubilize dietary fats, 
particularly lipolysis products of triglycerides, through the formation of mixed micelles 
with phospholipids and fatty acids, also facilitate the proteolysis by pancreatic enzymes 
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of several dietary proteins, such as β-lactoglobulin (Gass et al., 2007) and ovalbumin 
(Martos et al., 2010). However, in view of the low concentration of bile acids present in 
the human duodenal fluid, probably due to prolonged fasting (Kalantzi et al., 2006), it is 
not likely that it could favour the duodenal proteolysis of the bigger peptides generated 
from β-CN by pepsin hydrolysis. 
 There was a high degree of correlation between the digestion products released by 
simulated and human fluids, particularly after gastric digestion (Figure 5 and Annex 6). 
The peptides identified by RP-HPLC-MS/MS after pepsin digestion covered most of β-
CN sequence, except for the area between the residues 14 and 45, which comprises 5 
phophoseryl groups at positions 15, 17, 18, 19 and 35. The resistance of casein 
phosphopeptides to gastrointestinal digestion has been demonstrated in vitro and in vivo; 
therefore, the absence of peptides corresponding to this part of the protein is probably due 
to the low ionization efficiency of highly electronegative phosphorylated peptides during 
mass spectrometry analysis (García-Nebot et al., 2010). Following gastroduodenal 
digestion with simulated fluids, 68 peptides were found, many of which were either 
totally or partially coincident with fragments previously identified from gastroduodenal 
hydrolyses of β-CN using in vitro systems that mimic adult and an infant models of 
digestion (Dupont et al., 2010a, 2010b). Gastroduodenal digestion with the human fluids 
gave 45 peptides, most of which corresponded to fragments shorter than the ones 
produced by the simulated fluids as a result of a more extensive hydrolysis by the 
pancreatic extract as discussed above. Therefore, while other studies have shown large 
differences in the peptide sequences generated from hydrolysis of milk proteins when 
human and non-human digestive enzymes were compared (Almaas et al., 2011; Furlund 
et al., 2013), our results suggest that, in view of the similarities between the peptides 
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released by both systems, the in vitro digestion model utilizing commercial enzymes 
(Moreno et al., 2005) provides a good estimation of the allergenicity of a protein 
following gastrointestinal digestion. 
Accordingly, the IgE binding of the hydrolysates produced with both simulated 
and human fluids was similar, showing, in 4 out of 6 individual sera used, an increase at 
the end of the gastric phase, followed by an important decrease when the duodenal 
digestion was completed, particularly when using human enzymes (Figure 3). The 
increased IgE-reactivity of -CN found after the gastric phase, despite the fact that the 
protein was rapidly degraded upon pepsin digestion suggests that, even if -CN has a 
very flexible structure with no disulfide bonds and its major IgE-binding epitopes are 
assumed to be mainly sequential (Cocco et al., 2007), some IgE-binding epitopes were 
unmasked following hydrolysis. In fact, caseins constitute a frequently mentioned 
example of digestion-sensitive proteins that are nonetheless able to sensitize and elicit 
allergic reactions through the gastrointestinal tract (Wal, 1998). This could be attributed 
to the formation of IgE-binding protein fragments, such as that with molecular mass of 
approximately 6.5 kDa, which bound the sera of patients most immunoreactive towards 
the gastric digests (Figures 4b and c). In addition, MALDI-TOF MS revealed the 
presence in the gastric digests of peptides with molecular masses between 3,000 and 
10,000 Da that could carry IgE epitopes (Figure 6), but might not be detected by Western 
blotting following SDS-PAGE. 
With the development of microarray technology and peptide synthesis techniques, 
peptide microarray-based immunoassays have proven very useful for epitope mapping of 
milk allergens (Lin et al., 2009). The use of 58 overlapping peptides showed multiple 
IgE-binding epitopes distributed throughout the β-CN sequence (Figure 5), with the major 
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immunoreactive areas, i.e. fragments 31-101 and 124-209, being related with the most 
hydrophobic parts of the protein: 55-92, 133-150 and 151-202 (Leaver and DaLGleish, 
1990). This agrees with the results of previous studies using the peptide microarray 
technique (Cerecedo et al., 2008; Savilahti et al., 2010) and the SPOTs membrane 
technique (Chatchatee et al., 2001). Nevertheless, it should be noted that epitope diversity 
and binding affinity depend heavily on patient selection, especially on the severity of 
cow´s milk allergy and, in fact, provide prognostic information that may allow 
distinguishing between transient and persistent food allergy (Wang et al., 2010).  
Two IgE-binding synthetic peptides: β-CN (57-68) and β-CN (82-93), related to 
fragments released from β-CN following in vitro digestion with simulated and human 
fluids, were coincident with the most immunoreactive areas of the protein, in terms of 
frequency and intensity of IgE binding (Figure 5, Table 3), as well as with sequences 
previously identified as IgE-binding epitopes, particularly β-CN (57-66), β-CN (52-74) 
and β-CN (83-92) (Chatchatee et al., 2001; Cerecedo et al., 2008). Dupont et al. (2010a, 
2010b) also reported the appearance of β-CN (81-93) after simulated gastrointestinal 
digestion of β-CN. Six synthetic peptides that resembled products of gastroduodenal 
digestion, β-CN (96-105), β-CN (106-119), β-CN (108-125), β-CN (114-126), β-CN 
(143-156) and β-CN (171-180), did not react with any of the patient’s sera employed in 
the study. However, in some cases, IgE-binding was detected when these sequences were 
included in the 20 amino acid-peptides from the library (see for instance β-CN (143-156) 
and β-CN (171-180) in Figure 5 and Table 3), thus highlighting the influence of peptide 
length and the nature of nearby amino acids, in addition to the individual patient 
specificity, in determining the affinity for IgE antibodies (Cocco et al., 2007; Collis et al., 
2003). This raises the question of whether the IgE-binding fragments identified after 
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gastroduodenal digestion constitute a full epitope or only a part of it. Furthermore, their 
small molecular mass makes it unfeasible that they contain more than a single IgE 
binding epitope, suggesting marginal biological activity in terms of basophil activation 
properties (Albrecht et al., 2009). However, immunization of rats with small peptides, 
such as those arising from Ara h 1 digestion, induces antibody responses, which could be 
attributed to their aggregation into complexes of larger sizes (Bøgh, 2012). 
Taking into account the limitations inherent in the simulation of in vivo 
gastrointestinal conditions, which are characterised by large inter-individual variations in 
gastric and duodenal secretions and intra-individual differences due to the type and 
amount of food consumed or the time of the day (Hur et al., 2011), and the heterogeneous 
recognition of critical amino acids in -CN by individual milk allergic patients (Cocco et 
al., 2007), the similarities found between the in vitro simulated digestion system with 
commercial enzymes used in this work, broadly employed in studies aimed to assess the 
digestibility of food allergens, and that using human digestive fluids, suggest that the 
former would provide a reasonably good estimation of the potential allergenicity of 
protein digests. In fact, by using a peptide microarray-based immunoassay, similar IgE 
binding epitopes were found within the products of the digested β-CN utilizing both 
systems, which matched the regions recognized in the peptide library of 58 fragments 
covering the entire β-CN sequence. 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.2. Digestibility and allergenicity of β-Lactoglobulin: simulated 
gastrointestinal digestion with human and porcine enzymes, 
characterization, identification and microarray analysis of the 
hydrolysates 
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β-Lactoglobulin (β-LG, Bos d 5) is the most abundant whey protein in cow milk, 
accounting for about 58% of the whey and 10% of the total milk protein. As a member of 
the lipocalin protein family, β-LG shows a particular tertiary structrure, consisting in a β-
barrel with a central calyx with high affinity for hydrophobic ligands. Both 
characteristics, abundance and a structure endowing an exceptional resistance to digestive 
enzymes, specially to pepsin (Dalgalarrondo et al. 1995), make it a highly allergenic 
protein. For instance, bovine β-LG is identified unequivocally as one of the major 
allergen in cow´s milk, with a reported sensitization rate of 61% (Monaci et al., 2006) 
although 90% of patients had IgE that recognized β-LG peptide (Wal 1998).  
As known, most allergens (including β-LG) are thought to sensitize via the 
gastrointestinal tract (Bannon, 2004; Mills et al., 2003; Lehrer et al., 1996). Accordingly, 
there are some studies about digestibility of β-LG. Some of them have reported an 
enhanced β-LG digestion after heat treatment (80ºC and 1 h) (Chobert et al., 1995), high 
pressure (Chicón et al. 2008) or emulsification (Macierzanka et al., 2009), and in contrast, 
others authors have reported reduced digestibility of β-LG by interactions with 
polysaccharides (Mouecoucou et al., 2007). 
Some studies have characterized the resulting products of digestion (Defernez et 
al., 2010), and others have identified the major IgE binding epitopes (Ball et al., 1994; 
Wal, 1998; Sélo et al., 1999; Järvinen et al., 2001) but limited work have been reported 
analyzing the immunoreactive properties of gastrointestinal digests of β-LG, as its high 
resistance to pepsinolysis makes possible that intact or sufficiently big fragments of β-LG 
reach the small intestine, which can trigger allergic responses even at low concentrations.  
This section described the simulation of the orogastrointestinal proteolysis of β-
LG using using human fluids in an in vitro digestion system that mimics the successive 
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passage through the stomach and duodenum and it is compared it with another model that 
uses commercial enzymes. Then, the identification, IgE-binding properties and epitope 
mapping of the resulting digestion products have also been evaluated. 
 
4.2.1. RESULTS  
 4.2.1.1. Digestibility and IgE binding of β-LG 
 
The degradation of β-LG, during in vitro digestion with human and simulated fluids, 
was assessed by RP-HPLC and the chromatograms of native β-LG and its digests are 
shown in Figure 7. The assays were performed at the same enzyme to substrate ratio, 
taking into account the values described in Materials and Methods section. Native β-LG 
was eluted at 53 min and although it is hardly cleaved by pepsin throughout gastric 
digestion, few peptides that eluted at lower retention times in the chromatographic 
separation than the intact protein were observed, especially in the human fluids digests. 
Next, in the intestinal environment, β-LG undergoes highly susceptible to proteases, and 
these hydrophilic peptides increased in abundance as the digestion progressed into the 
duodenal phase (Fig 7e and 7f). No residual β-LG was observed at the end of the 
digestion. 
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Figure 7. RP-HPLC patterns of β-LG (a, b) subjected to gastric digestión for 60 min (c, d) 
followed by duodenal digestion for 30 min (e, f) with human (a, c, e) (1.8 mg/mL) and simulated 
fluids (b, d, f) (3.9 mg/mL). 
 
The human IgE recognition of β-LG before and after in vitro gastrointestinal 
digestions, was tested by inhibition ELISA on the intact protein and on its gastric and 
duodenal digests, using six different sera from milk allergic patients (nos. 1 to 6, Annex 
2). Immunoreactivity of β-LG decreased progressively during digestion, showing values 
from 40 to 90% of IgE binding in gastric digests when compared to the undigested 
protein and values close to zero after duodenal digestion (Figure 8). These results agree 
with the presence of intact protein at the end of the gastric digestion and with the 
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complete degradation at the end of the duodenal stage observed with both models of 
digestion studied. 
 
Figure 8. IgE binding of β-LG, expressed as percentage of the EC50 of the intact protein as 
estimated by inhibition ELISA with sera from six allergic patients (patients 1-6, Annex 2), after in 
vitro gastric digestion with simulated (      ) and human (      ) fluids and gastroduodenal  digestion 
with simulated (     ) and human (     ) fluids. 
 
 4.2.1.2. Peptide identification after in vitro digestions  
 
The gastric (60 min) and gastroduodenal (with a further 30 min of duodenal 
hydrolysis) digests of β-LG were subjected to RP-HPLC in tandem with mass 
spectrometry using a quadrupole ion trap. Figure 9 and Annex 7 show the sequences of 
the 195 peptides identified, which ranged between 3 and 26 amino acids. The sequence 
coverage was high: 90.8 and 72.4% after gastric digestion and 96.3 and 74.8% after 
subsequent duodenal digestion with simulated and human fluids, respectively. The 
identification of peptides in samples of β-LG digested with human fluids showed 37 
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peptides in the gastric phase and 57 in the duodenal phase, while simulated fluids 
produced 75 peptides in the gastric phase and 100 in the duodenal stage. Regarding to the 
peptides generated in the gastric phase, 21 peptides were coincident in both models of 
digestion and the most abundant cleavage site in both systems of digestion was leucine at 
the C-terminal position, showing this pattern the 33.3% of the peptides identified in the 
digestion carried with simulated fluids and the 29.7% of the peptides identified in the 
digestion with human fluids. Most of the remaining peptides found in the duodenal 
digests produced with both models of digestion could be products of hydrolysis of the 
intact protein remaining after the gastric phase by duodenal enzymes action as it is shown 
by the breakdown at the trypsin cleavage sites: Lys (8, 14, 60, 69, 75, 83, 91, 100, 135, 
138 and 141) and Arg (40, 124 and 148). In the duodenal digest produced with human 
fluids, 18 peptides were coincident with those produced with simulated fluids. 
 
 4.2.1.3. Peptide microarray immunoassay: Epitope recognition 
 
22 peptides, ranging from 10 to 19 amino acids, representative of those found in 
the gastroduodenal digests with simulated and human fluids as well as a library of 36 
peptides covering the whole sequence of β-LG were chemically synthetized and their IgE-
binding to 8 individual sera from milk allergic patients (nos. 7-14, Annex 2) was assessed 
by peptide microarray (Figure 9). Taking together the 20-amino acids synthetic peptides, 
the IgE binding areas identified with the peptide microarray were two, β-LG (21-74) and 
β-LG (100-149), although the areas of the protein that were recognized by most sera 
corresponded to that between residues β-LG (43-65) and β-LG (124-140) (Figure 9). 
These immunodominant reactive areas were coincident with the IgE-binding patterns of 
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the 22 printed peptides selected from the gastroduodenal digests with simulated and 
human fluids. Moreover, the area β-LG (86-99) was recognized by 50% of the patients 
used in this study, while any of the sera showed IgE binding against the same area when it 
was included in bigger peptides of 20 aminoacids. Peptides from both models of digestion 
are included in the three regions of the sequence with IgE binding. 
Table 4 compares the IgE binding frequency to the individual sera of the selected 
peptides from digestions with that of matching sequences from the 20-amino acids 
peptide library. The highest IgE binding (87.5% of patients) corresponded to the β-LG 
region comprised between positions 43-62 [β-LG (43-60), and β-LG (47-62)]. The 
peptide β-LG (135-147) was also very immunoreactive, reacting with the 62.5% of the 
patients. Between 12,5 to 50% of the sera´s patients reacted with peptides β-LG (86-99), 
β-LG (86-100), β-LG (108-125) β-LG (122-136) and β-LG (123-137), while peptides β-
LG (21-32), β-LG (25-35), β-LG (29-41), β-LG (56-69), β-LG (62-80), β-LG (71-82), β-
LG (74-88), β-LG (91-105), β-LG (98-111), β-LG (101-115), β-LG (107-116), β-LG 
(112-126), β-LG (115-129) and β-LG (134-146) did not react with any of the patient’s 
sera employed in the study. 
  
 
Figure 9. Peptide sequences, identified by RP-HPLC-MS/MS, in the gastric (60 min) and gastroduodenal digests of β-LG (60 min of gastric followed by 30 min of duodenal digestion), with simulated and human fluids, and IgE 
binding, estimated by peptide microarray with 8 sera of milk allergic patients (patients 7-14, Annex 2), of 22 peptides selected from the simulated digestions and 36 20-amino acid peptides from a peptide library that spans the 
whole β-LG sequence. The intensity of the IgE binding, low (      ), medium (      ) and high (      ) is shown for each individual serum. 
 
L I V T Q T M K G L D I Q K V A G T W Y S L A M A A S D I S L L D A Q S A P L R V Y V E E L K P T P E G D L E I L L Q K W E N D E C A Q K K I I A E K T K I P A V F K I D A L N E N K V L V L D T D Y K K Y L L V C M E N S A E P E Q S L V C Q C L V R T P E V D D E A L E K F D K A L K A L P M H I R L S F N P T Q L E E Q C H I
L I V T Q T M L A M A A S D I Y V E E W E N D E C A K I D A L N E M E N S A E P E Q S L V R T P E V D D E E Q C H I
L I V T Q T M K G L D A M A A S D I S L L Y V E E L K P T P E G D L E N D E C A K I D A L N E N K V L V L N S A E P E Q S V R T P E V D D E
I V T Q M A A S D Y V E E L K P T P E G D L E A Q K K I I A E K T K I P A V F N E N K V L V L S A E P E Q S V R T P E V D D E A
I V T Q T M K G I S L L D A Q S A P L R V V E E L K P T P E G D L I I A E K T K I P A V F N K V L V L E Q S L V C Q C V R T P E V D D E A L
I V T Q T M K G L D I I S L L V E E L K P T P E G D L E E K T K I P A V V L D T D Y K K Y L L P E V D D E A L E K F D
Q T M K G L D L D A Q S A P L R V E L K P T P E E K T K I P A V F L D T D Y K K Y L L A L E K F D K A L K A
I Q K V A G T L D A Q S A P L R V Y E L K P T P E G D L E K T K I P A V D T D Y K K Y L L A L E K F D K A L K A L P M H I R L
I Q K V A G T W D A Q S A P L R V L K P T P E G K T K I P A V F D T D Y K K Y L L V L E K F D K A L K A L P M H I R L
K V A G T W Q S A P L R V L K P T P E G D L T K I P A V F Y K K Y L L E K F D K A
L K P T P E G D L E K K Y L L E K F D K A L
K P T P E G D L E K F D K A L K A L
K P T P E G D L E I E K F D K A L K A L P M
E K F D K A L K A L P M H I R L
K F D K A L K A
K F D K A L K A L P M H I
D K A L K A L P M H I R L
K A L K A L P M H I
L K A L P M H I R L
L P M H I R L
S F N P T Q L
T Q T M K G L D A S D I S L L D L Q K W E N E K T K I P A V F V L V L D T D Y V R T P E V D D
Q T M K G L D D A Q S A P L R V K T K I P A V F D T D Y K K Y V R T P E V D D E
I Q K V A G T W Q S A P L R V T K I P A V F D T D Y K K Y L L A L E K F D K
Y V E E L K I P A V F K I D Y K K Y L L A L E K F D K A
Y V E E L K P T P E G D L P A V F K I D A L E K F D K A L K A
Y V E E L K P T P E G D L E A V F K I D A L N E N K V L E K F
E L K P T P E G D L E K I D A L N E E K F D K A
L K P T P E G D L E K F D K A L K A L P M H I R L
A L K A L P M H I R L
L K A L P M H I R L
A L P M H I R L
L P M H I R L
I R L S F N
S F N P T Q L
7
8
9
10
11
12
13
14
S L A M A A S D I S L L E K T K I P A V F K I D A L N E P E Q S L V C Q C L V R T P
A A S D I S L L D A Q A L N E N K V L V L D T D Y Q S L V C Q C L V R T P E V D
I S L L D A Q S A P L R V A L N E N K V L V L D T D Y K L V R T P E V D D E A L E K F
V E E L K P T P E G D L E I L L Q K K V L V L D T D Y K K Y L L V V R T P E V D D E A L E K F D
K P T P E G D L E I L L Q K W E D Y K K Y L L V C M E N S A E K F D K A L K A L P M H
I L L Q K W E N D E C A Q K K Y L L V C M E N S A E P E Q K F D K A L K A L P M H I
E N D E C A Q K K I I A E K T K I P A M E N S A E P E Q S
I I A E K T K I P A V F E N S A E P E Q S L V C Q C L V R T
14
13
12
11
10
9
8
7
L I V T Q T M V Y V E E L K P T P E G D L E I L E K T K I P A V F K I D A L N E N K V L V L D T D Y C Q C L V R T P E V D D E A L E K
L I V T Q T M K V Y V E E L K P T P E G D L E I L L T K I P A V F V R T P E V D D
I V T Q V Y V E E L K P T P E G D L E I L L Q I P A V F V R T P E V D D E
I V T Q T M K Y V E E F K I D A L N E V R T P E V D D E A
T M K G L D I Q K V A G T W Y Y V E E L K P T P E G D L K I D A L N E V R T P E V D D E A L
K G L D I Q K Y V E E L K P T P E G D L E K I D A L N E N K V R T P E V D D E A L E K
K G L D I Q K V A G T W Y V E E L K P T P E G D L K I D A L N E N K V L V R T P E V D D E A L E K F D K
G L D I Q K V E E L K P T P E G D L E I D A L N E N K T P E V D D E
K V A G T W V E E L K P T P E G D L E I L A L N E N K V L V L D T D Y K K Y L L V C M E N S A T P E V D D E A
V A G T W V E E L K P T P E G D L E I L L K V L V L D T D Y K K Y L L V C M E N S A E P E Q T P E V D D E A L E K
V A G T W Y V E E L K P T P E G D L E I L L Q K V L V L D T D Y T P E V D D E A L E K F
S L A M A A S D I S L L E L K P T P E V L V L D T D Y K T P E V D D E A L E K F D K
A M A A S D I S L L E L K P T P E G D L E V L V L D T D Y K K Y L L V C M E N S A E P E V D D E A L E K F D K A L K A
M A A S D L K P T P E G D L V L D T D Y L E K F D K
A A S D I S L L L K P T P E G D L E V L D T D Y K E K F D K
I S L L K P T P E G D L V L D T D Y K K E K F D K A
I S L L D A Q S A K P T P E G D L E I L L Q K W E D T D Y K E K F D K A L K A L P M H
I S L L D A Q S A P L R V I L L Q K W E N D E D T D Y K K K F D K
L D A Q S A P L I L L Q K W E N D E C A Q K D Y K K Y L L V C M E N S K F D K A L K A L P M H I
D A Q S A P L R L Q K W K Y L L V C M E N S A E D K A L K
R V Y E N D E C A Q K K I I A E K T K I P A V F Y L L V H I R
A Q K K I I A E K T K I P A V L L V H I R L
A Q K K I I A E K T K I P A V F E N S A E P E Q S L V C Q C L V R T S F N P T Q L
K I I A E K N S A E P
I I A E N S A E P E Q S
I I A E K S A E P E Q S
E P E Q S L V C Q C L V R T P E V D D E A L E K F
Q S L V C Q C L V R T P E V D D E A L E K F D
V C Q C L V R T P E V D D E A L
C Q C L V R T P E V D D E A L E
L I V T G L D I Q A A S D I S L L D A Q V Y V E E L K P T P E G D L K I I T K I P A V R T P E V D A L K A L P M R L S F N P T
A S D I S L L D V Y V E E L K P T P E G D L E I I A E P A V F K I D V R T P E V D D L S F N P T
D A Q S A P L Y V E E L K P T I I A E K K I D A V R T P E V D D E S F N P T
Y V E E L K P T P E G D L D A L N E N R T P E V D D E A L E Q L E E Q
Y V E E L K P T P E G D L E V L V L D T D Y T P E V D
V E E L K P T V L D T D Y K T P E V D D E
V E E L K P T P E G M E N S A E P E Q S T P E V D D E A L E
V E E L K P T P E G D L E E N S A E P E Q S L V C Q C L V T P E V D D E A L E K
V E E L K P T P E G D L E I S A E P E Q D E A L E
E E L K P T P E G D L E S A E P E Q S A L E K F D
E L K P T P E G D L E E Q S L V C Q C L V A L E K F D K
L K P T P E G D L  E K F D K
L K P T P E G D L  
K P T P E G D L C Q C L V R T P E V D D E A L E
K P T P E G D L E
K P T P E G D L E I
T P E G D L E
T P E G D L E I
P E G D L E
P E G D L E I
30 150 160
β-LG
1 70 80 90 100 110 120 1302010
GA
ST
RO
IN
TE
ST
IN
AL
 D
IG
ES
TI
ON
140
Si
m
ul
at
ed
 Fl
ui
ds
Hu
m
an
 Fl
ui
ds
Hu
m
an
 Fl
ui
ds
GA
ST
RI
C 
DI
GE
ST
IO
N
Ig
E 
bi
nd
in
g t
o 
pe
pt
id
es
 
Se
le
ct
ed
    
    
pe
pt
id
es
 
sy
nt
he
tic
20
-M
er
Si
m
ul
at
ed
 Fl
ui
ds
605040
  
Table 4. IgE-binding (expressed as the percentage of allergic patients with a positive response towards each peptide) to synthetic peptides derived from in vitro digestions 
of β-LG and related 20-amino acids peptides from a peptide library that spans the whole β-LG sequence. Highlighting in blue the part of the sequence that coincides with 
the synthetic peptide derived from digestions. 
 
Synthetic peptides derived 
from digestions 
β-LG 20-amino acids peptides 
β-LG 
fragments 
% 
Reactive 
patients 
SLAMAASDISLL  21-32 0 
 QKVAGTWYSLAMAASDISLL 13-32 0 
 AGTWYSLAMAASDISLLDAQ 16.35 0 
 WYSLAMAASDISLLDAQSAP 19-38 0 
AASDISLLDAQ  25-35 0 
 AGTWYSLAMAASDISLLDAQ 16-35 0 
 WYSLAMAASDISLLDAQSAP 19-38 0 
 LAMAASDISLLDAQSAPLRV 22-41 12.5 
ISLLDAQSAPLRV  29-41 0 
 LAMAASDISLLDAQSAPLRV 22-41 12.5 
 AASDISLLDAQSAPLRVYVE 25-44 0 
 DISLLDAQSAPLRVYVEELK 28-47 0 
VEELKPTPEGDLEILLQK  43-60 87.5 
 VEELKPTPEGDLEILLQKWE 43-62 50 
KPTPEGDLEILLQKWE  47-62 37.5 
 VEELKPTPEGDLEILLQKWE 43-62 62.5 
 LKPTPEGDLEILLQKWENDE 46-65 50 
ILLQKWENGECAQK  56-69 0 
 GDLEILLQKWENDECAQKKI 52-71 0 
 EILLQKWENDECAQKKIIAE 55-74 12.5 
ENDECAQKKIIAEKTKIPA  62-80 0 
    
IIAEKTKIPAVF  71-82 0 
 DECAQKKIIAEKTKIPAVFK 64-83 0 
EKTKIPAVFKIDALN  74-88 0 
    
ALNENKVLVLDTDY  86-99 37.5 
    
ALNENKVLVLDTDYK  86-100 50 
    
KVLVLDTDYKKYLLV  91-105 0 
 KVLVLDTDYKKYLLVCMENS 91-110 0 
DYKKYLLVCMENSA  98-111 0 
 TDYKKYLLVCMENSAEPEQS 96-116 0 
KYLLVCMENSAEPEQ  101-115 0 
 KKYLLVCMENSAEPEQSLVC 100-119 12.5 
MENSAEPEQS  107-116 0 
 KKYLLVCMENSAEPEQSLVC 100-119 12.5 
 LLVCMENSAEPEQSLVCQCL 103-122 25 
 CMENSAEPEQSLVCQCLVRT 106-125 25 
ENSAEPEQSLVCQCLVRT  108-125 12.5 
 CMENSAEPEQSLVCQCLVRT 106-125 25 
EPEQSLACQCLVRTP  112-126 0 
 NSAEPEQSLVCQCLVRTPEV 109-128 0 
QSLVCQCLVRTPEVD  115-129 0 
 QSLVCQCLVRTPEVDDEALE 115-134 12.5 
LVRTPEVDDEALEKF  122-136 25 
 VCQCLVRTPEVDDEALEKFD 118-137 25 
 CLVRTPEVDDEALEKFDKAL 121-140 50 
VRTPEVDDEALEKFD  123-137 25 
 VCQCLVRTPEVDDEALEKFD 118-137 25 
 CLVRTPEVDDEALEKFDKAL 121-140 50 
EKFDKALKALPMH  134-146 0 
 EVDDEALEKFDKALKALPMH 127-146 37.5 
 DEALEKFDKALKALPMHIRL 130-149 12.5 
 LEKFDKALKALPMHIRLSFN 133-152 0 
KFDKALKALPMHI  135-147 62.5 
 DEALEKFDKALKALPMHIRL 130-149 12.5 
 LEKFDKALKALPMHIRLSFN 133-152 0 
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4.2.2. DISCUSSION 
The results of RP-HPLC analysis of the hydrolysates from the two models of 
digestion showed the same pattern of breakdown showing human fluids a greater reaction 
rate based on the appearance of higher number of peaks during gastric digestion and 
higher degradation of intact β-LG, although both types of systems left the main part of β-
LG undigested at the end of this step (Figure 7). After duodenal phase with both in vitro 
models, β-LG was completely digested. Earlier digestion studies with simulated fluids 
showed similar results for both gastric and duodenal phases (Schmidt et al 1995; Fu et al. 
2002; Chicón et al., 2008). Our results are also consistent for the gastric phase in other 
previously reported studies with human fluids (Almaas et al. 2006a; Inglingstad et al. 
2010), but some differences were found after the duodenal phase. These authors reported 
about 83 and 60% respectively of intact β-LG in bovine milk at the end of the 
gastrointestinal digestion. This discrepancy between the results can be due to the different 
substrate used for the digestion. Minerals, carbohydrate content or buffer capacity of milk 
could have an impact on the enzymatic activity of human fluids. Moreover the presence 
of bile salts in the digestion also affects the proteolytic activity of the enzymes. Gass et al. 
(2007) demonstrated that the addition of bile acid mixture significantly enhanced the 
digestion of β-LG by trypsin and chymotrypsin. However, in view of the low 
concentration of bile acids present in the human duodenal fluid, probably due to 
prolonged fasting (Kalantzi et al., 2006), it is not likely that it could favour the duodenal 
proteolysis of β-LG. 
On the other hand, the lower number and less size of peptides identified in the 
duodenal stage of the digestion with human fluids compared with those from digestion 
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with simulated fluids could indicates a higher degradation during digestion using human 
fluids. This fact is in agreement with our previous findings in β-CN digestion (section 
4.1) but against the results obtained using caprine milk and whey by Eriksen et al. (2010) 
and Almaas et al. (2006b) respectively. However these differences are probably due to the 
higher ratio of enzyme to substrate used in our study.  
As mentioned above, both models of digestion have been carried out with the 
same ratio enzyme activity-substrate and the large number of different peptides obtained 
with simulated fluids digestion model and the differences in the cleavages of the peptides 
could be due to a species difference, with a higher specificity of porcine enzymes. These 
species-dependent results have also been observed in the hydrolysis of β-casein by human 
pepsin and bovine chymotrypsin (Guillou et al., 1991). Moreover different isoforms of 
pepsin (Dunn, 2002) and pancreatic enzymes (Scheele et al., 1981) present in the human 
fluids may be more efficient at degrading the β-LG than porcine enzymes in the simulated 
fluids model. 
Assessing the digestibility of a protein is not by itself a sufficient measure of its 
allergenic potential and hence we also have investigated the IgE binding capacity of the 
digests from both models of digestion. Immunoassays showed in general the same results 
with both models of digestion (Figure 8). The residual IgE binding capacity of β-LG after 
two stages of digestion was found to be entirely consistent with the levels of residual 
native protein found in the digests of the two models with the immunoreactivity of β-LG 
decreasing progressively after gastrointestinal digestion, due to the disruption of epitopes 
sites present in the gastric phase. In contrast, Bossios et al. (2011) observed that digestion 
did not modify the IgE binding capacity of β-LG may be due to differences in the 
protocol of digestion used. Β-LG has both linear and conformational epitopes and during 
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digestion a reduction in the binding strength between antibodies and antigens is expected, 
because of the reduced possibility of small peptides to sustain sufficient structural 
integrity to bind antibodies raised against conformational epitopes (Bøgh et al., 2012).  
Previous studies have identified some regions of the protein as epitopes. 
According to Adams et al. (1991), the main β-LG epitope corresponds to β-LG (124-134), 
while Ball et al. (1994) posteriorly reported the sequences β-LG (95-104), β-LG (96-105) 
and β-LG (97-108) as the most important fragment with IgE-binding capacity. Sélo et al. 
(1999) considered the tryptic peptides β-LG (41-60), β-LG (102-124) and β-LG (149-
162) as the major epitopes within β-LG, although other fragments also showed IgE 
binding capacity, such as β-LG (1-8) and β-LG (25-40). The sequences β-LG (12-27), β-
LG (95-113) and β-LG (124-135) were also characterized as IgE epitopes by Heinzmann 
et al. (1999). Järvinen et al. (2001) identified seven major epitopes of β-LG 
corresponding to β-LG (1-16), β-LG (31-48), β-LG (47-60), β-LG (67-78), β-LG (75-86), 
β-LG (127-144) and β-LG (141-152). Epitopes from the region β-LG (1-48), described 
previously by Sélo et al. (1999), Heinzmann et al. (1999) and Järvinen et al. (2001), β-LG 
(95-113) (Ball et al., 1994; Heinzmann et al., 1999) and β-LG (141-152) (Järvinen et al., 
2001) could be irrelevant when we study the immunoreactivity of the digests because the 
experimental data reported in this study show that the identified peptides from the 
gastroduodenal digestion containing in these regions are mostly from the model using 
simulated fluids and not from the human model. In contrast, the identified peptides from 
the gastroduodenal digestion containing in the region β-LG (149-162), reported by Sélo et 
al. (1999) as an epitope, are mainly from the digestion with human fluids. The peptides 
from gastroduodenal digestion contained in the previously described areas of β-LG as 
epitopes corresponding to β-LG (41-60) (Sélo et al., 1999; Järvinen et al., 2001), β-LG 
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(67-86) (Järvinen et al., 2001) and β-LG (102-144) (Adams et al., 1991; Sélo et al., 1999; 
Heinzmann et al., 1999; Järvinen et al., 2001) were identified in the digests of both 
human and simulated digestion models and could explain the residual immunogenicity 
detected by inhibition ELISA at the end of gastroduodenal digestions. Moreover, the 
fragment β-LG (75-86) has been reported as an important epitope only recognized by the 
patients with persistent cow´s milk allergy (Järvinen et al., 2001). 
With the development of microarray technology and evolution in peptide synthesis 
techniques, peptide microarray-based immunoassay has been developed for epitope 
mapping of milk allergens (Lin et al., 2009). In this study, we have identified 3 areas of 
epitopes of β-LG (Figure 9). Two of these areas have been previously identified as 
epitopes by microarray technology (Cerecedo et al., 2008; Wang et al., 2010). However, 
one of the reactive areas in this study (ALNENKVLVLDTDYK) was not identified in 
previous studies. This new area is only reactive if it corresponds to a complete peptide 
from digestion but it is not reactive if the sequence is included in peptides of 20 amino 
acids from the library, showing that in microarray technique the peptide generated during 
the digestion might have different behaviour than the same peptide included in a bigger 
sequence. The new region identified includes peptides from both models of digestion. 
This highlights the influence of peptide length and the nature of nearby amino acids, in 
addition to the individual patient specificity, in determining the affinity for IgE antibodies 
(Cocco et al., 2007; Collis et al., 2003). This raises the question of whether the IgE-
binding fragments identified after gastroduodenal digestion constitute a full epitope or 
only a part of it.  
In conclusion, the similarities found between the in vitro simulated digestion 
system with simulated fluids used in this work, broadly employed in studies aimed to 
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assess the digestibility of food allergens, and that using human digestive fluids, suggest 
that the former would provide a reasonably good estimation of the potential allergenicity 
of protein digests, although specific epitopes could be preferentially formed by either 
model. Additional studies are necessary to confirm these findings but peptide microarrays 
might be a useful technique to complete the research of digestibility and allergenicity of 
food allergens. Moreover, in order to study the allergenicity of hydrolysates by 
microarray technique maybe would be better test the real peptides and not an overlapping 
set of peptides, because the IgE binding can change depending on length of the peptides.  
 
  
  
 
 
 
 
 
 
 
 
4.3. Identification of IgE binding peptides in hen egg ovalbumin digested 
in vitro with human and simulated gastroduodenal fluids 
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Ovalbumin (OVA, Gal d 2), the most abundant protein in egg white (up to 54% of 
the protein content), is considered one of the dominant allergens (Mine and Zhang, 2008). 
OVA is a phosphoglycoprotein with a molecular mass of 45 kDa and 385 amino acids 
(McReynolds et al., 1978; Nisbet et al., 1981). X-ray crystallography studies have shown 
a three dimensional structure consisting of three layers of α-helices and nine β-sheets 
(Stein et al., 1990) (Figure 10a). OVA sequence includes six cysteines, with a single 
disulphide bond between Cys73 and Cys120, a glycosylation site at Asn292, and two 
phosphorylation sites at Ser68 and Ser344. Half the amino acid residues are hydrophobic 
(Figure 10b) and one third are charged residues (Figure 10c). 
 
 
Figure 10. Representation of (a) the secondary structure (α-helix in orange color, β-strand in 
green and random coil in light brown), (b) hydrophobic amino acid residues (orange color) and (c) 
charged amino acid residues (orange color) of OVA in the 3D structure of the protein. Molecular 
graphics and analyses were performed with the UCSF Chimera package (Pettersen et al., 2004). 
The X-ray coordinates (Stein et al., 1991) were obtained at the RCSB Protein Data Bank (PDB 
ID: 1OVA). 
 
As many other allergenic proteins, OVA partially resists hydrolysis with pepsin 
and pancreatic enzymes, an aspect that could contribute to its ability to sensitize or elicit 
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allergic reactions (Ruiter and Shreffler, 2012). So far, the studies investigating the 
gastrointestinal stability of OVA have been performed in vitro by the use of enzymes of 
bovine or porcine origin as part of different digestion models, ranging from simple one-
step hydrolyses (Fu et al., 2002; Takagi et al., 2003), to advanced physiologically relevant 
systems where subsequent gastric and duodenal digestions are conducted under 
conditions that mimic the in vivo processes in infants and adults (Dupont et al., 2010a; 
Martos et al., 2010). However, to the best of our knowledge, the digestibility with human 
digestive juices has not been assessed. 
In the present section, the digestibility of OVA using human gastric and duodenal 
juices was assessed, the peptides released were characterized and the IgE-binding 
properties of the most relevant digestion products were evaluated. Digestions were also 
conducted with simulated fluids for comparative purposes. This allowed the identification 
of relevant IgE binding epitopes that resisted digestion in both systems and could 
contribute to the allergenic potential of the protein. 
 
4.3.1. RESULTS 
 4.3.1.1. In vitro digestion of ovalbumin with human and simulated fluids 
 
Figure 11 shows the SDS-PAGE patterns (Figure 11a and 11c) and Western blots 
using a pool of sera from 6 allergic patients (nos. 7-12, Annex 3) (Figure 11b and 11d) of 
OVA after being subjected to two-step digestion protocols, mimicking the stomach and 
duodenal stages, by using human and simulated fluids. In general terms, after 60 min of 
incubation with human gastric fluid a remarkable amount of OVA still remained 
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undigested, while the intact protein virtually disappeared following the subsequent 
duodenal phase (Figure 11a).  
 
Figure 11. SDS-PAGE (a, c) using Bis-Tris 12% acrylamide gels, and Western blotting (b, d) of 
OVA after in vitro gastric and gastroduodenal digestion with human (a, b) and simulated (c, d) 
fluids. M: molecular mass marker, lane 1: OVA, lane 2: 60-min gastric digests; lane 3: 
gastroduodenal digest (60 min of gastric digestion followed by 30 min of duodenal digestion); 
lane 4: 60 min of gastric digestion followed by 60 min of duodenal digestion). * IgE-binding 
fragment originally present in the human duodenal fluid. 
 
Gastric and, particularly, duodenal hydrolyses were much faster with human fluids 
as compared with simulated fluids, with the appearance of more degradation products 
after the gastric phase, of  ~40, 22, 18, 13 and 5 kDa, and less degradation products, 
within the range of ~25 to 5 kDa, after the duodenal phase (Figure 11a and 11c). As a 
result, there were less IgE-binding from intact OVA and its 40 kDa fragment following 
gastroduodenal digestion with human fluids. Remarkably, a strong IgE-binding band of 
~21 kDa, that formed during duodenal digestion with simulated fluid, was absent from 
the corresponding digests produced with human fluid, which in turn, yielded lower 
molecular mass immunoreactive degradation products (Figure 11b and 11d). It should be 
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mentioned that no differences in the degradation patterns were detected when comparing 
30 and 60 min of duodenal digestion with either system. 
In consonance with these results, inhibition ELISA (Figure 12) showed that the 
gastric and gastroduodenal digests produced with human fluids exhibited the lowest IgE-
binding to 4 individual sera (nos. 1, 2, 4 and 5, in Annex 3). With other 2 sera (nos. 3 and 
6, Annex 3), IgE-reactivity towards the gastric digests produced by both systems was 
very similar, although the lowest IgE-binding always corresponded to the human 
gastroduodenal digests.  
 
 
Figure 12. IgE binding of OVA, expressed as percentage of the EC50 of the intact protein as 
estimated by inhibition ELISA with sera from six allergic patients (nos. 1-6, Annex3), after in 
vitro gastric digestion with simulated (     ) and human (     ) fluids and gastroduodenal digestion 
with simulated (      ) and human (     ) fluids. 
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 4.3.1.2. Identification of IgE-binding epitopes 
 
Figure 13 and Annex 8 show the sequences of the peptides identified by RP-
HPLC-MS/MS in the gastric (60 min) and gastroduodenal (60 min of gastric digestion 
followed by 30 min of duodenal digestion) digests of OVA. No peptides covering the first 
50 amino acids of the protein sequence were found in either model. Following gastric 
digestion with human and simulated fluids, 84 and 118 peptides were identified 
respectively, with 47 peptides in common. There were 52 identical pepsin cleavage sites 
in both systems, including: Leu (83, 105, 114, 124, 183, 216, 232, 242, 252, 255, 282, 
312, 321 and 365), Glu (70, 108, 143, 202, 248, 266, 274, 336, 340 and 357), Phe (59, 99, 
134, 198, 217 and 261), Ala (141, 171, 177, 187, 195. 332 and 345), Met (210, 211, 222, 
239 and 241) and Gln (89, 140, 203 and 325). 81 out of the 118 sequences identified after 
gastric hydrolysis with simulated fluid resisted subsequent duodenal hydrolysis, 
appearing as end products of digestion. Most of the remaining peptides found in the 
duodenal digests produced with simulated fluid could be products of hydrolysis of the 
low molecular mass peptides previously released by pepsin action, except for the C-
terminal sequence HIATNAVLFFGRCVS, resulting from the trypsin cleavage at Lys369. 
In addition, in this digestion system, breakdown at the trypsin cleavage sites: Lys (55, 92, 
226, 228, 277, 279, 286 and 322) and Arg (50, 84, 104, 142, 158 and 276) was detected. 
Only 47 peptides were identified after gastrointestinal digestion with human fluids. In this 
case, there were several fragments which could not arise from the peptides previously 
identified after gastric digestion and thus, they could derive from the hydrolysis of either 
intact OVA or the big proteolysis fragments that resisted pepsin hydrolysis. Only 6 
peptides were coincident with those produced with simulated duodenal fluid and, in 
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general terms, the human fluid gave rise less numerous and shorter peptides. Hydrolysis 
by trypsin at Lys 290 and Arg (50, 158, 284 and 359) was detected (Figure 13 and Annex 
8).  
27 peptides, ranging from 10 to 16 amino acids, representative of those found in 
the gastroduodenal digests with simulated and human fluids were chemically synthetized 
and their IgE-binding to 10 individual sera from egg-allergic patients was assessed by 
dot-blot. As shown in Figure 13, all peptides were recognized by, at least, 1 serum, except 
for two fragments, OVA (299-308) and (351-360), which did not react with any of the 
patient’s sera employed in the study. A high IgE-binding corresponded to the region 
comprised between positions 125-176, because 40 to 60% of the patients reacted to the 
synthetic peptides OVA (125-134), OVA (135-144), OVA (141-154), OVA (159-172) 
and OVA (164-176). The fragments OVA (188-198) and OVA (326-336) were 
recognised by sera from 60 and 50% of the patients respectively. The highest IgE-binding 
corresponded to the C-terminal fragment OVA (370-385), which reacted with 80% of the 
sera. 
 
  
 
 
 
 
Figure 13. Peptide sequences, identified by RP-HPLC-MS/MS, in the gastric (60 min) and subsequent duodenal digests of OVA (60 min of gastric digestion followed by 30 min of duodenal digestion), and IgE binding (    ), 
estimated  by dot-blot with 10 sera of egg-allergic patients (patients 13-22, Annex 3), of 27 synthetic peptides selected within the peptides identified in the simulated digestions. 
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Figure 4. Continuation.  
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4.3.2. DISCUSSION  
The results obtained with simulated gastric fluid agree with previously published 
information showing that OVA is quite stable to porcine pepsin at an E:S ratio of 182 
U/mg and pH 2.0 (Martos et al., 2010). A digestion pattern with two main degradation 
products, of 40.1 and 4.1 kDa, has been described (Dearman at al., 2002; Takagi et al., 
2003; Thomas et al., 2004), the first one probably corresponding to the fragment Ala23-
Pro385 (Martos et al., 2010). Moreover, Dupont et al. (2010a) using a gastric model 
under similar conditions (E:S 182 U/mg, pH 2.5) reported, in addition to smaller peptides 
of ~5,400 and 4,600 Da, the appearance of digestion products of  ~21,700 and 17,800 Da, 
which are analogous to those found in the gastric digests produced with human fluid in 
the present study (Figure 11a). In any case, and though there was intact protein remaining 
after the gastric phase in both systems, degradation of OVA was faster when digested 
with human than with simulated fluid (Figure 11a and 11c), an aspect that was already 
observed with β-CN and β-LG in sections 4.1 and 4.2. This suggests a more efficient 
performance of pepsin of human origin despite specificity was similar, as judged by the 
existence of 52 identical cleavage sites and a similar peptide pattern with 47 peptides in 
common (Figure 13 and Annex8. It is noteworthy that the in vitro digestion with human 
gastric juice released peptides with antihypertensive activity that act either as inhibitors of 
angiotensin-I-converting enzyme or exert a vasodilator action, such as FRADHPFL, 
YAEERYPIL, YRGGLEPINF, ESSINF or YQIGL, which were previously produced 
from OVA by hydrolysis with porcine pepsin for 3 h and also appeared in the 
hydrolysates produced with simulated fluid (Miguel et al,. 2004; García-Redondo et al., 
2010). 
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Following in vitro duodenal hydrolysis with trypsin (E:S 40 U/mg) and 
chymotrypsin (E:S 0.5 U/mg), the appearance of digestion products of ~20,700, 17,000, 
12,500, 10,400 and 6,500 Da has been described (Dupont et al., 2010a), which could 
coincide with those formed during duodenal digestion with the simulated fluid in our 
study (Figure 11c). These degradation products were absent from the gastroduodenal 
digests produced with human duodenal fluid (Figure 11a), as this caused a much more 
extensive proteolysis of the gastric digests than the simulated fluid. As mentioned in 
section 4.1, a difference between both duodenal digestion systems laid in the 
concentration of bile salts, which was much lower in the pool of human fluids, probably 
due to the prolonged fasting that preceded their extraction. It has been found that bile 
salts, at the concentration present in the simulated duodenal fluid, which is typical of a 
fed state, considerably increase the proteolysis of OVA by pancreatic enzymes (Martos et 
al., 2010). However, despite the lower concentration of bile acids in the human duodenal 
fluid, it promoted very effectively the proteolysis of intact OVA and of the peptides 
generated from it by pepsin hydrolysis. This could be attributed to differences in the 
specificity between human trypsin and -chymotrypsin and their bovine counterparts, as 
well as to the presence of peptidases in the human pancreatic extracts (Lyons and Fricker, 
2011). In fact, it has been reported that intact OVA and its 40 kDa fragment partially 
resist hydrolysis by porcine trypsin and chymotrypsin, but they are more readily degraded 
by an enzyme preparation from the pig pancreas gland that, in addition to both proteases, 
contains amino and carboxypeptidases (Martos et al., 2010). Furthermore, comparison of 
the peptide patterns produced by both systems showed that in vitro gastroduodenal 
digestion with human fluids released fewer and shorter peptides, revealing a most 
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extensive liberation of free amino acids from the short fragments previously formed 
during the gastric phase (Figure 13 and Annex 8).  
In accordance with the least extensive proteolytic degradation, and although there 
were, as expected, differences in donor’s specificity (Mine and Rupa, 2003), inhibition 
ELISA with individual sera from allergic patients revealed a comparatively higher IgE-
reactivity to the gastroduodenal digests produced with simulated fluids (Figure 12). This 
is probably because of the presence, in addition to intact OVA and its 40 kDa fragment, 
of a strong IgE-binding band of ~21 kDa and of other minor immunoreactive degradation 
products (Figure 11d). This pattern is similar to that previously observed after in vitro 
digestion of egg-white with simulated gastroduodenal fluids that allowed the 
identification of several IgE-binding fragments with molecular masses in the range of 35-
20 kDa, as well as others of 15 and 11 kDa, which derived from the hydrolysis of OVA 
(Martos et al., 2013). The corresponding digests produced with human fluids showed 
fainter and lower molecular mass IgE-binding degradation products and the virtual 
absence of intact protein and its high molecular mass fragment (Figure 11b).  
In addition, several IgE-binding epitopes were detected among the peptide 
fragments of molecular mass lower than 3 kDa identified in the digests by RP-HPLC-
MS/MS (Figure 13). Considering the binding frequency to human sera of the 27 synthetic 
peptides that mimicked the products of the gastrointestinal digestion, 4 main areas of the 
protein bound IgE from more than 40% of the egg allergic patients: 125-176, 188-198, 
326-336 and 370-385. Within the first one, 125-176, at least five distinct epitopes were 
found, including OVA (125-134) and OVA (159-172), as well as OVA (141-154) and 
OVA (164-176), which were present in the gastrointestinal digests produced with 
simulated and human fluids, respectively. The peptides OVA (188-198) and OVA (326-
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336), found in the gastrointestinal digests produced with simulated fluids, that bound, 
respectively, 60 and 50% of the sera from allergic patients, are related to previously 
defined allergenic epitopes. OVA (188-198) partially coincides with one of the five 
dominant human IgE-binding epitopes described by Mine and Rupa (2003), (38-49, 95-
102, 191-200, 243-248 and 251-260), while OVA (326-336) is comprised within the 
fragment 323-339, considered an immunodominant B and T cell epitope (Elsayed et al., 
1991). The discovery of this latter epitope gave rise to a transgenic mouse carrying the 
MHC class II restricted rearranged T cell receptor transgene, Tg(DO11.10)10Dlo, 
specific for OVA(323-339), broadly used in in vitro studies of T cell differentiation and 
in vivo studies of tolerance and immune responses (Sato et al., 1994).  
Finally, the C-terminal fragment, OVA (370-385), showed the highest binding 
frequency, reacting with 80% of the sera. Human IgE-binding has been demonstrated to 
broader areas of the C-terminal region of OVA, such as 301-385 (Kahlert et al., 1992) and 
347-385 (Honma et al., 1996). On the other hand, the existence of, at least, two epitopes 
within the shorter fragment OVA (367-385) was implied from a positive basophil 
stimulation in one allergic patient (Honma et al., 1996). Interestingly, the peptide OVA 
(375-384) was recognized by IgE from orally sensitized BALB/c mice but not from mice 
submitted to intraperitoneal or subcutaneous immunization (Mine and Yang, 2007)
 
what 
suggests that, even if it is protected within the native structure (Figure 14), it can be 
specifically exposed as a result of digestion. This immunoreactive fragment was present 
in the gastrointestinal digests produced with simulated fluids, but it could not be found in 
the gastrointestinal digests produced with human fluids.  
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Figure 14. Representation of the IgE-binding epitope OVA (370-385) in the 3D structure of the 
protein. Molecular graphics and analyses were performed with the UCSF Chimera package 
(Pettersen et al., 2004). The X-ray coordinates (Stein et al., 1991) were obtained at the RCSB 
Protein Data Bank (PDB ID: 1OVA). 
 
In agreement with the previous studies comparing the in vitro digestibility of 
bovine -CN and β-LG with human and simulated digestive fluids (Sections 4.1 and 4.2), 
and despite human fluids led to a much faster proteolytic degradation, a high degree of 
similarity within the peptide patterns arising from gastric digestion was detected, which 
was not so evident following duodenal digestion, likely because of the presence of active 
exopeptidases in the human duodenal extract. The accumulation of large degradation 
fragments and low molecular mass peptides with IgE-binding properties could contribute 
to the stronger residual IgE-binding capacity of the gastroduodenal digests produced with 
simulated fluids as compared with those produced with human fluids, although the 
gastrointestinal digests produced with human fluids also contained IgE-binding epitopes 
that could play a role in the allergenic potential of OVA. Among the epitopes released, 
OVA (370-385) seems to be of special importance, as it was able to bind the IgE in 80% 
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of the sera employed in the study. More research is needed in order to elucidate the 
biological activity of this fragment.  
  
 
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
4.4. Influence of the carbohydrate moieties on the immunoreactivity and 
digestibility of the egg allergen ovomucoid 
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Ovomucoid (OM, Gal d 1) makes up to 11% of the egg white and it is considered 
the immunodominant allergen as judged by its binding frequency to IgE from allergic 
patients. OM from hen egg is a glycoprotein with trypsin inhibitor activity, a molecular 
mass of approximately 28.0 kDa and an isoelectric point of 4.1. Its polypeptide chain 
consists of 186 amino acids, forming three structurally independent tandem domains each 
of 60 amino acids in length (Mine and Zhang, 2008). Each domain bears multiple 
conformational and linear epitopes that are recognized by IgE antibodies from egg 
allergic patients (Cooke and Sampson, 1997).  
One particular characteristic of OM is its high carbohydrate content, which is 
between 20–25%, with two carbohydrate chains on each of the first and second domains 
and one chain present on about 50% of the third domain (Mine and Zhang, 2008). Thus, a 
relevant question that arises is whether the covalently-bound carbohydrate moieties 
contribute to OM allergenicity. Using sera from allergic patients, Matsuda et al. (1985) 
reported that, in the third domain, the carbohydrate chain and/or its attachment site could 
be recognized as antigenic determinants, whereas Zhang and Mine (1998) postulated that 
the carbohydrate moiety of the third domain rather exerted an inhibiting effect on the IgG 
and IgE binding properties of OM.  Besler et al. (1997) and Cooke and Sampson (1997) 
concluded that the carbohydrate residues did not take part in the allergenic structures of 
OM. Hence, the issue of the relevance of the carbohydrate moiety of OM on its potential 
to sensitize or elicit an allergic response is still under debate.  
In the case of many food allergies, particularly to plant proteins, antibodies 
specific to carbohydrate determinants are frequently found, although they appear not to 
have clinical relevance (Altmann, 2007). In any case, the fact that glycosylation is a 
common feature to many food allergens has prompted investigations that showed that 
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glycans may enhance immunogenicity through the activation of innate Th2 responses 
(Ruiter and Shreffler, 2012). Furthermore, the carbohydrate chains normally exert a 
stabilizing effect on protein structure, offering protection towards processing and/or 
gastroduodenal digestion and thus contributing to the allergenic potential (Breiteneder 
and Mills, 2005). Regarding OM, there are a few studies dealing with the influence of 
gastrointestinal digestion on its immunoreactivity (Kovacs-Nolan et al., 2000; Takagi et 
al., 2005; Jiménez-Saiz et al., 2011a), however, the contribution of the glycan moieties to 
its digestibility has not been addressed. 
The general aim of this chapter is to further investigate the role of the 
carbohydrate moieties of OM in its allergenic properties and digestibility. To that end, 
OM was enzymatically deglycosilated and, using blood from egg-allergic patients, the 
IgE-binding, and basophil activation properties of the glycosylated and deglycosylated 
forms were compared. Glycosylated and deglycosylated OM were hydrolysed with a 
physiologically relevant model by mimicking three areas of the gastrointestinal tract: the 
mouth, stomach and small intestine, the nonglycosylated peptides obtained were 
identified by RP-HPLC-MS/MS and the IgE-binding properties of the most relevant 
resulting fragments were evaluated. 
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4.4.1. RESULTS 
 4.4.1.1. Deglycosilation of OM  
 
To perform OM deglycosylation, the enzyme PNGase F was used. Enzymatic 
deglycosylation was considered more appropriate than chemical deglycosylation to study 
the immunoreactivity of OM because, in principle, the polypeptide chain remains 
unaltered and, therefore, the protein retains the integrity of its epitopes. To assess the 
effectiveness of deglycosylation SDS-PAGE with Coomassie G-250 and periodic acid–
schiff staining was conducted. As shown in Figure 15a, OM appeared as a diffuse group 
of bands from 30 to 50 kDa, together with a protein band of 14 kDa corresponding to hen 
egg lysozyme, present due to an incomplete purification of the commercial product 
(Pellegrini et al., 1992). The electrophoretic pattern of OM was modified after treatment 
with PNGase F. The bands corresponding to dOM showed lower molecular mass and, 
consequently, higher electrophoretic mobility due to the removal of the carbohydrate 
chains. The absence of carbohydrate was confirmed by staining the gel with periodic 
acid-schiff (Figure 15b), which showed no bands in the lane corresponding to dOM. 
 
 
 
 
 
Figure 15. SDS-PAGE patterns, using Bis-
Tris 4-12% acrylamide gels, of OM and its 
deglycosylated form (dOM) with Coomassie 
blue (a) or PAS (b) staining. M: molecular 
mass marker; 1: OM, 2: dOM. 
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We further checked by circular dichroism spectroscopy that, in addition to an 
efficient removal of N-linked oligosaccharides, PNGase F treatment maintained the 
degycosylated protein in its native structure. The far-UV circular dichroism spectrum of 
OM was similar to that reported by Watanabe et al. (1981) and did not change by 
deglycosylation (Figure 16a). The estimated secondary structure percentages obtained 
were identical for α-helix (16%) and random coil (36%) features, and slightly different 
for β-sheet and β-turn (24 and 25% and 23 and 22% for OM and dOM, respectively). The 
near-UV circular dichroism spectra of native OM was not modified either (Figure 16b), 
revealing that the secondary and tertiary structures of dOM were not altered when the 
carbohydrate chains were cleaved. 
 
 
Figure 16. Circular dichroism spectra in the far (a) and near (b) ultra violet region of OM (—) 
and dOM (—). 
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 4.4.1.2. In vitro immunoreactivity  
 
IgE-binding to OM and dOM was evaluated by inhibition ELISA using the sera 
from 10 egg-allergic patients (nos. 1-10 in Annex 4). Immunoreactivity was expressed as 
EC50 (effective OM or dOM concentration (μg/mL) for 50% of the maximal IgE binding 
to OM) and, as depicted in Figure 17, in 8 out of 10 sera the immunoreactivity towards 
dOM was lower than that of OM. 
 
Figure 17. IgE binding of OM (light bars) and dOM (dark bars), expressed as EC50 as estimated 
by inhibition ELISA with sera from ten allergic patients (nos. 1-10, Annex 4). 
 
In order to investigate the IgE specificity, sera from the same 10 patients were 
used to perform Western blot analyses (Figure 18b-k). IgE from the 10 sera recognized 
the bands corresponding to both OM and dOM. However, a previous incubation with 
dOM completely inhibited the binding to dOM but failed to inhibit the binding to OM in 
two patients (2 and 6, Figure 18c and 18g) and inhibited the binding to dOM to a much 
higher extent than that of OM in another two (9 and 10, Figure 18j and 18k). This 
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provided evidence for the presence of IgE reactive epitopes specific for the glycosylated 
protein that did not react with the deglycosylated form. In the remaining 6 patients, 
preincubation with dOM either completely inhibited the IgE reactivity against dOM and 
OM (patients 1 and 8, Figure 18b and 18i), or partially inhibited both to a similar extent 
(patients 3, 4, 5 and 7; Figure 18d, 18e, 18f and 18h). The strong reactivity of many of the 
individual sera towards the contaminating lysozyme was noteworthy.  
 
Figure 18. SDS-PAGE (a), using Bis-Tris 4-12% acrylamide gels, and Western blotting (b-k) of 
OM (1) and dOM (2) with sera from the ten allergic patients (nos. 1-10, Annex 4). Human sera 
were either not incubated (A) or previously incubated (B) with the amount of dOM calculated to 
inhibit 100% of IgE binding. 
 
 4.4.1.3. Ex vivo biological activity  
 
The capacity to trigger basophil activation was determined on PBMCs from 6 egg-
tolerant adult donors passively sensitized with a pool of sera from patients 1, 3, 5, 7 and 9 
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(Annex 4). The results of the basophil activation analysis by flow cytometry are shown in 
Figure 19. Challenge of basophils with OM and dOM induced activation as measured by 
upregulation of CD63. Results showed that the removal of the carbohydrate chains 
moderately reduced the percentage of activated basophils at all the concentrations 
assayed, although the differences did not reach statistical significance. 
 
Figure 19. Percentage of activated basophils (CD63
+
CD123
+
CD203c
+
HLA-DRlow) after 
stimulation with OM and dOM at concentrations between 0.01 to 10 µg/mL. PBMCs from 6 egg-
tolerant adult donors were passively sensitized with a pool of sera from 5 children with egg allergy 
(nos. 1, 3, 5, 7 and 9, Annex 4). Bars indicate the mean of activated basophils. 
 
 4.4.1.4. In vitro simulated orogastrointestinal digestion and immunoreactivity 
 
Figures 20a and 20b show the SDS-PAGE patterns of OM and dOM following the 
in vitro oral, gastric and duodenal digestions. After the 2 min-oral phase, the SDS-PAGE 
patterns from both OM and dOM showed a much broader shape, which could be 
attributed to an incomplete reduction of the nine disulfide bridges caused by the low 
sample pH (pH 3.5 was used to stop α-amilase action), which diminished their mobility in 
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the acrylamide gel (Yousif and Kan, 2002). However, as judged by the RP-HPLC pattern 
(not shown), there were no changes after 2 min of hydrolysis that would point to an 
unspecific activity of the saliva enzyme.  
OM was degraded during the first min of gastric digestion, leaving no intact 
protein at the end of the gastric phase, and yielding fragments with molecular masses of 
~25, ~15 and <10 kDa. All these bands were faintly visible after 60 min of simulated 
gastric hydrolysis and the lower molecular mass ones (~15 and <10 kDa) persisted 
throughout the duodenal phase (Figure 20a). dOM was degraded more rapidly and 
produced bands of  ~18, ~ 15 and <10 kDa, with the band corresponding to ~18 kDa 
being no longer present after the first 7 min of pepsin hydrolysis, so that only the bands 
corresponding to ~15 and <10 kDa were found at the end of gastric digestion and 
throughout the subsequent duodenal digestion (Figure 20b).  
As shown in Figure 20c and 20d, the ~25, ~15 and <10 kDa fragments formed 
during gastric digestion of OM and those of ~15 and <10 kDa formed during gastric 
digestion of dOM were able to bind IgE from a pool of five egg-allergic patients (nos. 1, 
3, 5, 7 and 9, Annex 4), although the immunoreactivity of the band of ~15 kDa could be, 
at least partially, attributed to the presence of residual LYS. Once the duodenal digestion 
was completed, the bands corresponding to ~15 and <10 kDa, present in OM and dOM 
digests, still had detectable IgE-binding capacities. 
The IgE-binding of the digests was evaluated by inhibition ELISA using the sera 
from six patients (nos. 11-16, Annex 4). The immunoreactivity decreased to, 
approximately, 10.6% for OM and 1.2% for dOM at the end of the gastric stage, falling to 
4.16% and 1.1% after the duodenal phase for OM and dOM, respectively (not shown). 
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The lower IgE binding found in the digests of dOM correlated with its highest 
susceptibility to proteolysis. 
 
 
Figure 20. SDS-PAGE patterns (a, b), using Bis-Tris 4-12% acrylamide gels, and Western 
blotting (c, d) of OM (a, c) and dOM (b, d) after in vitro oral, gastric and gastroduodenal 
digestions. M: molecular mass marker; Lane 1: OM (a, c) and dOM (b, d); lane 2: oral digest; 
lanes 3-13: gastric digests at 1, 2, 3, 4, 5, 7, 10, 15, 20, 30 and 60-min; lane 14: duodenal digests 
(60 min of gastric digestion followed by 30 min of duodenal digestion). Membranes were 
incubated with a pool of sera of five allergic patients (nos. 1, 3, 5, 7 and 9, Annex 4). 
 
 
 4.4.1.5. Peptide identification after in vitro digestion and epitope recognition  
 
RP-HPLC-MS/MS was employed to analyze the peptides present in the gastric (60 
min) and duodenal (60 min of gastric digestion followed by 30 min of duodenal 
digestion) digests of OM and dOM and Figure 21 and Annex 9 shows the sequences of 
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the 146 peptides identified. Only identification of the non-glycosylated fragments was 
attempted, in view of the difficulty involved in the determination of glycosylated peptides 
in complex mixtures, because the signal intensity of glycopeptides is low compared to 
nonglycosylated peptides and often suppressed in their presence (Ongay et al., 2012). 
Some deglycosylated peptides containing Asn10, Asn53 and Asn75 were detected in the 
OM hydrolysates (Asn175 is naturally partially glycosylated) probably due to a partial 
deglycosylation of the commercial sample used. The peptide patterns of the hydrolysates 
produced were very similar, showing 56 peptides in common after the simulated 
orogastrointestinal digestion. This indicated that, while deglycosylation enhanced 
susceptibility to proteolysis, no major differences in the cleavage sites of the protein were 
detected after hydrolysis times representative of the transit times in the stomach and 
duodenum. In the N-terminal region, around the glycosylated Asn10, pepsin hydrolysed 
OM after Ala12 and dOM after Phe8, Asp13 and Glu15. Very few peptides were 
identified in the region between the glycosilated positions Asn53 and Asn75 even in the 
deglycosylated form (Figure 21 and Annex 9). In this area, pepsin hydrolysed dOM after 
His58 and Asp64 and trypsin after Lys63, in both OM and dOM. Met68 was also cleaved 
in the duodenal digests of dOM. The greatest similarities were found in the third domain, 
particularly following gastric digestion. Interestingly, peptides with a molecular weight 
above 2,400 Da only appeared during the digestion of OM, underlining a less extensive 
proteolytic degradation. 
  
 
Figure 21. Peptide sequences, identified by RP-HPLC-MS/MS, in the gastric (60 min) and subsequent duodenal digests of OM and dOM (60 min of gastric followed by 30 min of duodenal 
digestion), and IgE binding (    ), estimated by immunodot with 10 sera of egg-allergic patients (patients 1-10, Annex 4), of 17 synthetic peptides selected within the peptides identified in the 
simulated digestions. Y: Carbohydrate chains.                 : Disulphide bonds. 
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Considering the similarities between the peptide patterns of the orogastroduodenal 
digests of OM and dOM, 17 representative peptides, common to both hydrolysates, were 
selected as explained in the materials and methods section and chemically synthetized. 
Their IgE binding is shown in Figure 21. The highest IgE-binding (between 70 and 100% 
of the patients) corresponded to the peptide OM (80-89) and to the region 133-180 [OM 
(133-148), OM (146-161) and OM (168-180)], moderate binding (40-70% of the patients) 
to the regions 36-61 [OM (36-45), OM (41-53) and OM (45-61)] and 100-122 [OM (100-
110) and OM (109-122)], whereas low binding (<40% patients) was attributed to the 
peptides OM (25-38),  OM (90-103),  OM (114-129) and OM (122-140). Peptides OM 
(19-38), OM (54-68), OM (108-118) and OM (179-186) did not react with any of the 10 
patient´s sera employed in the study. 
 
4.4.2. DISCUSSION  
OM was successfully deglycosilated using microbial PNGase F (Figure 15a and 
15b), an amidase that cleaves between GlcNAc and Asn residues of high mannose, 
hybrid, and complex oligosaccharides from N-linked glycoproteins, without secondary or 
tertiary structural changes as determined by circular dichroism spectroscopy (Figure 16a 
and 16b). Previous reports, had studied the effect of glycosylation on reduced and 
alkylated OM (Cooke and Sampson, 1997) or on individual domains of the protein 
(Matsuda et al., 1985) (Zhang and Mine, 1998). However, because of the importance that 
conformational epitopes exert in some patients (Cooke and Sampson, 1997; Mine and 
Zhang, 2002b), the preservation of the structural stability and integrity is very important 
when assessing the immunoreactivity of OM. 
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In the present study, 80% of the patients showed lower IgE binding to dOM as 
compared with OM (Figure 17). The maintenance of the secondary and tertiary structures 
of the full native form suggests that the differences in IgE reactivity found between the 
glycosylated and deglycosylated forms are not merely due to changes in protein structure 
induced by glycans. Furthermore, in the case of some patients, IgE reactivity to OM could 
not be inhibited by pre-incubation with dOM (Figure 16b-k), what indicates that these 
patients might be sensitized not only to the peptide epitopes, but also to carbohydrate-
containing structures, although cross-reactivity between carbohydrate-containing and 
amino acid structures could not be excluded. Evidence for the sensitizing potential in 
humans of glycosylated allergens from major royal jelly proteins, beyond carbohydrate-
based cross-reactivity, has been provided (Blank et al., 2012). However, mice 
subcutaneously sensitized to OM third domains with and without carbohydrate do not 
show differences in IgE-binding towards each other, showing a high degree of cross-
reactivity between the glycosylated and deglycosylated forms (Rupa et al., 2007). At this 
respect, it should be taken into account that a considerably variability among egg allergic 
patients in their IgE binding to different linear and conformational epitopes of OM has 
been described (Cooke and Sampson, 1997; Järvinen  at al., 2007), that likely reflects 
sensitization to different OM forms. 
In accordance with the lower IgE binding, we found a subtle reduction in the 
percentage of activated basophils after incubation with dOM as compared to OM (Figure 
19). There are several examples of IgE antibodies against plant food N-glycans that exert 
biological activity in basophil activation assays (Batanero at al., 1994), but fail to 
demonstrate their capacity to elicit an immune response and trigger clinical symptoms 
(Altmann , 2007). On the other hand, other authors have obtained results that support the 
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immunological and clinical relevance of the carbohydrate determinants in allergens. A 
recent report from Chiang et al. (2012) states the direct implication of low-molecular-
weight oligosaccharides in IgE-mediated anaphylaxis to cow´s milk formula 
supplemented with prebiotics.  
The simulated digestion experiments showed that OM and dOM were not affected 
by in vitro oral digestion, but completely degraded by gastric digestion (Figure 20a and 
20b). A profile of 3 main degradation products with molecular masses of ~25, ~15 and 
<10 kDa was found in the 60 min gastric digests of OM, while dOM was digested more 
extensively and only bands of ≤ 15 kDa were present at that time. This might be a direct 
consequence of the removal of the carbohydrate chains that would allow a most efficient 
hydrolysis by pepsin. 
Kovacs-Nolan et al. (2000) described the rapid degradation of intact OM during 
simulated gastric digestion with the formation of large fragments that could act as 
allergens, albeit they exhibit reduced IgE-binding activity as compared with the native 
protein. Two of these, with molecular masses of ~24 and ~18 kDa were identified as OM 
(21-133) and OM (134-186) (Kovacs-Nolan et al., 2000). The bonds Leu20-Val21 and 
Ala133-Val134 were cleaved by pepsin in our system (Figure 21) and thus, any of these 
could correspond with the, likely glycosylated, IgE binding broad ~25 kDa band of the 
OM digest (Figure 20c) The absence of equivalent bands in the dOM digests after 7 min 
of hydrolysis could account for their lower immunoreactivity, only attributable to the 
lower molecular mass products (Figure 20d). Takagi et al. (2005) reported the formation 
of IgE-binding pepsin degradation products of 7 and 4.5 kDa, what reinforces the 
hypothesis that patients that positively react to digestion resistant fragments are unlikely 
to outgrow egg-allergy (Yamada et al., 2000). 
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Little change in the band pattern was observed during the duodenal phase, likely 
because the peptides released by pepsin action retain trypsin inhibitory activity that helps 
to maintain OM peptide fragment integrity (Kovacs-Nolan et al., 2000). Following 
duodenal digestion, the fragments of ~15 and ≤ 10 kDa that persisted in the digests of 
OM and dOM could be partially responsible for their residual IgE binding, which was 
similarly reduced, although not eliminated upon gastrointestinal digestion (Figure 20c and 
20d). In any case, IgE-binding of the gastroduodenal digests was very low (<5% of that of 
the intact protein), what is in agreement with previous results (Jiménez-Saiz et al., 
2011a).  
A further investigation on whether the peptides resulting from orogastrointestinal 
digestion of OM contained IgE-binding epitopes revealed that two regions of the protein, 
that is those within the residues 80-89 and 133-180, were recognized by more than 70% 
of the allergic patients studied, while from 40 to 70% of the patients recognized two other 
regions, 36-61 and 100-122 (Figure 21). Most of these high-frequency IgE-binding 
peptides were either totally or partially coincident with previously described epitopes 
(Cooke and Sampson, 1997; Zhang and Mine, 1998; Holen et al., 2001; Mine and Zhang, 
2002b; Järvinen et al., 2007; Martínez-Botas et al., 2013). However, there are not only 
numerous IgE binding epitopes distributed along the whole OM structure, but also very 
many differences in epitope recognition among patients depending on their sensitivity to 
the allergen (Järvinen et al., 2007). Furthermore, the length of the peptide and the nature 
of the nearby amino acids also determine the affinity for IgE antibodies. It should be 
mentioned that longer peptides were found in the gastric and duodenal digests of OM as 
compared to dOM, due to the more extensive degradation of the latter. In any case, and in 
view of the peptides identified in the digests of OM and dOM, multiple epitopes within 
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each domain would remain linked by disulfide bonds despite proteolytic cleavage, giving 
rise to complex sequences which may have the ability to cross-link several IgE molecules 
and activate effector cells. Nevertheless, according to Martos et al. (2011), simulated 
gastrointestinal digestion of OM greatly diminishes its basophyl activating capacity, 
therefore, considering the allergenicity of OM, the possibility that digestion may promote 
its sensitizing potential or abrogate its tolerizating capacity should be considered. 
In conclusion, this work provides evidence for an enhanced IgE reactivity towards 
carbohydrate containing OM in some egg-allergic patients that could be due to cross-
sensitization, but also to sensitization to the glycosylated components.  In addition to a 
direct implication of the carbohydrate chains of OM on its IgE binding, whose clinical 
relevance remains to be established, they contribute to an increased resistance to 
proteolysis, particularly during the first stages of gastric digestion, which may play a role 
in its allergenic potency. Although the residual IgE binding of the in vitro digests of OM 
and dOM was low, the evaluation of the presence of potential epitopes among the 
nonglycosylated orogastroduodenal products of digestion of OM and dOM revealed the 
presence of high-frequency IgE-binding fragments that could remain linked by disulphide 
bonds. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
4.5. Digestibility and immunoreactivity of lysozyme 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
143 In vitro digestibility of LYS 
4.5.1. Immunological behavior of in vitro digested egg-white lysozyme 
 
Lysozyme (LYS, Gal d 4), is found in many organisms including viruses, insects, 
amphibians, reptiles, birds and mammals. It appears in a multitude of tissues and fluids, 
including hen eggs, human milk, tears, saliva and is also secreted by leukocytes 
(Niyonsaba and Ogawa, 2005). Hen egg is probably the richest source of LYS, containing 
1-3 g/L, being egg white LYS one of the best chemically characterized proteins. With 129 
amino acid residues (14.3 kDa), an isoelectric point of 10.7 and four disulphide bonds 
that confer it a stable tertiary structure, LYS has emerged as a model for investigations on 
protein structure and function.  
The structure of LYS, shown in Figure 24, consists of two domains, the α domain 
comprising residues (1-40 and 90-129) and the β domain (41-89), connected by a long α-
helix. The α-domain consists of five α-helical segments shown in purple in Figure 24 (A-
E) and the β domain is rich in β sheet structure (Mine et al., 2004) shown in green. The 
alpha region has two disulphide bridges (Cys 6-Cys 127 and Cys 30-Cys 115), the β 
domain has another (Cys 64-Cys 80) and the fourth bridge (Cys 76-Cys 94) is located 
between the two domains (Figure 24). These four disulphide bridges confer high thermal 
stability to LYS (Jolles and Jolles, 1984). As expected, most of the nonpolar side chains 
are facing the interior of the molecule, away from contact with the aqueous solvent.  
In addition to its valuable biological properties, such as being a potent 
antibacterial agent  against gram-positive bacteria, LYS is also a major allergen in egg 
white, although its allergenic potential has not been studied in depth and no relevant IgE-
binding epitopes have been identified (Mine and Yang, 2008). At least 35% of patients 
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with clinically observed hen egg hypersensitivity have IgE against LYS (Frémont et al., 
1997; Walsh et al., 2005) and this high frequency of sensitization poses a risk, not only 
when egg is consumed, but also when LYS is used as an antibacterial additive to prevent 
spoilage of cheese, wine or other food products (Weber et al., 2009).  
 
 
Figure 24. MOLSCRIPT representations of native hen lysozyme showing the α- (purple) and β-
domain (green). (Adapted from Van den Berg et al., 1999). 
 
Regarding LYS digestion, previous experiments, aimed at relating the 
immunogenicity of LYS to its resistance to digestion, showed that in vitro gastric 
proteolysis is extremely pH dependent and only occurs at low pH, yielding peptides with 
allergenic potential. The remaining intact protein subsequently precipitates at pH values 
and surfactant concentrations typical of the duodenal medium (Jiménez et al., 2011b). 
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This would affect the amount of immunoreactive protein that could be absorbed and 
either sensitize or elicit and allergic reaction. 
The section aims to the identification of the peptides produced upon in vitro 
gastrointestinal digestion of LYS, together with their IgE-binding and biological activity, 
as a contribution to the understanding of what makes LYS a relevant allergen.  
 
4.5.1.1. RESULTS 
 4.5.1.1.1. The pH of gastric hydrolysis determines gastroduodenal digestibility 
and resultant immunoreactivity of LYS 
 
In vitro gastric digestion was conducted at pH 1.5, 2.0 and 3.2, in the presence and 
absence of phosphatidylcholine, followed by in vitro duodenal digestion, in the presence 
and absence of bile salts, and the results were monitored by RP-HPLC (Figures 25 and 
26) and SDS-PAGE (Figure 27).  
LYS was efficiently hydrolysed by pepsin at pH 1.5. There was intact protein left 
after 30 min of gastric hydrolysis  that completely disappeared after 60 min. The presence 
of phosphatidylcholine slightly protected the protein from the enzyme action, although it 
did not lead to qualitative changes in the peptide pattern (Figure 25a-d). Gastric digestion 
released fragments of molecular mass lower than 10 kDa, which were degraded 
throughout the subsequent in vitro duodenal digestion, independently of the absence or 
presence of phosphatidylcholine (Figure 25e-f, Figure 27a and 27b).  
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Figure 25. RP-HPLC patterns of LYS subjected to gastric digestion at pH 1.5 for 30 (a, b) and 60 
min (c, d), followed by duodenal digestion for 30 min (e, f), in the absence (-PC, left) and 
presence of phosphatidylcholine (+PC, right). 
 
Pepsin hydrolysed LYS more slowly at pH 2.0 than at pH 1.5 and the protective 
effect of phosphatidylcholine on LYS degradation was not so apparent, but it gave rise to 
the same degradation products as determined by RP-HPLC (Figure 26a-d) and SDS-
PAGE (Figure 27a). There was intact LYS surviving pepsin action after 60 min at pH 2.0 
which precipitated at pH 6.5 in the simulated duodenal medium. After 30 min of in vitro 
duodenal digestion, precipitated LYS was separated by centrifugation and re-solubilized 
above its isoelectric point. SDS-PAGE analysis of the soluble (Figure 27b) and 
precipitate fractions (Figure 27c) showed the precipitated protein avoided hydrolysis. 
However, when phosphatidylcholine was added, it favored LYS solubility and its 
hydrolysis by pancreatic enzymes, with the appearance of a main degradation product of, 
approximately, 12 kDa.  
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When hydrolysis was conducted in a duodenal simulated fluid without bile salts, 
all LYS remained soluble, being partly hydrolyzed by pancreatic enzymes (Figure 26g). 
This suggested that the main hydrolysis product of 12 kDa, released during in vitro 
duodenal digestion, was produced from intact LYS by the pancreatic enzymes, an aspect 
which was further confirmed by hydrolyzing LYS with trypsin and chymotrypsin 
omitting the previous gastric phase (not shown). In any case, even in the absence of bile 
salts, when the protein was fully soluble, its proteolysis by trypsin and chymotrypsin was 
very limited. It is noteworthy that the duodenal peptide patterns subsequent to gastric 
digestion at pH 2.0 were qualitatively similar to those corresponding to pH 1.5. 
Furthermore, the enhanced solubility and digestibility of residual LYS in the duodenal 
medium with added phosphatidylcholine did not lead to the appearance of new or more 
abundant degradation products (Figure 26 e-f). This indicates that the RP-HPLC peptides 
detected upon duodenal digestion mainly derived from the peptides previously released 
from LYS by pepsin action, while partial hydrolysis of the intact LYS surviving gastric 
digestion, which was restricted to the fraction that remained soluble depending on the 
medium conditions, mainly yielded the fragment with 12 kDa of molecular mass. 
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Figure 26. RP-HPLC patterns of LYS subjected to gastric digestion at pH 2.0 for 30 (a, b) and 60 
min (c, d) followed by duodenal digestion for 30 min (e, f, g), in the absence (-PC, left) and 
presence of phosphatidylcholine (+PC, right). Gastroduodenal digests were also conducted in the 
absence of phosphatidylcholine and bile salts (-BS, g). 
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Finally, LYS was virtually unaffected by pepsin at pH 3.2 (Figure 27a). The 
remnant protein precipitated under duodenal conditions, although, in the presence of 
phosphatidylcholine, soluble intact LYS as well as its 12 kDa fragment became apparent, 
yet to a lesser extent than when in vitro gastric digestion was conducted at pH 2.0 (Figure 
27b). 
 
Figure 27. SDS-PAGE patterns under reducing conditions of: (a) LYS subjected to gastric 
digestion in the presence of phosphatidylcholine at pH 1.5, 2.0 and 3.2, for 0, 15, 30 and 60 min; 
(b) soluble fraction of LYS subjected to duodenal digestion following gastric digestion at pH 1.5, 
2.0 and 3.5 in the absence (-PC) and presence of phosphatidylcholine (+PC); and (c) precipitated 
fractions (re-solubilized above the isoelectric point of the protein) of the duodenal digests 
following gastric digestion at pH 2.0 and 3.5, in the absence (-PC) and presence of 
phosphatidylcholine (+PC). Bis-Tris 12% (a) and Tris-Tricine 16.5% (b, c) acrylamide gels were 
used. M: molecular mass marker.  
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Western blotting of the gastric digests was conducted following SDS-PAGE under 
non-reducing and reducing conditions using a pool of sera from 6 allergic patients (nos. 
1-6, Annex 5) (Figure 28). The results indicated that gastric digestion released proteolysis 
fragments linked by disulfide bridges, showing the appearance of an immunoreactive 
band of, approximately, 4 kDa after hydrolysis at pH 1.5 and 2.0, albeit only under 
reducing conditions. Western blotting also showed that intact LYS was more 
immunoreactive after being reduced (Figure 28b and 28d).  
 
 
Figure 28. SDS-PAGE patterns, using Bis-Tris 12% acrilamide gels, under non-reducing (a), and 
reducing (c) conditions, and subsequent Western blotting (b, d) of LYS subjected to gastric 
digestion in the presence of phosphatidylcholine at pH 1.5 and 2.0 for 60 min. L: intact LYS. M: 
molecular mass marker. Membranes were incubated with a pool of sera from six allergic patients 
(nos. 1-6, Annex 5). 
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As revealed by Western blots of the gastroduodenal digests following SDS-PAGE 
under reducing conditions, the immunoreactive 4 kDa-band, arising from pepsin 
hydrolysis at pH 1.5 and 2.0, disappeared upon subsequent duodenal digestion and the 
new 12 kDa-band, formed from intact LYS, exhibited a considerably IgE-binding (Figure 
29). Unlike the sera from non-allergic donors, all the individual sera from egg-allergic 
patients tested were immunoreactive against LYS and the 12 kDa-band. 
 
 
Figure 29. Western blotting subsequent to SDS-PAGE, using Bis-Tris 12% acrilamide gels, 
under reducing conditions of LYS subjected to duodenal digestion for 30 min, following gastric 
digestion at pH 1.5, 2.0 and 3.2 for 60 min, in the presence of phosphatidylcholine and bile salts. 
Individual sera nº 1-9 (Annex 5) (a-i, respectively) and a serum from a non-allergic donor (j) were 
used. L: intact LYS. 
 
Inhibition ELISA with a pool of sera from allergic patients (nos. 1-6, Annex 5) 
showed that the gastroduodenal digests following gastric digestion at pH 1.5 and 2.0, and 
obtained in the absence of both phosphatidylcholine and bile salts, to avoid LYS 
precipitation that could hinder the quantitative estimation of the resulting 
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immunoreactivity, still maintained 55 and 35%, respectively, of the IgE binding of the 
intact protein. This suggested that the lowest gastric pH favored the release of degradation 
products that could bear IgE-binding epitopes and contribute to the high IgE-binding 
capacity of the subsequent duodenal digests, despite the absence of intact LYS. In order 
to estimate the contribution of LYS structure, with 4 disulfide bonds, to its IgE-binding 
activity, LYS modified by carboxymethylation was also analyzed by inhibition ELISA, 
showing 20 times more IgE-binding than native LYS (not shown).  
 
 4.5.1.1.2. The gastric and gastroduodenal digestion products of LYS retain IgE-
binding epitopes 
 
Identification of the peptides derived from in vitro digestions was attempted by 
RP-HPLC-MS/MS. The direct analysis of the samples allowed the unambiguous 
recognition of a limited number of peptides devoid of cysteinyl residues (not shown). 
Treatment with dithiothreitol gave rise to new peaks, indicating that gastric and 
subsequent duodenal digestion released many proteolysis fragments linked by disulfide 
bridges although, due to the complexity in the peptide pattern, it was not possible to trace 
the appearance of these new fragments to the presence of distinct disulfide bonded 
sequences before dithiothreitol reduction.  
Despite differences in susceptibility to pepsin action depending on the pH, the 
same peptides were identified in the gastric and gastroduodenal digests following in vitro 
gastric digestion at pH 1.5 and 2.0, though in different amounts. Figure 30 illustrates the 
sequences arising from gastric digestion at pH 2.0, subsequent duodenal digestion, and 
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direct duodenal digestion, under conditions avoiding LYS precipitation (without the 
inclusion of bile salts in the duodenal phase).  
The identified peptides produced by pepsin ranged from 803 to 3,077 Da and 
covered the whole LYS sequence. Taking into account the existence of 4 disulfide bridges 
in the native LYS structure, connecting Cys6-Cys127, Cys30-Cys115, Cys64-Cys80 and 
Cys76-Cys94, the possibility arises that larger fragments were formed. In particular, 2 or 
3 peptides within the area comprised from residues 53 and 107, which includes Cys64, 
Cys76, Cys80 and Cys94, could remain linked by 1 or 2 intermolecular disulfide bridges 
or by 1 intramolecular and 1 intermolecular disulfide bridge, thus forming longer 
sequences despite the cleavage of several peptide bonds during gastric phase (Figure 
30a). Duodenal enzymes released shorter fragments from those previously produced by 
pepsin that could also be part of bigger disulfide cross-linked peptides as explained above 
(Figure 30b). In the direct duodenal digestion, and in agreement with their specificities, 
trypsin hydrolysed LYS after Lys (1, 13, 33, 96, 97) and Arg (21, 45, 61, 73, 114); and 
chymotrypsin hydrolysed LYS after Tyr (20, 23, 53), Trp (28, 62, 63, 108, 123), Phe (3, 
34, 38), Leu (56, 75, 83, 84) and Met (12). There were also peptides corresponding to the 
cleavage of bonds with Asp (18), Asn (37, 74, 93) and Cys (76, 80) (Figure 30c). Some of 
these peptides were also found in the gastroduodenal digests.  
To identify the LYS fragments that were responsible for IgE binding, as 
determined by Western blotting, the immunoreactive bands of, approximately, 4 and 12 
kDa were subjected to tryptic digestion and MALDI-TOF/TOF. Table 5 shows the tryptic 
peptides produced by in-gel digestion and Figures 30a-c show the identified LYS 
fragments. The immunoreactive gastric fragment contained three different products that 
corresponded to: LYS (11-27), LYS (57-83) and LYS (108-122), which had been 
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identified by RP-HPLC-MS/MS (Figure 30a) except for the peptide LYS (57-83) that was 
not within the mass range scanned (100-3,000 m/z). The immunoreactive gastroduodenal 
fragment, LYS (24-129), of 11.7 kDa, resulted from the chymotrypsin cleavage of Tyr23-
Ser24, and probably contained multiple IgE-binding epitopes, as it comprised most of the 
LYS sequence. 
 
  
 
 
 
Figure 30. Peptide sequences identified by RP-HPLC-MS/MS in the gastric digests of LYS at pH 2.0 for 60 min (a), subsequent duodenal digest for 30 min (b), and direct duodenal digest at pH 6.5 for 30 min (c), in the 
absence of phosphatidylcholine and bile salts. The fragments identified by MALDI-TOF/TOF after in-gel tryptic digestion of the LYS bands recognized by human IgE after gastric digestion (Figure 5) and subsequent 
duodenal digestion (Figure 6) are highlighted in red in the primary sequence of the protein.                  : Disulphide bonds. 
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Table 5. Peptides identified by MALDI-TOF/TOF after in-gel tryptic digestion of the IgE-
binding fragments derived from gastric (Figure 5) and subsequent duodenal digestion (Figure 29) 
of LYS. 
 
 
Identified 
fragment 
Tryptic 
peptide      
(Ion Mass) 
Protein 
residues 
Sequence 
 
11-27 
1464.712 
15-27 
HGLDNYRGYSLGN 
  
1966.995 11-27 AMKRHGLDNYRGYSLGN 
 
57-83 2089.122 57-73 QINSRWWC*NDGRTPGSR 
 
 
1491.820 62-73 WWC*NDGRTPGSR 
  
1160.558 74-83 NLC*NIPC*SAL 
  
3231.477 57-83 QINSRWWC*NDGRTPGSRNLC*NIPC*SAL 
 
108-122   716.335 108-112 WVAWR 
  
  986.600 108-114 WVAWRNR 
  
 
1788.908 108-122  WVAWRNRCKGTDVQA 
 
24-129      1105.009 24-33 SLGNWVCAAK 
  
1428.350 34-45 FESNFNTQATNR 
  
1752.650 46-61 NTDGSTDYGILQINSR 
 
 
  992.764 62-68 WWC*NDGR 
  
  515.977 69-73 TPGSR 
  
2507.463 74-96 NLC*NIPC*SALLSSDITASVNC*AK 
  
1820.181 97-112 KIVSDGNGMNAWVAWR 
  
1691.409 98-112 IVSDGNGMNAWVAWR 
  
1332.535 115-125 C*KGTDVQAWIR 
  
1044.973 117-125 GTDVQAWIR 
C* indicates carbamidomethylated cysteine 
 
 
 
 
 
 
G
a
st
ri
c 
d
ig
es
ti
o
n
 
D
u
o
d
en
a
l 
d
ig
es
ti
o
n
 
 
 
 
 
158 Results and Discussion 
 4.5.1.1.3. The gastric and gastroduodenal digestion products of LYS exert 
biological activity 
   
LYS and its digests were tested in basophil activation assays and used to stimulate 
peripheral blood mononuclear cells of egg allergic patients. The results shown in Figure 
31 refer to basophils from a non-allergic donor, passively sensitized with a pooled sera 
from 5 egg allergic patients (nos. 4, 7, 10, 11 and 12, Annex 5), stimulated with intact LYS 
and with its gastric (pH 1.2 and 2.0 for 60 min) and subsequent duodenal digests (pH 6.5 
for 30 min) obtained in the absence of phosphatidylcholine in the gastric phase and bile 
salts in the duodenal phase. The intact protein and its digests induced basophil activation 
to practically the same extent, as judged by the enhanced expression of the basophil 
activation marker CD63, showing that digestion mimicking gastrointestinal conditions 
that provided the highest degree of LYS hydrolysis (as when the pH of the simulated 
gastric fluid was 1.5) did not substantially reduce its basophil activating capacity. There 
was no activation of the non-stripped basophils of the non-allergic donor after incubation 
with LYS or its digests (not shown). 
 
 
Figure 31. Basophil activating capacity of 
LYS (    ), its gastric digests obtained at pH 
1.5 (    ) and 2.0 (   ) for 60 min and 
subsequent duodenal digests for 30 min            
(    ,    ), in the absence of phosphatidylcholine 
and bile salts. The results correspond to 
basophils from a nonallergic donor, passively 
sensitized with a pooled serum from five egg-
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allergic patients (nos. 4, 7, 10, 11, and 12, Annex 5). 
Peripheral blood mononuclear cells from 3 egg allergic (nos. 13, 14 and 15, Annex 
5) and non-allergic donors were stimulated with intact LYS and its digests. Proliferation 
was assessed by the incorporation of MTT. No proliferation was detected in peripheral 
blood mononuclear cell from non-allergic donors, while peripheral blood mononuclear 
cells from allergic patients proliferated more to intact than to digested LYS. The T-cell 
response towards the gastric digests obtained at pH 1.5 was the highest, decreasing during 
subsequent duodenal digestion, while the gastric digests at pH 2.0 and subsequent 
duodenal digests, both containing intact LYS, produced similar responses (Figure 32). 
 
 
 
Figure 32. Proliferating responses of 
peripheral blood mononuclear cells from 
three allergic patients (nos. 13, 14, and 15, 
Annex 5) to 5 and 20 μg/mL of LYS   (      ), 
its gastric digests obtained at pH 1. 5  (    ) 
and 2.0 (    ) for 60 min, and subsequent 
duodenal digests for 30 min (   ,     ) in the 
absence of phosphatidylcholine and bile 
salts. 
 
 
4.5.1.2. DISCUSSION  
In agreement with previous results (Jiménez-Saiz et al., 2011b), after 60 min of 
simulated gastric phase, LYS was completely hydrolysed by pepsin at pH 1.5, partially 
hydrolysed at pH 2.0 and virtually intact at pH 3.2, and the presence of 
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phosphatidylcholine, during hydrolysis at pH 1.5 and 2.0, slightly protected the protein 
from the enzyme action without changing the fragmentation pattern. Intact LYS, 
surviving gastric digestion at pH 2.0 and 3.2 precipitated under duodenal conditions and 
phosphatidylcholine partially avoided protein precipitation. We now sought to investigate 
to what degree the pH of gastric hydrolysis could determine the extent of subsequent 
duodenal digestion and the immunogenicity and potential allergenicity of LYS. In this 
study, we found that, despite differences in proteolytic resistance to pepsin depending on 
the pH of the simulated gastric fluid, which conditioned subsequent proteolysis by 
pancreatic enzymes, the gastric and gastroduodenal digests maintained allergenic 
potential, as determined by the basophil activation assay, and preserved T-cell 
immunogenicity, although to a somewhat lesser extent than the intact protein. These 
biological activities were specific, because basophils and peripheral blood mononuclear 
cell from non-allergic donors did not show any reactivity. 
Differences in susceptibility to pepsin (Figure 25 and 26), that probably result 
from a more compact conformation at pH 2.0 than at pH 1.5 that makes LYS a poorer 
substrate (Polverino de Laureto et al., 2002), gave rise to the same peptide pattern in the 
gastric and gastroduodenal digests in both cases, as estimated by RP-HPLC-MS/MS, 
indicating that the increased flexibility at the lowest pH was not accompanied by new 
cleavage sites. Nevertheless, the pH of gastric digestion greatly conditioned the 
proportion of LYS that resisted hydrolysis. In this respect, it should be considered that 
after ingestion of a meal, and because of its buffering effects, the pH of the gastric 
contents is around 7, decreasing thereafter at a rate that depends on the rate of gastric 
emptying (which takes on average 48±28 min) and only dropping from around 3 to 1 at 
the end of this process (Carrière et al., 2001). Therefore, without disregarding the effect 
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of the food matrix in the extent of LYS digestion, it is likely that a high proportion of 
intact LYS would reach the duodenum in an in vivo situation.  
Intact LYS precipitated under duodenal conditions, probably due to electrostatic 
interaction with negatively charged bile salts at pH 6.5 (Cakir-Kiefer et al., 2011), and 
this helped it to resist digestion by pancreatic enzymes, as hydrolysis of LYS by trypsin 
and chymotrypsin occurred only in solution aided by the solubilizing effect of the 
presence of phosphatidylcholine in the simulated duodenal medium (Figure 27). The 
nature of the antigen determines its route of uptake, with soluble antigens generally being 
less immunogenic than denatured or particulate ones, because the latter could use follicle-
associated epithelia and M cells to be absorbed, which promotes allergic sensitization 
(Pabst et al., 2012). However, it is also likely that the insoluble LYS-bile salts complexes 
are not reabsorbed in the intestine and are eventually excreted in the feces. In addition, 
even under conditions that favored LYS solubility (such as in the absence or bile salts), it 
was partially resistant to trypsin and chymotrypsin, leaving intact protein and a high 
relative mass IgE-binding fragment lacking the N-terminal 1-23 residues. The LYS (24-
129) fragment, stabilized by 3 disulfide bridges, that presumably maintains many of the 
IgE-binding epitopes of LYS, remained unhydrolysed for, at least, 30 min of duodenal 
digestion, despite possessing several trypsin and chymotrypsin cleavage sites. Given that 
the reduction of the Cys6-Cys127 S-S bond of LYS results in a very efficient T-cell 
processing of the C-terminal dominant epitope LYS (107-116) and in a higher intrinsic 
allergy in BALB/c mice (So et al., 2001), it could be speculated that the release of 
fragment LYS (24-129), whose C-terminal portion is also free from the body of the 
protein, may similarly increase LYS allergenic potential.  
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Structural features of food proteins, such as extensive disulfide bonding, increase 
protein stability decreasing susceptibility towards proteolytic enzymes. Disulfide bonds 
are important in the resistance of allergens, such as Ber e 1 from Brazil nut, riboflavin 
binding protein from egg-white, Act d 2 from kiwifruit and grape lipid transfer protein to 
digestion (Moreno et al., 2005; Martos et al., 2012; Bublin et al., 2008; Vassilopoulou  et 
al., 2006). In addition, there are several examples of food allergens that, once digested, 
retain the IgE-binding, basophil mediator release capacity and/or T-cell stimulatory 
properties of the intact protein, such as Ara h 1 from peanut (Eiwegger et al., 2006), Pers 
a 1 from avocado (Díaz-Perales et al., 2003) or Act d 1 and Act d 2 from kiwifruit (Bublin  
et al., 2008), mainly because the proteolytic fragments form stable disulfide-bonded 
cores. In some cases, it has been described that proteolytic fragmentation can enhance the 
induction of an effective allergic response, likely because digestion unmasks B-cell 
epitopes (Pomes, 2010). On the contrary, the easily digestible pollen-related diet 
allergens, Mal d 1 (apple), Api f 1 (celery) and Cor a (hazelnut) lose their ability to bind 
IgE and induce basophil degranulation, although they retain activating capacity towards 
pollen specific T-cells (Schimek  et al., 2005).   
As shown, LYS, with a high molecular stability due to the presence of 4 disulfide 
bonds, was very resistant to digestion at pH ≥ 2.0 (Figure 27). However, even under 
conditions that promoted LYS proteolysis, such as when gastric digestion was conducted 
at pH 1.5, ELISA inhibition assays indicated that the duodenal digestion products 
maintained a considerable IgE-binding activity and, in fact, these digests cross-linked 
allergen specific IgE, retaining practically unaltered the basophil activating capacity of 
the intact protein and thus its allergenic potential (Figure 31). MALDI-TOF/TOF allowed 
the identification of three possible IgE-binding fragments: LYS (11-27), LYS (57-83) and 
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LYS (108-122) in an immunoreactive band detected by Western blotting following SDS-
PAGE under reducing conditions of the gastric digests obtained at pH 1.5 and 2.0 (Figure 
28, 29 and 30 and Table 5. These peptides, which could include relevant IgE-binding 
epitopes, did not resist subsequent duodenal digestion because they contained several 
trypsin and chymotrypsin cleavage sites. Considering the peptide profiles arising from 
RP-HPLC-MS/MS analyses, it is likely that gastric digestion generated nonlinear LYS 
fragments kept together by disulfide linkages that, in addition to these [particularly LYS 
(57-83) and LYS (108-122)], could contain similar peptides carrying IgE-binding 
epitopes, that would not be detected by Western blotting (Díaz-Perales et al., 2003). 
Furthermore, disulfide linked fragments partially survived subsequent duodenal phase. 
These peptides could contribute to the strong residual IgE-binding and resulting 
biological activity of the gastroduodenal digests, compensating for the loss of other 
epitopes during digestion.  
Unfolding by disruption of intramolecular disulfide bonds usually decreases or 
even abolishes the allergenicity of proteins that display conformational IgE epitopes, 
which indicates their importance compared to sequential ones (Hazebrouck et al., 2012). 
The observation that IgE from allergic patients was more reactive to reduced and S-
alkylated LYS in inhibition ELISA suggests that reduction of the disulfide bonds 
increased its IgE-binding capacity, although the possibility that this was due to chemical 
modification of the epitopes by carboxymethylation cannot be excluded. Similarly, an 
increased IgE-binding to reduced LYS was detected in Western blots. In contrast, Mine 
and Zang (2008) reported that partial denaturation of LYS by urea treatment increases its 
IgE-binding activity, while severe denaturation by reduction and S-alkylation 
significantly decreases it. Our results suggest that, in addition to the contribution of 
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conformational epitopes to its allergenic potential, there are relevant IgE-binding epitopes 
buried within the native structure, that once disclosed by proteolytic degradation could 
contribute to the allergenicity of the digested protein.  
We have found that intact and digested LYS specifically induced proliferation in 
PBMCs from allergic individuals (Figure 32). According to So et al. (1997), unfolded 
(reduced and S-alkylated) LYS was 100 times more potent in T-cell stimulation than the 
native protein, which was associated with a higher susceptibility to be presented by 
antigen presenting cells. In fact, immunization of BALB/c mice with LYS derivatives 
with different conformational stability revealed that the least stable derivative led to the 
most potent Th2 response and IgE production (So et al., 2001). Regarding humans, Holen 
and Elsayed (1996) detected primary proliferation responses in peripheral blood 
mononuclear cell from an egg allergic subject on stimulation with LYS but, to the best of 
our knowledge, there are no reports dealing with the effect of LYS gastroduodenal 
digestion products on human T-cell proliferation. The observation that the gastric and 
gastroduodenal digests of LYS induce peripheral blood mononuclear cell proliferation of 
allergic patients suggests the existence of immunologically active protein fragments that 
could reach the proximal part of the intestine where most of protein absorption occurs.  
In conclusion, in vitro gastric and gastroduodenal digests of LYS with different 
degrees of hydrolysis, depending on the pH of gastric digestion, maintained IgE-binding 
and basophil activation capacity and preserved T-cell immunogenicity. These biological 
activities could be attributed to the persistence of intact LYS, due to incomplete gastric 
degradation and subsequent duodenal precipitation, to the formation of fragment LYS 
(24-129) by chymotrypsin action on the soluble intact protein or to the release, upon 
combined gastric and duodenal digestion, of immunoreactive peptides linked by 
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disulphide bonds. LYS may contain relevant linear epitopes that could be disclosed by 
digestion increasing its allergenic potential. 
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4.5.2. Anaphylaxis induced by a drug containing lysozyme and papain. 
Influence of papain in the IgE response  
 
LYS of egg origin is being increasingly used as an antibacterial additive to prevent 
spoilage of cheese, wine or other foodstuffs (Iaconelli et al., 2008; Weber et al., 2009), as 
well as in medicinal products for respiratory tract infections and congestions, which do 
not usually declare its source (Audicana et al., 2011), thus posing a risk for consumers 
allergic to hen egg. Hypersensitivity reactions to drugs containing LYS have been 
described that, in some cases, happen to occur in children that had never intentionally 
eaten egg and either ignore they are sensitized to egg proteins or react at the first 
ingestion (Artesani et al., 2008; Ledesma et al., 2007).  
This work, conducted in collaboration with the allergy section from the Hospital 
Infantil Universitario Niño Jesús (Madrid), reports a severe reaction to Lizipaina
®
, a drug 
used for the symptomatic relief of mild conditions of the throat and mouth, which 
contains 5 mg of LYS, in a 15 years old patient able to tolerate, an accumulated dose of at 
least 60 mg of LYS during a double-blind placebo-controlled food challenge. 
Furthermore, a successful desensitization after undergoing a rapid oral immunotherapy 
protocol to hen egg is described. 
In addition to LYS, Lizipaina
®
 contains papain (2 mg) and bacitracin (3 mg). 
Papain is a cysteine proteinase allergen, such as Bromelain and Der p 1, whose intrinsic 
proteolytic activity has been associated to its capacity to induce Th2-mediated allergic 
responses (Wills-Karp et al., 2010). This study investigates a possible role for papain in 
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increasing the allergenicity of LYS through the release of IgE-binding degradation 
products.  
 
4.5.2.1. RESULTS 
 4.5.2.1.1. Case report and oral desensitization 
 
A 15-year-old boy diagnosed with persistent allergy to egg, fish and tree nuts, 
atopic dermatitis, rhino conjunctivitis and asthma with sensitization to pollens and 
epithelia had been previously subjected to a controlled open oral challenge with yolk with 
a negative result and, since then, the patient had been eating yolk with good tolerance, but 
avoiding egg in other presentations. In April 2012, he took a tablet of Lizipaina
®
 (5 mg 
lysozyme, 3 mg bacitracin, and 2 mg papain) due to a mild respiratory viral infection. 
Fifteen min later, he developed pharyngeal itching, dysphonia, dysphagia, and 
bronchospasm. These symptoms were controlled with intramuscular epinephrine, 
intravenous antihistamines and corticosteroids at the Emergency Unit. The boy avoided 
egg rigorously after the reaction, until attending medical consultation at the allergy 
section from the Hospital Infantil Universitario Niño Jesús (Madrid) in September 2012.  
He was subjected to a double-blind placebo-controlled food challenge with 
increasing doses of raw dehydrated egg white (OVO-DES NM, Madrid, Spain. 3600 mg 
corresponding to a whole egg white) after signing an informed consent. The patient 
developed immediate oral allergy syndrome, and long lasting abdominal pain, pyrosis and 
diarrhea 1 h after taking a 1,800 mg dose (which corresponded to an accumulated dose of 
3,559 mg) with spontaneous clinical resolution.  
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Table 6. Results of the in vivo and in vitro tests performed on the allergic patient 
submitted to a rapid desensitization protocol at different evaluation times before and after oral 
immunotherapy. 
  T0 T1 T2 T3 
Skin prick tests (mm) *         
        Egg 5 4 4 6 
        Egg white 8 3 2 9 
        Yolk 6 2 2 4 
        Ovalbumin 5 2 4 4 
        Ovomucoid 10 3 4 4 
Prick-by-prick test with Lizipaina
®
 in saline (mm) *     
   6  8  8  6 
Serum total IgE (UI/mL)     
  661   792  609  588 
Serum specific IgE (kU/mL)         
        Egg 5.95 5.25 6.88 9.95 
        Egg white 4.72 5.37 6.65 9.32 
        Yolk 2.18 1.21 1.58 1.54 
        Ovalbumin 0.76 0.45 0.57 0.68 
        Ovomucoid 0.92 1.28 1.33 1.44 
        Lysozyme 4.87 8.59 11.3 14.7 
Serum specific IgG4 (mg/mL)         
        Egg white 2.37 16.4 23.6 14.6 
        Ovalbumin 1.79 16.4 25 20.2 
        Ovomucoid 0.66 4.46 6.49 4.24 
Sera from patient before oral immunotherapy (T0) and after 15 (T1), 30 (T2) and 90 days (T3) of 
oral immunotherapy.  
* Positive if >3. 
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Then, the patient underwent a rapid desensitization protocol with OVO-DES at the 
Hospital Allergy Day Unit under the direct supervision of medical and nursing staff. Pre-
treatment with 10 mg Cetirizine was conducted the day before initiating the specific oral 
tolerance induction. A build-up was performed daily, starting with the last tolerated dose 
in the double-blind, placebo-controlled food challenge. The corresponding doses were 
administered in sweetened orange juice 1 h apart (900 and 1,800 mg on the 1
st
 day; 1,800 
and 3,600 mg on the 2
nd
 day) with no clinical incidences. Cetirizine was discontinued 3 
days after reaching the highest dose of raw dehydrated egg white. The patient took 3,600 
mg daily during the first week of maintenance at home, and thereafter hen egg was 
introduced into the patient diet. Given the good clinical evolution, a controlled open food 
challenge with a tablet of Lizipaina
®
 was carried out after 45 days of maintenance with 
egg following oral immunotherapy. Increasing amounts were administered every 30 min 
in 3 doses (0.25, 0.25 and 0.5 of a tablet) to achieve the therapeutic dose. This confirmed 
tolerance to the drug containing LYS that had elicited the patient’s reaction.  
The results of the skin prick tests, serum total and specific IgE, and serum specific 
IgG4 to different egg protein fractions were assessed before (T0) and after 15 (T1), 30 (T2) 
and 90 days (T3) of oral immunotherapy (Table 6). In general terms, skin prick tests 
decreased markedly at T1, although skin prick tests to egg white increased again at T3. 
Prick-by-prick test with Lizipaina
®
 in saline remained positive at the end of the study. 
Serum IgE specific to whole egg, egg white and, particularly, to LYS continuously 
increased during the time period considered. Serum IgG4, specific to egg white, OVA and 
OM also increased, with the highest levels being detected at T2.  
Because the LYS amount that elicited the anaphylactic reaction (5 mg) was much 
lower than that tolerated during the double blind controlled food challenge, with 900 mg 
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of dehydrated egg white, corresponding to an accumulated dose of 1,759 mg 
(approximately equivalent to 30 and 60 mg of LYS, respectively), the possibility that the 
presence of papain could increase the allergenic potential of LYS was investigated. 
 
 4.5.2.1.2. Reactivity of IgE from egg allergic patients towards lysozyme and 
Lizipaina
®
 
 
Western blotting of LYS, Lizipaina
®
 and egg white was conducted following 
SDS-PAGE under reducing conditions with sera from the allergic patient at T0, T1 and T2 
(Figure 33). Before immunotherapy, the patient’s serum was reactive towards the main 
egg white proteins (Figure 33b, lane 3). LYS, with a molecular mass of 14.3 kDa, was 
strongly recognized by the serum, both as pure protein (Figure 33b, lane 1) and as part of 
the egg white (Figure 33b, lane 3). In the Lizipaina
®
 sample there were IgE-reactive 
bands corresponding to papain (approximately 23 kDa), LYS, and lower molecular mass 
peptides (Figure 33b, lane 2). Bacitracine, a 1.4 kDa antibiotic peptide, is too small to be 
resolved and retained in the polyacrylamide gel. The reactivity of the IgE from the 
patient’s sera towards the main egg protein was maintained along immunotherapy, while 
that towards LYS and the lower molecular mass bands increased, as judged by the 
progressively stronger staining of the bands (Figure 33 b-d). This is in accordance with 
the detected increase in the levels of LYS-specific IgE shown in Table 6. 
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Figure 33. SDS-PAGE patterns (a), using Bis-Tris 12% acrilamide gels, and Western 
blotting (b, c, d) of LYS (1), Lizipaina
®
 (2) and egg white (3). Electrophoresis was performed 
under reducing conditions. M: molecular mass marker. Sera from patient before oral 
immunotherapy (T0), after 15 days (T1), and after 1 month (T2) of oral immunotherapy, were used. 
 
The possibility that the lower molecular mass IgE-binding bands were released 
from LYS by papain action was tested in an experiment where LYS was incubated with 
papain for 3 h at 54ºC. SDS-PAGE under reducing conditions showed that papain 
hydrolysed LYS producing lower molecular mass fragments (Figure 34a, lane 3) which 
were to a great extent coincident with the bands present in the Lizipaina
®
 sample (Figure 
34a, lane 4). According to the Western blot using the serum from patient after 1 month (T2) 
of oral immunotherapy, depicted in Figure 2b, these bands strongly bound IgE (Figure 34b, 
lanes 3 and 4). On the other hand, papain gave, in addition to the 23 kDa band, two other 
IgE-binding bands of ~15 and ~10 kDa (Figure 34b, lane 1) 
. 
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Figure 34. SDS-PAGE patterns (a), 
using Bis-Tris 12% acrilamide gels, 
and Western blotting (b) of papain at 
0.5 mg/mL (1), LYS at 0.42 mg/mL 
(2), LYS (0.42 mg/mL) hydrolysed 
with papain (0.17 mg/mL) at 54ºC for 
3h (3) and Lizipaina
®
 (0.5 mg 
LYS/mL) (4). M: molecular mass 
marker.  
Sera from 5 egg-allergic patients (nos. 10, 16, 7, 17 and 18, Annex 5) were 
analysed for IgE binding to LYZ, papain and papain treated LYZ, by performing an SDS-
PAGE analysis followed by a western blot with and without -mercaptoethanol (Figure 
35). Comparison between the SDS-PAGE patterns under reducing and non-reducing 
conditions in bis-tris 12% acrylamide gels, showed that the degradation products 
produced by papain hydrolysis on LYS were only visible after reduction of the disulfide 
bonds of the protein (Figure 35a). All the allergic donors exhibited IgE reactivity to LYZ, 
but varied in their reactivity to the bands released by papain action under reducing 
conditions (Figure 35b-f), which did not seem to depend on the levels of total serum or 
LYS-specific IgE, except for the patient with the highest titer (266 kU/mL, Annex 5) who 
exhibited a very strong reaction (Figure 35f). This binding was specific of egg allergy, as 
no IgE binding was detected when using a serum sample form a non-allergic donor (not 
shown). All the sera also recognized non-reduced and reduced papain bands, albeit with 
different intensity. 
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Figure 35. SDS-PAGE pattern (a), using Bis-Tris 12% acrilamide gels, and Western blotting (b-
h) with sera from 5 egg allergic patients, (10 (b), 16 (c), 7 (d), 17 (e), 18 (f), Annex 5). Lane 1: 
LYS; lane 2: LYS hydrolysed with papain at 54ºC for 3h; and lane 3: papain at the same 
concentration as in lane 2, all dissolved in sample buffer with (+β-ME) and without (-β-ME) 
reducing agent.  
 
 
 
 
 
 
 
 
174 Results and Discussion 
 
As shown in Figure 36, SDS-PAGE analysis of Lizipaina
®
 was also performed 
under non-reducing and reducing conditions, using a tris-tricine polyacrylamide gel 
specific to resolve low molecular mass bands, followed by Western blot (with a pool of 6 
sera, nos. 1-6, Annex 5). This confirmed that in the non-reduced sample of Lizipaina
®
, only 
a band of intact LYS was present, but when the sample was reduced with β-
mercaptoethanol before SDS-PAGE, the band of intact LYS decreased and several 
degradation products were released (Figure 36), including two IgE-binding fragments of 
molecular mass > 6,500 Da (Figure 36b,).  
 
 
 
 
 
Figure 36. SDS-PAGE patterns (a), 
using Tris-Tricine 16.5% acrilamide 
gels, and Western blotting (b) of LYS 
under nonreducing (-β-ME) and 
reducing (+β-ME) conditions. 
 
To identify the LYS fragments that contributed to IgE binding, both 
immunoreactive bands were subjected to in-gel tryptic digestion, as well as intact 
molecular weight determination by MALDI-TOF/TOF (Table 7).  
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Table 7. Peptides identified by MALDI-TOF/TOF after in-gel tryptic digestion of the 
LYS IgE-binding fragments derived from electrophoresis SDS-PAGE under reducing 
conditions (Figure 4). 
  
Identified 
fragment 
Tryptic 
peptide   
(Ion Mass) 
Protein 
residues 
Sequence 
B
A
N
D
 1
 
22-129 1324.525 22-33 GYSLGNWVC*AAK 
  1427.631 34-45 FESNFNTQATNR  
  1752.819 46-61 NTDGSTDYGILQINSR  
  992.361 62-68 WWC*NDGR 
  2506.992 74-96 NLC*NIPC*SALLSSDITASVNC*AK  
  1816.992 97-112 KIVSDGNGMNAWVAWR  9: Oxidation (M) 
  1691.775 98-112 IVSDGNGMNAWVAWR  8: Oxidation (M) 
  1675.783 98-112 IVSDGNGMNAWVAWR  
  901.499 106-112 NAWVAWR  
  1044.513 117-125 GTDVQAWIR  
B
A
N
D
 2
 
34-96 1427.734 34-45 FESNFNTQATNR  
  1752.961 46-61 NTDGSTDYGILQINSR  
  992.445 62-68 WWC*NDGR  
  2504.835 74-96 NLC*NIPC*SALLSSDITASVNC*AK  
62-128 992.445 62-68 WWC*NDGR  
  2504.835 74-96 NLC*NIPC*SALLSSDITASVNC*AK  
  1674.904 98-112 IVSDGNGMNAWVAWR  
  1044.61 117-125 GTDVQAWIR  
C* indicates carbamidomethylated cysteine 
 
The higher molecular mass band, with an estimated mass of 11,869.889 Da, 
corresponded to LYS (22-129) (molecular mass 11,887.641 Da). The lower molecular 
mass band contained two different products (with estimated masses of 7,220 and 7,394 
Da) that corresponded, respectively, to LYS (34-96) (6,892) and LYS (62-128) (7,380). 
Cleavage at Arg21, Lys33, Arg68, Arg61, Lys96 and Arg128 is consistent with papain 
specificity, which prefers to cleave at the C-terminal side of Arg or Lys, N-linked to a 
hydrophobic amino acid residue. 
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4.5.2.2. DISCUSSION  
We report a case of a boy suffering from egg allergy who, once desensitized to 
egg following a successful rapid oral immunotherapy, could also tolerate a LYS 
containing drug which had previously caused him a severe allergic reaction. This 
indicated the effectiveness of the rapid oral desensitization protocol used, although 
sustained unresponsiveness remains to be established. Successful immunotherapy to egg 
is associated with increases in specific IgG4, although, as it was the case of the present 
study (Table 6), this is not always accompanied by decreases in total or specific IgE 
levels (Burks et al., 2012). Moreover, a slow rate of change in SPT and total IgE, which 
only decreased significantly after 6 months of tolerance, was reported after a rush 
protocol (5 days) of desensitization to egg (García-Rodriguez et al., 2011). In our study, 
even an increase in IgE specific to whole egg, egg white and LYS was detected. 
Similarly, it was reported that peanut specific IgE increased during the first year of peanut 
oral immunotherapy, reaching approximately 3-fold after 3 months of treatment, and 
decreased by 12 to 18 months (Jones et al., 2009). 
It was noteworthy that 5 mg of LYS contained in a Lizipaina
®
 tablet caused this 
patient a severe allergic reaction, while during the double blind placebo controlled food 
challenge, at least 30 mg of LYS, contained in a single dose of 900 mg of dehydrated egg 
white (corresponding to an accumulated dose of 1,759 mg containing 60 mg of LYS), 
were well tolerated. In fact, the IgE present in the sera from this patient reacted more 
strongly towards Lizipaina
®
 than to an equivalent LYS amount (Figures 33 and 34), and 
this raised the possibility that the presence of papain could increase the allergenic 
potential of LYS.  
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Inhaled papain is not only a potent allergen found in occupational settings (Soto-
Mera et al., 2000), but also papain (if enzymatically active, as it is the case of other 
cysteine proteinases) is able to induce Th2 responses and to exert an adjuvant effect on 
the sensitizing potential of other allergens, independently of its own antigenicity (Sokol et 
al., 2008; Cunningham et al., 2012). In addition, its proteolytic properties can enhance its 
mode and route of transport across the epithelial barriers, which may have an impact on 
the immune responses generated (Bufe, 1998). Therefore, a role for papain in the 
initiation of allergic responses to LYS cannot be excluded. In fact, a case of angioedema 
due to the ingestion of Lizipaina
®
 was reported in a non-egg allergic woman who was 
regularly eating egg (Pérez-Calderón et al 2007). On the other hand, it is also feasible that 
papain can increase the eliciting properties of an allergen, such as LYS, in already 
sensitized patients, by enhancing its bioavailability and the inflammatory response it 
provokes. Furthermore, the proteolytic action of papain on LYS, described in this work, 
could boost its allergenicity by producing fragments with increased IgE binding ability. In 
fact, even if the individual patients tested were shown to vary in their reactivity towards 
papain-produced LYS fragments, qualitative results suggested that, in some of them, IgE-
binding to LYS hydrolysed with papain was more intense than to an equivalent amount of 
LYS. We had previously found that pepsin digestion of LYS released peptides that 
carried an important epitope load, so that the IgG and IgE binding properties of the 
digests were maintained to a high extent (Jiménez-Saiz et al., 2011b; Section 4.5.1).  
In fact, the SDS-PAGE patterns of both LYS treated with papain and Lizipaina
®
, 
under non-reducing conditions, showed the presence of intact LYS that partially 
disappeared following reduction with -mercaptoethanol releasing IgE reactive fragments 
(Figures 35 and 36). This indicated that papain degraded LYS giving rise to epitopes that 
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could remain linked through the disulfide bonds present in the LYS molecule. MALDI-
TOF/TOF allowed the identification of three possible IgE-binding fragments: LYS (22-
129), LYS (34-96) and LYS (62-128) in the immunoreactive bands detected by Western 
blotting following SDS-PAGE under reducing conditions (Table 7). These peptides 
comprised the IgE-binding epitopes, described in the previous section (4.5.1), such as 
LYS (57-83) and LYS (108-122). As illustrated in Figure 37, LYS (22-129) and LYS (62-
128) could form part of bigger structures owing to the disulfide bonds connecting Cys6-
Cys127, Cys30-Cys115, Cys64-Cys80 and Cys76-Cys94, and the possibility arises that these 
new structures could present an enhanced allergenic potential.  
 
 
 
Figure 37. Representation of the identified bands of LYS (Figure 36 and Table 7) in the 3D 
structure of LYS (orange color). Drawn with UCSF Chimera software (Pettersen et al., 2004) 
using the crystal structure of LYS described by Naresh et al. (to be published) in the protein data 
bank website. 
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A further possibility is that the administration of tablets to be dissolved slowly in 
the mouth could enhance pregastric absorption of LYS in the oral cavity. These would 
explain the occurrence of symptoms few min after ingestion of Lizipaina
®
, as described in 
this work. Allergen absorption from the human mucosa has been demonstrated (Dirks et 
al., 2005) and it would be worth investigating if it could be intensified in the presence of 
proteases. In fact, targeting proteolytic activity by inhibitors has proved potential for 
adjunct airway allergy therapy (Saw et al., 2012).  
In conclusion, the combined administration of lysozyme and papain in drugs may 
trigger severe allergic reactions that underline the importance of declaring the origin of 
the active principles. More research is being conducted to determine if specific avoidance 
of such combinations should be recommended. 
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1.- The comparison of two models of digestion using human or simulated fluids on β-LG, 
β-CN and OVA leaded to similar results respect to hydrolysis patterns and 
immnunoreactivity of the digests, suggesting that in vitro digestion model with simulated 
fluids used in this thesis provide a good estimation of the potential allergenicity of protein 
digests. 
 
2.- Digestion with human and simulated fluids has allowed the identification of 195, 152 
and 213 peptides from degradation of β-LG, β-CN and OVA respectively. Several of 
them are comprised in prominent immunoreactive areas of the proteins detected by 
peptide microarray and dot-blot corresponding to sequences β-LG (43-62), β-LG (86-
100), β-LG (122-147), β-CN (57-68), β-CN (82-93) and OVA (370-385).  
 
3.- The carbohydrate moieties of OM exert a protective effect against proteolysis, 
particularly during the first stages of gastric digestion, contributing to a higher allergenic 
potency. Some egg-allergic patients present an enhanced IgE reactivity towards glycated 
OM compared with deglycosylated OM but seems to have no clinical relevance. 
 
4.- The evaluation of the presence of potential epitopes among the digests of OM and 
dOM revealed the presence of high-frequency IgE-binding fragments that could remain 
linked by disulphide bonds. However, the total residual IgE binding of the in vitro digests 
was low. 
 
5.- In vitro gastric and gastroduodenal digests of LYS maintain IgE binding and basophil 
activation capacity and preserve T-cell immunogenicity. 
 
 
 
 
184 Conclusions 
6.- In vitro digestion of LYS has allowed the identification of three products with IgE 
binding capacity, that corresponded to the fragments LYS (11-27), LYS (57-83) and LYS 
(108-122) in the gastric stage and the fragment LYS (24-129), resulted from the 
chymotrypsin cleavage of Tyr23-Ser24 during duodenal phase. These fragments could be 
linked by disulphide bonds. 
 
7.- The combined administration of LYS and papain in drugs may trigger and/or enhance 
severe allergic reactions that underline the importance of understand in depth the 
interactions between the constituents of drugs or food. 
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1 -. La comparación de dos modelos de digestión utilizando fluidos humanos en un caso y 
fluidos simulados en otro, aplicados a importantes alérgenos de huevo y leche como β-Lg, 
β-CN y OVA ha demostrado que ambos modelos proporcionan una buena estimación de 
la alergenicidad potencial de la proteína digerida. 
 
2 -. La digestión sobre dichas proteínas,  β-Lg, β-CN y OVA, ha permitido la 
identificación de 195, 152 y 213 péptidos respectivamente, entre los productos 
resultantes. Se han descrito epítopos con alta capacidad inmunorreactiva, destacando los 
fragmentos β -LG (43-62), β-LG (86-100), β-LG (122-147), β-CN (57-68), β-CN (82-93) 
y OVA (370-385). 
 
3 -. Las cadenas de carbohidratos presentes en la estructura del OM ejercen un efecto 
protector frente a la proteolisis, en particular durante las primeras etapas de la digestión 
gástrica, lo que puede contribuir a que algunos pacientes alérgicos al huevo presentan 
mayor reactividad hacia IgE en OM glicosilado en comparación con la forma 
desglicosilada (dOM).  
 
4 -. La evaluación de potenciales epítopos entre los digeridos de OM y dOM reveló la 
presencia de fragmentos con alta capacidad de unión a IgE que podrían permanecer 
unidos por enlaces disulfuro. Sin embargo, la capacidad total de unión a IgE de los 
digeridos fue baja. 
 
5 -. Los digeridos gástricos y gastroduodenales de LYS mantienen la capacidad de unión 
a IgE y activación de basófilos e incrementan la proliferación celular.  
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6.- En la digestión in vitro de LYS se han identificado 3 productos con capacidad de 
unión a IgE, que corresponden a los fragmentos  LYS (11-27), LYS (57-83) and LYS 
(108-122) generados durante la digestión gástrica y el fragmento LYS (24-129), que se 
obtiene por acción de la quimotripsina sobre el enlace Tyr23-Ser24 durante la fase 
duodenal. Estos fragmentos podrían permanecer unidos por enlaces disulfuro.  
 
7.- La administración conjunta de LYS y papaína en fármacos puede provocar y/o 
potenciar severas reacciones alérgicas, lo que subraya la importancia de conocer en 
profundidad las interacciones entre los constituyentes de los medicamentos o de los 
alimentos. 
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Annex 1. Specific IgE levels (kU/L) towards milk and β-casein of the sera used in the 
inhibition ELISA (patients 1 to 6), Western blotting (patients 1 to 4) and microarray 
assays (patients 7 to 18), shown in section 4.1. 
 
Patient 
Age 
(years) 
IgE levels (kU/L) 
Milk β-CN 
1 2 95.3 91.7 
2 6 98.8 90.9 
3 7 99.7 94.9 
4 5 85.6 62.4 
5 1 54.5 48.1 
6 1 24.2 32.1 
7 1 >100.0 ND 
8 1 >100.0 ND 
9 0.5 >100.0 ND 
10 7 >100.0 ND 
11 7 91.3 ND 
12 1 30.4 ND 
13 2 30.2 ND 
14 1 26.4 ND 
15 3 19.2 ND 
16 4 17.8 ND 
17 2 14.2 ND 
18 1 5.1 ND 
 ND: Not determined 
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Annex 2. Specific IgE levels (kU/L) towards milk and β-lactoglobulin of the sera used in 
the inhibition ELISA (patients 1 to 6), and microarray assays (patients 7 to 14), shown in 
section 4.2. 
 
Patient 
Age 
(years) 
IgE levels (kU/L) 
Milk β-LG 
1 6 98.8 62.9 
2 5 85.6 34.0 
3 10 89.4 31.9 
4 1 >100.0 >100.0 
5 1 >100.0 >100.0 
6 1 27.6 18.9 
7 1 26.4 ND 
8 2 30.2 ND 
9 1 91.3 ND 
10 0.5 >100.0 ND 
11 1 >100.0 ND 
12 1 >100.0 ND 
13 0.5 >100.0 ND 
14 7 >100.0 ND 
 ND: Not determined 
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Annex 3. Specific IgE levels (kU/L) towards egg white, yolk and ovalbumin of the sera 
used in the inhibition ELISA (patients 1 to 6), Western blotting (patients 7 to 12) and dot 
blot assays (patients 13 to 22), shown in section 4.3. 
 
Patient 
Age 
(years) 
IgE levels (kU/L) 
Egg     
white 
Egg    
Yolk 
OVA 
1 6 40.4 15.8 16.7 
2 6 >100 >100 >100 
3 7 20 1.67 25.1 
4 3 75.9 14.1 65.6 
5 4 50.9 16.2 57.7 
6 7 41.7 25.7 7.29 
7 12 14.7 6.07 2.16 
8 3 1.62 0.82 2.89 
9 9 11.5 7.25 9.35 
10 7 41.7 25.7 7.29 
11 11 13.1 6.78 8.33 
12 3 >100 90.9 73.7 
13 11 54.7 32.9 26 
14 7 27.6 20.6 12.3 
15 7 41.7 25.7 7.29 
16 3 73.2 42.5 46.4 
17 12 66 42.9 35.6 
18 9 92.7 63.8 76 
19 7 >100 >100 70.9 
20 3 >100 90.9 73.7 
21 6 >100 >100 60.9 
22 8 >100 >100 >100 
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Annex 4. Specific IgE levels (kU/L) towards egg white, yolk and ovomucoid of the sera 
used in the inhibition ELISA (patients 1-16), Western blotting (patients 1-10), dot blot 
(patients 1-10) and basophil activation assays (patients 1, 3, 5, 7 and 9), shown in section 
4.4. 
 
Patient 
Age 
(years) 
IgE levels (kU/L) 
Egg     
white 
Egg    
Yolk 
OM 
1 11 54.7 32.9 37.1 
2 7 27.6 20.6 41.1 
3 7 41.7 25.7 61.5 
4 3 73.2 42.5 62.2 
5 12 66 42.9 70.4 
6 9 92.7 63.8 77.4 
7 7 >100 >100 90.7 
8 3 >100 90.9 >100 
9 6 >100 >100 >100 
10 8 >100 >100 229 
11 3 75.9 14.1 46.6 
12 7 36.7 5.1 48.3 
13 6 >100 >100 87.8 
14 6 11.6 4.32 12 
15 6 40.4 15.8 49.5 
16 4 50.9 42.1 62.1 
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Annex 5. Specific IgE levels (kU/L) towards egg white, yolk and lysozyme of the sera 
used in the inhibition ELISA (1-6), Western blotting (patients 1-9), basophil activation 
(patients 4, 7, 10, 11, 12) and assays of PBMC proliferation assays (patients 13-15), 
shown in section 4.5. 
 
Patient 
Age 
(years) 
IgE levels (kU/L) 
Egg     
white 
Egg    
Yolk 
LYS 
1 12 14.7 6.07 0.35 
2 3 1.62 0.82 0.35 
3 9 11.5 7.25 0.11 
4 7 41.7 25.7 0.12 
5 11 13.1 6.78 0.12 
6 3 >100 90.9 1.26 
7 6 >100 >100 0.59 
8 6 >100 >100 2.31 
9 6 11.6 4.32 0.71 
10 11 54.7 32.9 1.13 
11 12 66 42.9 0.12 
12 7 >100 >100 13.6 
13 10 56.6 44.2 0.85 
14 27 5.53 3.08 0.04 
15 2 64 13.8 4.3 
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Annex 6. Peptide sequences identified by RP-HPLC-MS/MS in the gastric (60 min, G60) 
and gastroduodenal digests of β-CN (60 min of gastric followed by 30 min of duodenal 
digestion, D30), with simulated and human fluids, shown in section 4.1. 
Calculated 
mass 
Sequence 
β-CN 
Fragment 
Simulated 
Fluids 
Human 
Fluids 
G60 D60 G60 D30 
674.324  RELEE  1-5 + + + + 
787.408  RELEEL  1-6 + - - - 
1283.636  RELEELNVPGE  1-11 + - - - 
1624.831  RELEELNVPGEIVE  1-14 + - - - 
627.323  LNVPGE  6-11 - - + + 
740.407  LNVPGEI  6-12 - - - + 
968.518  LNVPGEIVE  6-14 - - + - 
627.323  NVPGEI  7-12 - - - + 
414.211  PGEI  9-12 - - - + 
516.327  KIEK  29 - 32 - + - + 
748.288  QQTEDE  39 - 44 - - - + 
747.292  EDELQD  42 - 47 - + - - 
502.275  LQDK  45 - 48 - - - + 
996.539  LQDKIHPF  45 - 52 - + - - 
1296.683  LQDKIHPFAQT  45 - 55 + - + - 
1511.773  LQDKIHPFAQTQS  45 - 57 + - + - 
1624.857  LQDKIHPFAQTQSL  45 - 58 + - + - 
883.455  QDKIHPF  46 - 52 - + - - 
1183.599  QDKIHPFAQT  46 - 55 + - + - 
1398.689  QDKIHPFAQTQS  46 - 57 + - + - 
755.397  DKIHPF  47 - 52 - + - - 
940.513  KIHPFAQT  48 - 55 - - + - 
1155.604  KIHPFAQTQS  48 - 57 - - + - 
812.418  IHPFAQT  49 - 55 - - + - 
1027.509  IHPFAQTQS  49 - 57 - - + - 
646.329  AQTQSL  53 - 58 - + - - 
1088.591  SLVYPFPGPI  57 - 66 - - - + 
1299.686  SLVYPFPGPIPN  57 - 68 - - - + 
1499.802  SLVYPFPGPIPNSL  57 - 70 - - + - 
1001.559  LVYPFPGPI  58 - 66 - - - + 
1212.654  LVYPFPGPIPN  58 - 68 - + - + 
1412.770  LVYPFPGPIPNSL  58 - 70 - - + - 
1637.882  LVYPFPGPIPNSLPQ  58 - 72 - + - - 
2502.352  LVYPFPGPIPNSLPQNIPPLTQT  58 - 80 + - + - 
888.475  VYPFPGPI  59 - 66 - - - + 
1099.570  VYPFPGPIPN  59 - 68 - + - + 
1299.686  VYPFPGPIPNSL  59 - 70 - - + - 
1524.798  VYPFPGPIPNSLPQ  59 - 72 - + - - 
2389.268  VYPFPGPIPNSLPQNIPPLTQT  59 - 80 + - + - 
529.290  FPGPI  62 - 66 - - - + 
1301.734  IPNSLPQNIPPL  66 - 77 - - + - 
1307.709  SLPQNIPPLTQT  69 - 80 - + - - 
1107.592  PQNIPPLTQT  71 - 80 - - + - 
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Annex 6. Continuation    
Calculated 
mass 
Sequence 
β-CN 
Fragment 
Simulated 
Fluids 
Human 
Fluids 
G60 D60 G60 D30 
882.481  NIPPLTQT  73 - 80 - - - + 
2315.260  NIPPLTQTPVVVPPFLQPEVM  73 - 93 - + - - 
655.354  PPLTQT  75 - 80 + - - - 
994.585  PVVVPPFLQ  81 - 89 - - + - 
1220.681  PVVVPPFLQPE  81 - 91 - - - + 
1319.749  PVVVPPFLQPEV  81 - 92 + + - + 
1450.789  PVVVPPFLQPEVM  81 - 93 + + + - 
1507.811  PVVVPPFLQPEVMG  81 - 94 + - + - 
1056.531  PPFLQPEVM  85 - 93 + + - - 
474.215  PEVM  90 - 93 - - + - 
745.433  GVSKVKE  94 - 100 + - + - 
2401.265  GVSKVKEAMAPKHKEMPFPKY  94 - 114 - - + - 
1709.896  SKVKEAMAPKHKEMP  96 - 110 + - - - 
872.479  VKEAMAPK  98 - 105 - + - - 
645.316  EAMAPK  100 - 105 - + - + 
1673.842  AMAPKHKEMPFPKY  101 - 114 - - + - 
1012.516  HKEMPFPK  106 - 113 - + - + 
1744.865  HKEMPFPKYPVEPF  106 - 119 - + - - 
747.363  EMPFPK  108 - 113 - + - + 
1479.711  EMPFPKYPVEPF  108 - 119 - + - - 
2125.008  EMPFPKYPVEPFTESQSL  108 - 125 - + - - 
603.290  YPVEP  114 - 118 - - - + 
750.359  YPVEPF  114 - 119 - + - - 
1496.703  YPVEPFTESQSLT  114 - 126 - + - - 
440.227  PVEP  115 - 118 - - - + 
817.386  PVEPFTE  115 - 121 - - + - 
1119.508  PVEPFTESQS  115 - 124 - - + - 
794.345  PFTESQS  118 - 124 - - + - 
663.308  TESQSL  120 - 125 - + - - 
1800.040  LTLTDVENLHLPLPLL  125 - 140 + + - - 
790.371  TLTDVEN  126 - 132 - - + + 
903.455  TLTDVENL  126 - 133 - + - - 
1686.956  TLTDVENLHLPLPLL  126 - 140 + + - - 
1902.046  TLTDVENLHLPLPLLQS  126 - 142 - + - - 
2088.126  TLTDVENLHLPLPLLQSW  126 - 143 - + - - 
1585.908  LTDVENLHLPLPLL  127 - 140 - + - - 
576.239  TDVEN  128 - 132 - - + + 
1359.740  TDVENLHLPLPL  128 - 139 - + - - 
1472.824  TDVENLHLPLPLL  128 - 140 + + + - 
1600.882  TDVENLHLPLPLLQ  128 - 141 - - + - 
1687.914  TDVENLHLPLPLLQS  128 - 142 + + + - 
1371.776  DVENLHLPLPLL  129 - 140 + + - - 
1586.867  DVENLHLPLPLLQS  129 - 142 + + - - 
1256.749  VENLHLPLPLL  130 - 140 + + + - 
1384.808  VENLHLPLPLLQ  130 - 141 + - - - 
1471.840  VENLHLPLPLLQS  130 - 142 + + - - 
688.427  LHLPLP  133 - 138 - - - + 
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Annex 6. Continuation    
Calculated 
mass 
Sequence 
β-CN 
Fragment 
Simulated 
Fluids 
Human 
Fluids 
G60 D60 G60 D30 
801.511  LHLPLPL  133 - 139 - + + - 
914.595  LHLPLPLL  133 - 140 - - + - 
1042.654  LHLPLPLLQ  133 - 141 - - + - 
1129.686  LHLPLPLLQS  133 - 142 - - + - 
365.206  HLP  134 - 136 - - - + 
575.343  HLPLP  134 - 138 - - - + 
688.427  HLPLPL  134 - 139 - + - - 
1016.602  HLPLPLLQS  134 - 142 - + - - 
1202.681  HLPLPLLQSW  134 - 143 - + - - 
1912.908  QSWMHQPHQPLPPTVM  141 - 156 - - + - 
1784.849  SWMHQPHQPLPPTVM  142 - 156 - - + - 
1697.817  WMHQPHQPLPPTVM  143 - 156 + + + - 
648.280  MHQPH  144 - 148 - - - + 
1511.738  MHQPHQPLPPTVM  144 - 156 - + - - 
2280.155  MHQPHQPLPPTVMFPPQSVL  144 - 163 - + - - 
1013.529  QPHQPLPPT  146 - 154 - - - + 
885.471  PHQPLPPT  147 - 154 - - - + 
651.359  QPLPPT  149 - 154 - - - + 
1350.701  QPLPPTVMFPPQ  149 - 160 - - - + 
1437.733  QPLPPTVMFPPQS  149 - 161 - - - + 
426.248  LPPT  151 - 154 - - - + 
1012.505  PPTVMFPPQ  152 - 160 - + - - 
786.428  FPPQSVL  157 - 163 + + + - 
639.359  PPQSVL  158 - 163 + + - - 
761.428  LSLSQSK  163 - 169 - + - - 
520.249  SLSQS  164 - 168 - - - + 
648.344  SLSQSK  164 - 169 - + - - 
358.258  KVL  169 - 171 - - + - 
651.396  VLPVPQ  170 - 175 - - - + 
779.491  VLPVPQK  170 - 176 - + - - 
1110.644  LPVPQKAVPY  171 - 180 - - - + 
371.217  PQK  174 - 176 - + - - 
801.438  KAVPYPQ  176 - 182 - - - + 
957.540  KAVPYPQR  176 - 183 - + - - 
673.344  AVPYPQ  177 - 182 - - - + 
829.445  AVPYPQR  177 - 183 - + - - 
1484.745  AVPYPQRDMPIQA  177 - 189 - - + - 
1314.639  PYPQRDMPIQA  179 - 189 - - + - 
474.215  DMPI  184 - 187 - - - + 
673.311  DMPIQA  184 - 189 - + - - 
933.463  DMPIQAFL  184 - 191 - + - - 
462.284  AFLL  189 - 192 + - - - 
391.247  FLL  190 - 192 + - + - 
1226.691  LLYQEPVLGPV  191 - 201 - - - + 
1382.792  LLYQEPVLGPVR  191 - 202 - + - - 
2106.224  LLYQEPVLGPVRGPFPIIV  191 - 209 + + - - 
1269.708  LYQEPVLGPVR  192 - 202 - + - - 
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Calculated 
mass 
Sequence 
β-CN 
Fragment 
Simulated 
Fluids 
Human 
Fluids 
G60 D60 G60 D30 
1993.140  LYQEPVLGPVRGPFPIIV  192 - 209 + + - - 
634.296  YQEPV  193 - 197 - - - + 
804.402  YQEPVLG  193 - 199 - - + - 
1156.624  YQEPVLGPVR  193 - 202 - + - - 
1457.767  YQEPVLGPVRGPF  193 - 205 - + + - 
1780.988  YQEPVLGPVRGPFPII  193 - 208 + + - - 
1880.056  YQEPVLGPVRGPFPIIV  193 - 209 + + + - 
580.358  PVLGPV  196 - 201 - - - + 
736.460  PVLGPVR  196 - 202 - + - - 
1037.602  PVLGPVRGPF  196 - 205 - - + - 
1459.892  PVLGPVRGPFPIIV  196 - 209 + + - - 
1150.686  GPVRGPFPIIV  199 - 209 + - + - 
1093.665  PVRGPFPIIV  200 - 209 + - + - 
685.391  RGPFPI  202 - 207 - - - + 
741.443  GPFPIIV  203 - 209 - + - - 
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Annex 7. Peptide sequences identified by RP-HPLC-MS/MS in the gastric (60 min, G60) 
and gastroduodenal digests of β-LG (60 min of gastric followed by 30 min of duodenal 
digestion, D30), with simulated and human fluids, shown in section 4.2. 
Calculated 
mass 
Sequence 
β-LG 
Fragment 
Simulated 
Fluids 
Human 
Fluids 
G60 D60 G60 D30 
444.295 
 
LIVT  1-4 - - - + 
804.442 
 
LIVTQTM 1-7 + + - - 
932.537 
 
LIVTQTMK 1-8 - + - - 
1217.669 
 
LIVTQTMKGLD 1-11 + - - - 
459.27 
 
IVTQ 2-5 + + - - 
819.453 
 
IVTQTMK 2-8 - + - - 
876.474 
 
IVTQTMKG 2-9 + - - - 
1217.669 
 
IVTQTMKGLDI 2-12 + - - - 
892.432 
 
TQTMKGLD  4-11 - - + - 
791.385 
 
QTMKGLD 5-11 + - + - 
1709.881 
 
TMKGLDIQKVAGTWY 6-20 - + - - 
800.476 
 
KGLDIQK 8-14 - + - - 
1477.793 
 
KGLDIQKVAGTWY 8-20 - + - - 
544.286 
 
GLDIQ  9-13 - - - + 
672.381 
 
GLDIQK 9-14 - + - - 
715.423 
 
IQKVAGT 12-18 + - - - 
901.502 
 
IQKVAGTW 12-19 + - + - 
660.36 
 
KVAGTW 14-19 + + - - 
532.265 
 
VAGTW 15-19 - + - - 
695.328 
 
VAGTWY 15-20 - + - - 
1190.622 
 
SLAMAASDISLL 21-32 - + - - 
790.39 
 
LAMAASDI 22-29 + - - - 
990.506 
 
AMAASDISLL 23-32 + + - - 
493.185 
 
MAASD 24-28 + + - - 
788.428 
 
AASDISLL 25-32 - + - - 
1102.551 
 
AASDISLLDAQ  25-35 - - - + 
832.418 
 
ASDISLLD  26-33 - - + + 
444.295 
 
ISLL 29-32 + + - - 
916.487 
 
ISLLDAQSA 29-37 - + - - 
1381.793 
 
ISLLDAQSAPLRV 29-41 + + - - 
813.424 
 
LDAQSAPL 32-39 - + - - 
1068.593 
 
LDAQSAPLRV 32-41 + - - - 
1231.656 
 
LDAQSAPLRVY 32-42 + - - - 
700.339 
 
DAQSAPL  33-39 - - - + 
856.441 
 
DAQSAPLR 33-40 - + - - 
955.509 
 
DAQSAPLRV 33-41 + - + - 
769.445 
 
QSAPLRV 35-41 + - + - 
436.244 
 
RVY 40-42 - + - - 
1587.803 
 
VYVEELKPTPEGDL  41-54 - - - + 
1716.846 
 
VYVEELKPTPEGDLE  41-55 - - - + 
1943.014 
 
VYVEELKPTPEGDLEIL 41-57 - + - - 
2056.098 
 
VYVEELKPTPEGDLEILL 41-58 - + - - 
2185.157 
 
VYVEELKPTPEGDLEILLQ 41-59 - + - - 
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Calculated 
mass 
Sequence 
β-LG 
Fragment 
Simulated 
Fluids 
Human 
Fluids 
G60 D60 G60 D30 
538.218 
 
YVEE 42-45 + + - - 
779.407 
 
YVEELK  42-47 - - + - 
977.507 
 
YVEELKPT  42-49 - - - + 
1488.735 
 
YVEELKPTPEGDL 42-54 + + + + 
1617.778 
 
YVEELKPTPEGDLE 42-55 + + + + 
814.444 
 
VEELKPT  43-49 - - - + 
1097.561 
 
VEELKPTPEG  43-52 - - - + 
1325.672 
 
VEELKPTPEGDL 43-54 + + - - 
1454.714 
 
VEELKPTPEGDLE 43-55 + + - + 
1567.798 
 
VEELKPTPEGDLEI  43-56 - - - + 
1680.882 
 
VEELKPTPEGDLEIL 43-57 - + - - 
1793.967 
 
VEELKPTPEGDLEILL 43-58 - + - - 
2050.12 
 
VEELKPTPEGDLEILLQK 43-60 - + - - 
1355.646 
 
EELKPTPEGDLE  44-55 - - - + 
812.428 
 
ELKPTPE 45-51 + + - - 
1226.603 
 
ELKPTPEGDLE 45-55 + + + + 
740.407 
 
LKPTPEG 46-52 + - - - 
968.518 
 
LKPTPEGDL 46-54 + + + + 
1097.561 
 
LKPTPEGDLE 46-55 + + - + 
855.434 
 
KPTPEGDL 47-54 + + - + 
984.477 
 
KPTPEGDLE  47-55 - - - + 
1097.561 
 
KPTPEGDLEI 47-56 + - - + 
1895.004 
 
KPTPEGDLEILLQKWE 47-62 - + - - 
759.329 
 
TPEGDLE  49-55 - - - + 
872.413 
 
TPEGDLEI  49-56 - - - + 
658.281 
 
PEGDLE  50-55 - - - + 
771.365 
 
PEGDLEI  50-56 - - - + 
1228.645 
 
ILLQKWENDE 55-64 - + - - 
1658.845 
 
ILLQKWENDECAQK 56-69 - + - - 
573.328 
 
LQKW 58-61 - + - - 
816.413 
 
LQKWEN  58-63 - - + - 
807.286 
 
WENDECA 61-67 + - - - 
621.207 
 
ENDECA 62-67 + - - - 
2374.257 
 
ENDECAQKKIIAEKTKIPAVF 62-82 - + - - 
1637.024 
 
AQKKIIAEKTKIPAV 67-81 - + - - 
1784.093 
 
AQKKIIAEKTKIPAVF 67-82 + + - - 
372.274 
 
KII  70-72 - - - + 
700.449 
 
KIIAEK 70-75 - + - - 
444.259 
 
IIAE 71-74 - + - + 
572.354 
 
IIAEK 71-75 - + - + 
1328.807 
 
IIAEKTKIPAVF 71-82 + - - - 
884.533 
 
EKTKIPAV 74-81 + - - - 
1031.602 
 
EKTKIPAVF 74-82 + - + - 
2974.993 
 
EKTKIPAVFKIDALNENKVLVLDTDY 74-99 - + - - 
755.491 
 
KTKIPAV 75-81 + - - - 
902.559 
 
KTKIPAVF 75-82 + - + - 
528.327 
 
TKIPA  76-80 - - - + 
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Calculated 
mass 
Sequence 
β-LG 
Fragment 
Simulated 
Fluids 
Human 
Fluids 
G60 D60 G60 D30 
774.464 
 
TKIPAVF 76-82 + + + - 
545.322 
 
IPAVF 78-82 - + - - 
786.501 
 
IPAVFKI  78-84 - - + - 
788.444 
 
PAVFKID  79-85 - - + + 
1572.888 
 
AVFKIDALNENKVL  80-93 - - + - 
948.492 
 
FKIDALNE 82-89 - + - - 
445.254 
 
KIDA  83-86 - - - + 
801.424 
 
KIDALNE 83-89 + + + - 
1043.561 
 
KIDALNENK 83-91 - + - - 
1255.714 
 
KIDALNENKVL 83-93 - + - - 
1467.866 
 
KIDALNENKVLVL 83-95 + - - - 
915.466 
 
IDALNENK 84-91 - + - - 
674.287 
 
DALNEN  85-90 - - - + 
3033.519 
 
ALNENKVLVLDTDYKKYLLFCMENSA 86-111 - + - - 
927.539 
 
NENKVLVL 88-95 + - - - 
684.454 
 
NKVLVL 90-95 + - - - 
2975.466 
 
KVLVLDTDYKKYLLFCMENSAEPEQ 91-115 - + - - 
936.481 
 
VLVLDTDY 92-99 - + + + 
1064.576 
 
VLVLDTDYK 92-100 - + - - 
2719.313 
 
VLVLDTDYKKYLLFCMENSAEPE 92-114 - + - - 
724.328 
 
VLDTDY 94-99 - + - - 
852.423 
 
VLDTDYK 94-100 - + - + 
980.518 
 
VLDTDYKK 94-101 - + - - 
1369.75 
 
VLDTDYKKYLL 94-104 + - - - 
1270.681 
 
LDTDYKKYLL 95-104 + - - - 
640.271 
 
DTDYK 96-100 - + - - 
768.73 
 
DTDYKK 96-101 - + - - 
931.429 
 
DTDYKKY  96-102 - - + - 
1157.597 
 
DTDYKKYLL 96-104 + - + - 
1304.666 
 
DTDYKKYLLV 96-105 + - - - 
941.522 
 
DYKKYLL  98-104 - - + - 
1652.758 
 
DYKKYLLVCMENS 98-110 - + - - 
826.496 
 
YKKYLL 99-104 + - - - 
663.432 
 
KKYLL 100-104 + - - - 
1446.653 
 
KYLLVCMENSAE 101-112 - + - - 
554.311 
 
YLLV 102-105 - + - - 
391.247 
 
LLV 103-105 - + - - 
1120.435 
 
MENSAEPEQS  107-116 - - - + 
1233.519 
 
MENSAEPEQSL 107-117 + - - - 
1747.776 
 
ENSAEPEQSLVCQCLV  108-123 - - - + 
2004.925 
 
ENSAEPEQSLVCQCLVRT 108-125  - + - - 
516.218 
 
NSAEP 109-113 - + - - 
860.351 
 
NSAEPEQS 109-116 + + - - 
659.277 
 
SAEPEQ  110-115 - - - + 
746.309 
 
SAEPEQS 110-116 + + - + 
2848.326 
 
EPEQSLACQCLVRTPEVDDEALEKF 112-136 - + - - 
908.373 
 
EQSLVCQC 114-121 + - - - 
1120.526 
 
EQSLVCQCLV  114-123 - - - + 
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Calculated 
mass 
Sequence 
β-LG 
Fragment 
Simulated 
Fluids 
Human 
Fluids 
G60 D60 G60 D30 
2920.431 
 
QSLVCQCLVRTPEVDDEALEKFD 115-140 - + - - 
1760.808 
 
VCQCLVRTPEVDDEAL 118-133 - + - - 
1818.813 
 
CQCLVRTPEVDDEALE 119-134 - + - + 
1946.908 
 
CQCLVRTPEVDDEALEK 119-135 - + - - 
814.419 
 
VRTPEVD  123-129 - - - + 
929.446 
 
VRTPEVDD 123-130 + + + + 
1058.488 
 
VRTPEVDDE 123-131 + + + + 
1129.525 
 
VRTPEVDDEA 123-132 + + - - 
1243.609 
 
VRTPEVDDEAL 123-133 + + - - 
1499.747 
 
VRTPEVDDEALEK 123-135 - + - - 
1889.937 
 
VRTPEVDDEALEKFDK 123-138 - + - - 
1272.584 
 
RTPEVDDEALE  124-134 - - - + 
559.249 
 
TPEVD  125-129 - - - + 
803.319 
 
TPEVDDE 125-131 - + - + 
874.356 
 
TPEVDDEA 125-132 - + - - 
1116.483 
 
TPEVDDEALE  125-134 - - - + 
1244.578 
 
TPEVDDEALEK 125-135 - + - + 
1391.646 
 
TPEVDDEALEKF 125-136 - + - - 
1634.768 
 
TPEVDDEALEKFDK 125-138 - + - - 
1405.625 
 
PEVDDEALEKFD 126-137 + - - - 
1690.878 
 
VDDEALEKFDKALKA 128-142 - + - - 
575.244 
 
DEALE  130-134 - - - + 
721.365 
 
ALEKFD  132-137 - - - + 
849.46 
 
ALEKFDK  132-138 - - + + 
920.497 
 
ALEKFDKA  132-139 - - + - 
1232.713 
 
ALEKFDKALKA 132-142 + - + - 
2093.219 
 
ALEKFDKALKALPMHIRL 132-149 + - - - 
778.423 
 
LEKFDK 133-138 - + - - 
2022.182 
 
LEKFDKALKALPMHIRL 133-149 + - - - 
422.217 
 
EKF  134-136 - - + - 
665.339 
 
EKFDK 134-138 - + - + 
736.376 
 
EKFDKA 134-139 + + + - 
849.46 
 
EKFDKAL 134-140 + - - - 
977.555 
 
EKFDKALK 134-141 + - - - 
1048.592 
 
EKFDKALKA 134-142 + - - - 
1526.828 
 
EKFDKALKALPMH 134-146 + + - - 
1909.097 
 
EKFDKALKALPMHIRL 134-149 + - + - 
536.296 
 
KFDK 135-138 - + - - 
919.549 
 
KFDKALKA 135-142 + - - - 
1510.87 
 
KFDKALKALPMHI 135-147 + + - - 
573.349 
 
DKALK 137-141 - + - - 
1504.891 
 
DKALKALPMHIRL 137-149 + - - - 
1120.679 
 
KALKALPMHI 138-147 + - - - 
742.441 
 
ALKALPM  139-145 - - - + 
1261.77 
 
ALKALPMHIRL  139-149 - - + - 
1190.732 
 
LKALPMHIRL 140-149 + - + - 
949.553 
 
ALPMHIRL  142-149 - - + - 
878.516 
 
LPMHIRL 143-149 + - + - 
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Annex 7. Continuation    
Calculated 
mass 
Sequence 
β-LG 
Fragment 
Simulated 
Fluids 
Human 
Fluids 
G60 D60 G60 D30 
424.255 
 
HIR 146-148 - + - - 
537.339 
 
HIRL 146-149 - + - - 
748.423 
 
IRLSFN  147-152 - - + - 
833.44 
 
RLSFNPT  148-154 - - - + 
677.339 
 
LSFNPT  149-154 - - - + 
564.255 
 
SFNPT  150-154 - - - + 
805.397 
 
SFNPTQL 150-156 + + + - 
645.297 
 
QLEEQ  155-159 - - - + 
757.307  EEQCHI 157-162 + - - - 
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Annex 8. Peptide sequences identified by RP-HPLC-MS/MS in the gastric (60 min, G60) 
and gastroduodenal digests of OVA (60 min of gastric followed by 30 min of duodenal 
digestion, D30), with simulated and human fluids, shown in section 4.3. 
Calculated 
mass 
Sequence 
OVA 
Fragment 
Simulated 
Fluids 
Human 
Fluids 
G60 D60 G60 D30 
474.244  TQIN 51-54 - + - + 
1103.645  TQINKVVRF  51-59 + - + - 
874.539  INKVVRF 53-59 - + - - 
1327.798  INKVVRFDKLP  53-63 - - - + 
647.412  KVVRF 55-59 + + - - 
519.317  VVRF 56-59 + + - - 
677.386  RFDKL 58-62 + - - - 
1550.773  RFDKLPGFGDSIEA  58-71 - - - + 
1176.567  DKLPGFGDSIE 60-70 + + + - 
1247.604  DKLPGFGDSIEA  60-71 - - - + 
413.264  KLPG 61-64 + - - + 
1292.571  LPGFGDSIEAQCG  62-74 - - + - 
664.285  AQCGTSV  71-77 - - - + 
465.190  CGTSV  73-77 - - - + 
754.398  VNVHSSL 77-83 + + + - 
655.329  NVHSSL 78-83 + + - - 
1719.963  VHSSLRDILNQITKP  79-93 - - + - 
689.371  SSLRDI  81-86 - - - + 
629.350  RDILN  84-88 - - - + 
757.409  RDILNQ 84-89 + + + - 
943.534  DILNQITK 85-92 + + - - 
813.435  NQITKPN  88-94 - - - + 
928.462  NQITKPND  88-95 - - - + 
1027.530  NQITKPNDV  88-96 - - + + 
1190.593  NQITKPNDVY 88-97 + + - - 
1277.625  NQITKPNDVYS 88-98 + + + - 
1424.694  NQITKPNDVYSF  88-99 - - + - 
686.360  ITKPND  90-95 - - - + 
785.429  ITKPNDV 90-96 + + + + 
948.492  ITKPNDVY 90-97 + + - - 
1035.524  ITKPNDVYS 90-98 + + + - 
672.345  TKPNDV  91-96 - - - + 
743.313  NDVYSF  94-99 - - + - 
829.386  DVYSFSL  95-101 - - - + 
792.450  FSLASRL 99-105 + - - - 
645.381  SLASRL 100-105 + + + - 
445.265  LASR 101-104 + + - - 
445.265  ASRL  102-105 - - + - 
381.154  YAE 106-108 + + - - 
829.361  YAEERY 106-111 + + + - 
1152.582  YAEERYPIL 106-114 + + + - 
1378.677  YAEERYPILPE  106-116 - - - + 
1215.614  AEERYPILPE  107-116 - - - + 
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Annex 8. Continuation    
Calculated 
mass 
Sequence 
OVA 
Fragment 
Simulated 
Fluids 
Human 
Fluids 
G60 D60 G60 D30 
676.355  ERYPI  109-113 - - - + 
789.439  ERYPIL 109-114 + + + - 
1063.566  KELYRGGLE 122-130 + - - - 
1277.677  LYRGGLEPINF 124-134 + - - - 
693.345  YRGGLE  125-130 - - - + 
1164.593  YRGGLEPINF 125-134 + + + - 
740.418  RGGLEPI  126-132 - - - + 
854.461  RGGLEPIN 126-133 - + - - 
1001.530  RGGLEPINF 126-134 + + + - 
845.429  GGLEPINF  127-134 - - + - 
1416.689  LEPINFQTAADQA  129-141 - - + - 
632.277  QTAADQ 135-140 + + + + 
859.415  QTAADQAR 135-142 - + - - 
988.458  QTAADQARE 135-143 + + + - 
688.314  ADQARE  138-143 - - - + 
617.277  DQARE 139-143 - + - - 
801.435  ARELINS 141-147 + + + - 
987.514  ARELINSW  141-148 - - + - 
1645.806  ARELINSWVESQTN  141-154 - - - + 
730.398  RELINS 142-147 + + - - 
445.254  LINS 144-147 + + - - 
519.233  WVES  148-151 - - - + 
862.382  WVESQTN 148-154 - + - - 
919.404  WVESQTNG 148-155 + + + - 
733.325  VESQTNG 149-155 + + - - 
400.280  IIR 156-158 - + - - 
514.323  IIRN  156-159 - - + - 
1224.719  IIRNVLQPSSV 156-166 + - - - 
1554.837  IIRNVLQPSSVDSQ 156-169 + - - - 
1726.922  IIRNVLQPSSVDSQTA 156-171 + - + - 
1857.962  IIRNVLQPSSVDSQTAM 156-172 + - - - 
812.451  RNVLQPS  158-164 - - - + 
1344.652  NVLQPSSVDSQTA  159-171 - - + - 
1475.693  NVLQPSSVDSQTAM 159-172 - + - - 
656.350  NVLQPS  159-164 - - - + 
542.307  VLQPS  160-164 - - - + 
728.407  VLQPSSV 160-166 + + - - 
843.434  VLQPSSVD  160-167 - - + - 
1058.525  VLQPSSVDSQ 160-169 + + - - 
1230.609  VLQPSSVDSQTA  160-171 - - + - 
1361.650  VLQPSSVDSQTAM 160-172 + + - - 
631.282  QPSSVD  162-167 - - + - 
1349.650  SSVDSQTAMVLVN  164-176 - - - + 
651.254  DSQTAM 167-172 + + - - 
675.432  IVFKGL 178-183 + - + - 
861.512  IVFKGLW 178-184 + - + - 
830.465  KGLWEKA 181-187 + - - - 
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Annex 8. Continuation    
Calculated 
mass 
Sequence 
OVA 
Fragment 
Simulated 
Fluids 
Human 
Fluids 
G60 D60 G60 D30 
532.265  WEKA 184-187 + + - - 
1841.830  WEKAFKDEDTQAMPF 184-198 + - - - 
753.318  FKDEDT  188-193 - - + + 
952.414  FKDEDTQA 188-195 + + + - 
1180.507  FKDEDTQAMP 188-197 + + - - 
1327.576  FKDEDTQAMPF 188-198 + + + - 
1812.836  FKDEDTQAMPFRVTE  188-202 - - + - 
1940.894  FKDEDTQAMPFRVTEQ  188-203 - - + - 
878.432  MPFRVTE 196-202 + - - - 
1006.491  MPFRVTEQ 196-203 + - + - 
1805.881  MPFRVTEQESKPVQM 196-210 + - - - 
875.450  PFRVTEQ  197-203 - - + - 
1577.787  FRVTEQESKPVQM 198-210 + + - - 
503.271  RVTE 199-202 + + - + 
631.329  RVTEQ 199-203 + + + + 
1171.620  RVTEQESKPV  199-208 - - - + 
1299.679  RVTEQESKPVQ 199-209 + + - - 
1430.719  RVTEQESKPVQM 199-210 + + - - 
1561.760  RVTEQESKPVQMM 199-211 + + - - 
686.360  QESKPV  203-208 - - - + 
945.459  QESKPVQM 203-210 + + + - 
7076.500  QESKPVQMM 203-211 + + - - 
558.302  ESKPV  204-208 - - - + 
686.360  ESKPVQ 204-209 + + - - 
817.401  ESKPVQM 204-210 + + + - 
948.441  ESKPVQMM 204-211 + + - - 
723.363  MYQIGL  211-216 - - + - 
592.322  YQIGL 212-216 + + + - 
748.423  GLFRVAS  215-221 - - - + 
709.358  FRVASM 217-222 + + - - 
562.290  RVASM 218-222 + + + - 
693.301  VASMASE  219-225 - - + - 
1193.615  VASMASEKMKI  219-229 - - + - 
692.353  ASEKMK 223-228 + + + - 
805.437  ASEKMKI  223-229 - - + - 
1160.648  ASEKMKILEL 223-232 + - + - 
631.409  KMKIL  226-230 - - + - 
745.441  MKILEL 227-232 - + + - 
486.306  ILEL 229-232 - + - - 
709.311  PFASGTM 233-239 + + + - 
927.383  PFASGTMSM 233-241 + + + - 
797.454  LVLLPDE 242-248 + + + - 
896.522  LVLLPDEV  242-249 - - - + 
684.370  VLLPDE 243-248 + + - - 
1040.576  VLLPDEVSGL 243-252 + + + - 
828.423  LPDEVSGL 245-252 + + - - 
631.318  VSGLEQ  249-254 - - - + 
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Annex 8. Continuation    
Calculated 
mass 
Sequence 
OVA 
Fragment 
Simulated 
Fluids 
Human 
Fluids 
G60 D60 G60 D30 
574.297  ESIIN  256-260 - - - + 
721.365  ESIINF 256-261 + + + - 
618.323  EKLTE 262-266 + + + + 
804.402  EKLTEW 262-267 + + - - 
1193.557  EKLTEWTSSN  262-271 - - + - 
823.335  TEWTSSN  265-271 - - + - 
593.245  WTSSN 267-271 + + + - 
1307.727  MEERKIKVYL 273-282 + - - - 
1063.603  EERKIKVY 274-281 + - - - 
1176.687  EERKIKVYL 274-282 + - - - 
672.429  ERKIK 275-279 + + - - 
934.560  ERKIKVY 275-281 + - - - 
1047.644  ERKIKVYL 275-282 + - + - 
387.285  KIK 277-279 - + + - 
649.417  KIKVY 277-281 - + - - 
762.501  KIKVYL  277-282 - - + - 
521.322  IKVY 278-281 - + - - 
634.406  IKVYL 278-282 - + - - 
887.560  IKVYLPR  278-284 - - + - 
774.425  LPRMKM 282-287 + - - - 
661.341  PRMKM 283-287 + - - - 
666.272  MKMEE  285-289 - - - + 
794.367  MKMEEK  285-290 - - - + 
826.390  KMEEKY 286-291 - + - - 
698.295  MEEKY 287-291 - + - - 
567.254  EEKY 288-291 - + - - 
836.377  MAMGITDV 298-305 + + - - 
983.446  MAMGITDVF 298-306 + - - - 
852.405  AMGITDVF 299-306 - + - - 
781.368  MGITDVF 300-306 + + - - 
650.328  GITDVF 301-306 + + - - 
823.408  VFSSSANL 305-312 + + - - 
725.323  FSSSADL 306-312 + + + - 
1079.510  SSSANLSGISSA 307-318 + + - - 
736.324  SGISSAES  313-320 - - - + 
849.408  SGISSAESL 313-321 + + - - 
803.439  ESLKISQ 319-325 + + - - 
1460.774  ESLKISQAVHAAHA 319-332 + - - - 
1945.986  ESLKISQAVHAAHAEINE 319-336 + - - - 
3243.612  ESLKISQA……VVGSAEA 319-350 + - - - 
587.365  LKISQ  321-325 - - + - 
459.306  LKIS  321-324 - - - + 
1729.911  LKISQAVHAAHAEINE  321-336 - - + - 
781.445  KISQAVH 322-328 - + - - 
1131.615  KISQAVHAAHA 322-332 + - + - 
1616.827  KISQAVHAAHAEINE 322-336 + - + - 
2030.030  KISQAVHAAHAEINEAGRE 322-340 + - - - 
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Calculated 
mass 
Sequence 
OVA 
Fragment 
Simulated 
Fluids 
Human 
Fluids 
G60 D60 G60 D30 
655.350  ISQAVH 323-328 - + - - 
675.346  AVHAAHA 326-332 + + + - 
1160.558  AVHAAHAEINE 326-336 + + + - 
1231.595  AVHAAHAEINEA  326-337 - - + - 
1573.760  AVHAAHAEINEAGRE 326-340 + - - - 
1986.987  AVHAAHAEINEAGREVVGSA 326-345 + - - - 
853.393  AAHAEINE 329-336 + + - - 
1266.596  AAHAEINEAGRE 329-340 + + - - 
1679.823  AAHAEINEAGREVVGSA 329-345 + + - - 
916.425  EINEAGRE 333-340 + + - - 
374.180  INE  334-336 - - - + 
844.441  AGREVVGSA 337-345 + + + - 
973.483  AGREVVGSAE  337-346 + - + - 
1315.637  AGREVVGSAEAGVD 337-350 + + - - 
902.435  VVGSAEAGVD 341-350 + + - - 
631.282  AEAGVDA  345-351 - - + - 
1628.743  VDAASVSEEFRADHP  349-363 - - + - 
691.303  AASVSEE 351-357 + + + - 
1750.832  ASVSEEFRADHPFLF  352-366 - - + - 
1130.551  EFRADHPFL 357-365 + - - - 
741.356  FRADHP  358-363 - - - + 
888.425  FRADHPF 358-364 - + - - 
1001.509  FRADHPFL 358-365 + - + - 
854.440  RADHPFL 359-365 + + - - 
438.187  ADHP  360-363 - - - + 
681.418  IKHIAT 368-373 + + - - 
795.461  IKHIATN  368-374 - - + - 
866.498  IKHIATNA  368-375 - - + - 
1730.893  HIATNAVLFFGRCVSP 370-385 - + - + 
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Annex 9. Peptide sequences identified by RP-HPLC-MS/MS in the gastric (60 min, G60) 
and gastroduodenal digests (60 min of gastric followed by 30 min of duodenal digestion, 
D30) of OM and dOM with simulated fluids, shown in section 4.4. 
Calculated 
mass 
Sequence 
OM 
Fragment 
OM dOM 
G60 D60 G60 D30 
778.328  AEVDCSR  1-7 - + - + 
925.326  AEVDCSRF   1-8 - - + - 
1207.529  AEVDCSRFPNA  1-11 + - - - 
1423.604  AEVDCSRFPNATD  1-13 - - + - 
1980.885  AEVDCSRFPNATDKEGKD  1-18 - + - + 
603.313  RFPNA  7-11 - - - + 
1432.720  FPNATDKEGKDVL  8-20 + - - - 
902.449  DKEGKDVL  13-20 - - - - 
575.19  KEGKD  14-18 - - - - 
787.444  KEGKDVL  14-20 - - + + 
1728.901  GKDVLVCNKDLRPICG  16-31 - - + - 
917.333  KDVLVCNK  17-24 - - - - 
674.379  VLVCNK  19-24 - + - + 
789.405  VLVCNKD  19-25 + + + + 
1644.833  VLVCNKDLRPICGTD  19-33 + - - - 
1701.854  VLVCNKDLRPICGTDG  19-34 + - + - 
1800.923  VLVCNKDLRPICGTDGV  19-35 - - + - 
1901.970  VLVCNKDLRPICGTDGVT  19-36 + - + - 
2065.034  VLVCNKDLRPICGTDGVTY  19-37 + + + + 
2166.081  VLVCNKDLRPICGTDGVTYT  19-38 + - + - 
1432.680  VCNKDLRPICGTD  21-33 + - + - 
1489.702  VCNKDLRPICGTDG  21-34 + - + - 
1689.818  VCNKDLRPICGTDGVT  21-36 + + + + 
1852.881  VCNKDLRPICGTDGVTY  21-37 + + + + 
1953.929  VCNKDLRPICGTDGVTYT  21-38 + - - - 
2399.092  VCNKDLRPICGTDGVTYTNDCL  21-42 + - - - 
741.244  NKDLRP  23-28 - - - - 
740.454  KDLRPI  24-29 + - + - 
988.465  DLRPICGTD  25-33 - - - + 
1245.602  DLRPICGTDGVT  25-36 - + - + 
1408.666  DLRPICGTDGVTY  25-37 - + - + 
1509.713  DLRPICGTDGVTYT  25-38 - + - - 
930.459  LRPICGTDG  26-34 - - + - 
1130.575  LRPICGTDGVT  26-36 + + + + 
1293.639  LRPICGTDGVTY  26-37 - - + - 
1040.485  VTYTNDCLL  35-43 + - - - 
511.104  YTND  37-40 - - - - 
727.285  YTNDCL  37-42 + + + + 
1014.415  YTNDCLLCA  37-45 + + + + 
564.221  TNDCL  38-42 - + - + 
851.352  TNDCLLCA  38-45 - + - - 
1432.637  CLLCAYSIEFGTN  41-53 - - - + 
1103.53  CAYSIEFGTN  44-53 - - - - 
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Annex 9. Continuation    
Calculated 
mass 
Sequence 
OM 
Fragment 
OM dOM 
G60 D60 G60 D30 
1766.811  AYSIEFGTNISKEHDG  45-60 - + - - 
510.233  YSIE  46-49 + + + + 
657.301  YSIEF  46-50 + + + + 
679.264  EFGTNI  49-54 - - - - 
437.113  FGTN  50-53 - - - - 
1144.518  ISKEHDGECK  54-63 - + - + 
1701.77  ISKEHDGECKETVPM  54-68 - - - + 
816.307  EHDGECK  57-63 - - - + 
679.262  DGECKE  59-64 - - + - 
575.262  ETVPM  64-68 - - - + 
1830.813  SYANTTSEDGKVMVLCN  72-88 + - - - 
734.345  TSEDGKV  77-83 - - + - 
865.346  TSEDGKVM  77-84 - - - - 
548.263  DGKVM  80-84 - + - + 
647.322  DGKVMV  80-85 - - - - 
760.415  DGKVMVL  80-86 + - + - 
961.520  KVMVLCNR  82-89 - + - - 
805.394  MVLCNRA  84-90 + - + - 
603.316  VLCNR  85-89 - + - + 
674.353  VLCNRA  85-90 - - + + 
1507.691  VLCNRAFNPVCGTD  85-98 + - - - 
1564.713  VLCNRAFNPVCGTDG  85-99 + - + - 
1764.829  VLCNRAFNPVCGTDGVT  85-101 + - - - 
2042.919  VLCNRAFNPVCGTDGVTYD  85-103 + - + - 
933.381  LCNRAFNP  86-93 - - - - 
1465.644  LCNRAFNPVCGTDG  86-99 - - + - 
462.201  CNRA  87-90 - - - + 
609.269  CNRAF  87-91 - + - - 
1552.676  CNRAFNPVCGTDGVT  87-101 + - + - 
1830.767  CNRAFNPVCGTDGVTYD  87-103 - - + - 
1613.714  RAFNPVCGTDGVTYD  89-103 + - + - 
922.385  AFNPVCGTD  90-98 - - - + 
979.407  AFNPVCGTDG  90-99 - - - + 
1342.586  AFNPVCGTDGVTY  90-102 - + - + 
1457.613  AFNPVCGTDGVTYD  90-103 - + - + 
851.348  FNPVCGTD  91-98 - - - + 
908.37  FNPVCGTDG  91-99 - - - + 
1386.576  FNPVCGTDGVTYD  91-103 - + - + 
704.280  NPVCGTD  92-98 - + - + 
961.417  NPVCGTDGVT  92-101 - + - + 
1124.481  NPVCGTDGVTY  92-102 - + - + 
1239.508  NPVCGTDGVTYD  92-103 - + - + 
1125.465  PVCGTDGVTYD  93-103 + + + + 
553.238  GVTYD  99-103 - + - - 
1068.480  VTYDNECLL  100-108 - + - + 
1764.781  TYDNECLLCAHKVEQ  101-115 - - + - 
868.364  YDNECLL  102-108 - - - + 
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Annex 9. Continuation    
Calculated 
mass 
Sequence 
OM 
Fragment 
OM dOM 
G60 D60 G60 D30 
590.273  NECLL  104-108 - + - + 
764.320  NECLLCA  104-110 - + - + 
1513.702  NECLLCAHKVEQGA  104-117 + - + - 
1600.734  NECLLCAHKVEQGAS  104-118 + - + - 
1699.802  NECLLCAHKVEQGASV  104-119 + - - - 
1357.648  CLLCAHKVEQGAS  106-118 + - + - 
1141.555  LCAHKVEQGAS  108-118 + + + + 
870.402  CAHKVEQG  109-116 - + - + 
1028.471  CAHKVEQGAS  109-118 - + - + 
1127.539  CAHKVEQGASV  109-119 - + - - 
1242.566  CAHKVEQGASVD  109-120 - + - + 
1526.762  CAHKVEQGASVDKR  109-122 - + - + 
925.462  AHKVEQGAS  110-118 - + - + 
1267.652  AHKVEQGASVDK  110-121 - - + - 
1423.753  AHKVEQGASVDKR  110-122 - - - + 
767.338  HKVEQGA  111-117 - - - - 
854.425  HKVEQGAS  111-118 + + + + 
953.409  HKVEQGASV  111-119 - - - - 
717.366  KVEQGAS  112-118 - + - + 
1215.657  KVEQGASVDKR  112-122 - + - + 
988.494  EQGASVDKR  114-122 - + - - 
1613.733  EQGASVDKRHDGGCR  114-128 - + - - 
1097.521  GASVDKRHDGG  116-126 - - - + 
926.457  ASVDKRHD  117-124 - - - + 
1040.529  ASVDKRHDGG  117-126 - - - - 
1740.869  SVDKRHDGGCRKELAA  118-133 + - + - 
516.302  VDKR  119-122 - + - - 
1398.679  VDKRHDGGCRKE  119-130 - - + - 
1511.763  VDKRHDGGCRKEL  119-131 - - + - 
1582.800  VDKRHDGGCRKELA  119-132 + - + - 
1653.837  VDKRHDGGCRKELAA  119-133 + - + - 
1554.769  DKRHDGGCRKELAA  120-133 + - - - 
1901.884  RHDGGCRKELAAVSVDCS  122-139 - + - - 
643.250  HDGGCR  123-128 - + - + 
771.345  HDGGCRK  123-129 - + - + 
900.387  HDGGCRKE  123-130 - + - - 
1013.471  HDGGCRKEL  123-131 - + - + 
1155.545  HDGGCRKELAA  123-133 - + - - 
1493.697  GGCRKELAAVSVDCS  125-139 + - - - 
718.248  CRKELA  127-132 - - - - 
402.211  ELAA  130-133 - + - + 
3162.358  AVSVDCSEYP……PLCGSDNKTY  133-161 - + - - 
1741.718  VSVDCSEYPKPDCTAE  134-149 + + + + 
2222.982  VSVDCSEYPKPDCTAEDRPL  134-153 - + - + 
2827.210  VSVDCSEYPKPDCTAEDRPLCGSDNK  134-159 - + - - 
1555.617  VDCSEYPKPDCTAE  136-149 + + + + 
2036.882  VDCSEYPKPDCTAEDRPL  136-153 - + - + 
 
 
 
 
229 Annexes 
Annex 9. Continuation    
Calculated 
mass 
Sequence 
OM 
Fragment 
OM dOM 
G60 D60 G60 D30 
1341.522  CSEYPKPDCTAE  138-149 + + + + 
1822.787  CSEYPKPDCTAEDRPL  138-153 - + - - 
622.296  SEYPK  139-143 - - - + 
859.375  PKPDCTAE  142-149 + - - - 
1340.639  PKPDCTAEDRPL  142-153 - + - - 
1018.439  DCTAEDRPL  145-153 - - - + 
1380.529  DCTAEDRPLCGSD  145-157 - - - + 
800.403  TAEDRPL  147-153 - - - + 
1061.445  AEDRPLCGSD  148-157 - + - - 
1103.503  DRPLCGSDNK  150-159 - + - + 
1367.614  DRPLCGSDNKTY  150-161 - + - + 
1515.645  LCGSDNKTYGNKCN  153-166 + - + - 
622.238  CGSDNK  154-159 - - - + 
886.349  CGSDNKTY  154-161 - + - + 
1040.427  NKTYGNKCN  158-166 - - - - 
681.290  GNKCNF  162-167 - + - - 
1105.507  CNAVVESNGTL  168-178 - + - + 
1319.639  CNAVVESNGTLTL  168-180 - + - + 
718.350  VESNGTL  172-178 - + - + 
819.402  VESNGTLT  172-179 - - - - 
932.481  VESNGTLTL  172-180 + + + + 
603.302  TLSHF  179-183 - + - + 
788.418  TLSHFGK  179-185 - - - + 
891.427  TLSHFGKC  179-186 + + + + 
790.380  LSHFGKC  180-186 + - + + 
677.296  SHFGKC  181-186 + + + - 
 
  
 
 
